Tokushima University / Educator and Researcher Directory --- Kanayama, Hiro-omi

Personal Web Page

https://researchmap.jp/read0017318 (researchmap)

Field of Study

○	Medicine

Subject of Study

○

Book / Paper

Book:

1.	Kunihisa Yamaguchi and Hiro-omi Kanayama : 閉塞性腎不全, NIPPONRINSHOSHA Co.,Ltd., 2022.
2.	Masayuki Takahashi and Hiro-omi Kanayama : 海外のガイドラインと本邦の腎癌診療ガイドライン, NIPPONRINSHOSHA Co.,Ltd., Tokyo, May 2021.
3.	Masayuki Takahashi and Hiro-omi Kanayama : II RCC long-term prognosis RCC薬物療法のリスク分類別長期成績改善の変遷」1. Favorable risk, Dec. 2020.
4.	Masayuki Takahashi and Hiro-omi Kanayama : 腎癌の薬物療法のクリニカル・パール, Oct. 2020. (Link to Publication Site) ● Publication site (DOI): 10.11477/mf.1413207032 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.11477/mf.1413207032 (DOI: 10.11477/mf.1413207032)
5.	Masayuki Takahashi and Hiro-omi Kanayama : 高齢者に対する手術の適応と限界高齢者の腎癌に対する手術, May 2020. (Link to Publication Site) ● Publication site (DOI): 10.11477/mf.1413206934 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.11477/mf.1413206934 (DOI: 10.11477/mf.1413206934)
6.	Masayuki Takahashi and Hiro-omi Kanayama : 腎癌診療ガイドライン2019年度小改訂のポイント, 科学評論社, Mar. 2020.
7.	Masayuki Takahashi and Hiro-omi Kanayama : II Topics of RCC 「Yes or No ―cytoreductive nephrectomy―」 1.Overview: 転移性RCCに対するcytoreductive nephrectomyの歴史的変遷, Dec. 2019.
8.	Masayuki Takahashi and Hiro-omi Kanayama : 【これ一冊でパーフェクト!!泌尿器科薬物療法】腎癌ソラフェニブ, Apr. 2019.
9.	Yasuyo Yamamoto and Hiro-omi Kanayama : 健康長寿と排尿機能高齢女性の排尿障害について(解説), Apr. 2019.
10.	Yasuyo Yamamoto, Kei Daizumoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 膀胱への穿通胎盤にて帝王切開，子宮全摘，膀胱部分切除術施行後に骨盤内尿腫を形成し，真性尿失禁をきたした1例, Oct. 2018.
11.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 間質性膀胱炎が疑われ，膀胱水圧拡張術が診断の契機となった膀胱アミロイドーシスの1例, Dec. 2017.
12.	Masayuki Takahashi and Hiro-omi Kanayama : 泌尿器科処方のすべてーすぐに使える実践ガイド 9腫瘍転移性腎細胞癌, IGAKU-SHOIN Ltd.Tokyo,Japan, Apr. 2016.
13.	Yoshito Kusuhara, Masayuki Takahashi and Hiro-omi Kanayama : 【骨盤部感染症の画像診断-迅速な診断と治療のストラテジー-】泌尿器領域の感染症の臨床像と治療戦略, Dec. 2015.
14.	Masayuki Takahashi and Hiro-omi Kanayama : 長期投与を目指したAEマネジメント 4) アキシチニブ, Medical Review Co.,Ltd, 大阪市, Dec. 2015.
15.	Masayuki Takahashi and Hiro-omi Kanayama : II What's New in RCC 1 Immune Checkpoint阻害剤 3) 抗PD-L1抗体，抗CTLA-4抗体の開発状況, Medical Review Co.,Ltd, Osaka, Feb. 2015.
16.	Masayuki Takahashi, 横田三樹 and Hiro-omi Kanayama : 【レジメンから理解する泌尿器科の化学療法副作用症状コントロール】患者さんへの説明に使える!腎がんの化学療法レジメン, Medicus SHUPPAN, Osaka, Jul. 2014.
17.	Masayuki Takahashi and Hiro-omi Kanayama : 根治的腎摘除術後のadjuvant治療の現状と展望, 医学図書出版, Tokyo, May 2014.
18.	Masayuki Takahashi and Hiro-omi Kanayama : 第17章泌尿器科腫瘍:進行性腎細胞癌の治療 III.手術, 放射線治療等, 日本泌尿器科学会, Mar. 2014.
19.	Masayuki Takahashi and Hiro-omi Kanayama : II.Topics of RCC―分子標的治療の最前線― 2.分子標的治療の実際―診療の現場から:私はこう使っている― スニチニブ③, Oct. 2011.
20.	Masayuki Takahashi and Hiro-omi Kanayama : 前治療歴によるセカンドライン治療のアルゴリズムを探る, SENTAN IGAKU-SHA, Jul. 2011.
21.	Hiro-omi Kanayama : 嵌頓包茎に対する処置, 2011.
22.	Masayuki Takahashi, Hiro-omi Kanayama, 野口京子, 柴山純子 and 谷口啓子 : 【見ること・することリストで一目瞭然!術式別泌尿器科の術前・術後ケア】泌尿器科手術の術前・術後ケア腎臓の手術腎瘻造設術, 2011. (Keyword) 留置カテーテル
23.	Hiro-omi Kanayama : 腎嚢胞性疾患, 2010.
24.	赤座英之, 並木幹夫, Susumu Kagawa, 本間之夫, 杉村芳樹, 堀江重郎, Hiro-omi Kanayama, 藤岡知昭, 宮川征男, 荒井陽一, 藤沢正人, 高橋悟, 小川修, 野々村克也, 頴川晋, 山口脩, 島田誠, 田邉一成, 松本哲郎, 郡健二郎, 藤目真, 塚本泰司, 河合弘二, 柿崎秀宏, 並木幹夫, 仲谷達也, 松田公志 and 内藤誠二 : 標準泌尿器科学, 2010.
25.	Hiro-omi Kanayama and Masa-aki Nishitani : 泌尿器疾患の症状の特徴, Medicus SHUPPAN, Osaka, May 2005.

Academic Paper (Judged Full Paper):

1.	Keisuke Ozaki, Tomoya Fukawa, Kei Daizumoto, Yutaro Sasaki, Yoshiteru Ueno, Megumi Tsuda, Takayuki Uchida, Yoshito Kusuhara, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : The impact of nutritional status and changes of body composition on the prognosis of metastatic renal cell carcinoma patients., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 80-87, 2023. (Summary) Nutritional status of mRCC patients may predict changes in body composition and be associated with their prognosis. J. Med. Invest. 70 : 80-87, February, 2023. (Keyword) Humans / Carcinoma, Renal Cell / Kidney Neoplasms / Nutritional Status / Prognosis / Body Composition / Retrospective Studies / Protein Kinase Inhibitors (Tokushima University Institutional Repository) ● Metadata: 118311 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.80 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164748 ● Search Scopus @ Elsevier (PMID): 37164748 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.80 (Tokushima University Institutional Repository: 118311, DOI: 10.2152/jmi.70.80, PubMed: 37164748)
2.	Yoshiteru Ueno, Tomoharu Fukumori, Yoshito Kusuhara, Tomoya Fukawa, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Ryotaro Tomida, Yasuyo Yamamoto, Kunihisa Yamaguchi, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima, Masayuki Takahashi and Hiro-omi Kanayama : Prostate-specific Antigen Levels Following Brachytherapy Impact Late Biochemical Recurrence in Japanese Patients With Localized Prostate Cancer., In Vivo, Vol.37, No.2, 738-746, 2023. (Summary) PSA levels at 5 years post-treatment were associated with long-term recurrence of localized prostate cancer, which can help alleviate patient anxiety concerning prostate cancer recurrence if PSA levels remain low at 5 years after LDR-BT. (Keyword) Male / Humans / Prostate-Specific Antigen / Brachytherapy / Cohort Studies / East Asian People / Prostatic Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.13136 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36881090 ● Search Scopus @ Elsevier (PMID): 36881090 ● Search Scopus @ Elsevier (DOI): 10.21873/invivo.13136 (DOI: 10.21873/invivo.13136, PubMed: 36881090)
3.	尾﨑啓介, Kunihisa Yamaguchi, 多田亜沙香, Tomoya Fukawa, Yutaro Sasaki, Yoshito Kusuhara, Yasuyo Yamamoto, 林秀樹, Masayuki Takahashi, Yoshihiro Tsuruo, 橋本寛文 and Hiro-omi Kanayama : 未固定凍結遺体を用いた心停止下献腎摘出教育の試み, 日本臨床腎移植学会雑誌, Vol.10, No.2, 259-261, 2022.
4.	Kouki Tada, Kei Daizumoto, Masayuki Takahashi, Hisanori Uehara, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment., IJU Case Reports, Vol.6, No.1, 41-44, 2022. (Summary) Sunitinib after an IO-drug showed a significant effect in spite of only slight efficacy with other VEGFR-TKIs, which may have occurred through the alteration of the immunological microenvironment. (Tokushima University Institutional Repository) ● Metadata: 118791 (Link to Publication Site) ● Publication site (DOI): 10.1002/iju5.12545 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36605682 ● Search Scopus @ Elsevier (PMID): 36605682 ● Search Scopus @ Elsevier (DOI): 10.1002/iju5.12545 (Tokushima University Institutional Repository: 118791, DOI: 10.1002/iju5.12545, PubMed: 36605682)
5.	ANAYT ULLA, Kanae Osaki, Mizanur Md Rahman, Reiko Nakao, Takayuki Uchida, Isafumi Maru, Kazuaki Mawatari, Tomoya Fukawa, Hiro-omi Kanayama, Iori Sakakibara, Katsuya Hirasaka and Takeshi Nikawa : Morin improves dexamethasone-induced muscle atrophy by modulating atrophy-related genes and oxidative stress in female mice., Bioscience, Biotechnology, and Biochemistry, Vol.86, No.10, 1448-1458, 2022. (Summary) This study investigated the effect of morin, a flavonoid, on dexamethasone-induced muscle atrophy in C57BL/6J female mice. Dexamethasone (10 mg/kg body weight) for 10 days significantly reduced body weight, gastrocnemius and tibialis anterior muscle mass, and muscle protein in mice. Dexamethasone significantly upregulated muscle atrophy-associated ubiquitin ligases, including atrogin-1 and MuRF-1, and the upstream transcription factors FoxO3a and Klf15. Additionally, dexamethasone significantly induced the expression of oxidative stress-sensitive ubiquitin ligase Cbl-b and the accumulation of the oxidative stress markers malondialdehyde and advanced protein oxidation products in both the plasma and skeletal muscle samples. Intriguingly, morin treatment (20 mg/kg body weight) for 17 days effectively attenuated the loss of muscle mass and muscle protein and suppressed the expression of ubiquitin ligases while reducing the expression of upstream transcriptional factors. Therefore, morin might act as a potential therapeutic agent to attenuate muscle atrophy by modulating atrophy-inducing genes and preventing oxidative stress. (Keyword) Animals / Body Weight / Dexamethasone / Female / Flavones / Malondialdehyde / Mice / Mice, Inbred C57BL / Muscle Proteins / Muscle, Skeletal / Muscular Atrophy / Oxidative Stress / Tripartite Motif Proteins / Ubiquitin-Protein Ligases (Link to Publication Site) ● Publication site (DOI): 10.1093/bbb/zbac140 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35977398 ● Search Scopus @ Elsevier (PMID): 35977398 ● Search Scopus @ Elsevier (DOI): 10.1093/bbb/zbac140 (DOI: 10.1093/bbb/zbac140, PubMed: 35977398)
6.	Kyotaro Fukuta, Keito Shiozaki, Ryoichi Nakanishi, Hirofumi Izaki, Eiji Kudo, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : Leptomeningeal carcinomatosis in small cell carcinoma of the prostate., IJU Case Reports, Vol.5, No.6, 493-496, 2022. (Summary) Careful monitoring of the central nervous system should be considered in small cell carcinoma of the prostate patients. (Tokushima University Institutional Repository) ● Metadata: 118792 (Link to Publication Site) ● Publication site (DOI): 10.1002/iju5.12524 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36341201 ● Search Scopus @ Elsevier (PMID): 36341201 ● Search Scopus @ Elsevier (DOI): 10.1002/iju5.12524 (Tokushima University Institutional Repository: 118792, DOI: 10.1002/iju5.12524, PubMed: 36341201)
7.	K. Ozaki, Takashi Kawanaka, Tomoya Fukawa, Kei Daizumoto, Yutaro Sasaki, Megumi Tsuda, Yoshito Kusuhara, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Appropriate management reduces radiation exposure in daily urological practice, International Journal of Urology, 2022. (Summary) To identify and raise awareness of the radiation exposure of urologists due to X-ray fluoroscopic procedures in daily practice. This was a single-center, cohort study of 30 consecutive patients who underwent periodic percutaneous or transurethral replacements of urinary tract catheters. A total of 55 replacements every 3 months with cases aligned were performed by a single urologist. The urologist's radiation exposure and the incident dose to patients per case were measured with thermoluminescent dosimeters. In the latter 3-month period, the pulse fluoroscopy condition was changed from 15 to 7.5 pulses per second, and collimation was added to the field of view. In the analysis of all patients, the use of a modified pulse rate and collimation did not affect the fluoroscopy time, but it did significantly reduce the air kerma and dose area product; in addition, with respect to the medical exposure dose during percutaneous catheter replacement, fluoroscopy time was longer, but air kerma and dose area product showed significant decreases. As with decreases in medical exposure of patients, the equivalent dose for eye lenses of the urologist decreased from 1.2 mSv in the first 3-month period to 0.2 mSv in the second 3-month period. Similarly, the exposure dose for the extremities also decreased significantly, from 33.9 mSv to 8.1 mSv. Urologists are exposed to non-negligible amounts of radiation due to fluoroscopy. Appropriate management such as modified pulse fluoroscopy condition and precautions are required. (Tokushima University Institutional Repository) ● Metadata: 118219 (Link to Publication Site) ● Publication site (DOI): 10.1111/iju.14971 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35851694 ● Search Scopus @ Elsevier (PMID): 35851694 ● Search Scopus @ Elsevier (DOI): 10.1111/iju.14971 (Tokushima University Institutional Repository: 118219, DOI: 10.1111/iju.14971, PubMed: 35851694)
8.	Yutaro Sasaki, Kei Daizumoto, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto and Hiro-omi Kanayama : Efficacy of the Mercedes-Benz closure technique for vaginal reconstruction in female robot-assisted radical cystectomy, Asian Journal of Endoscopic Surgery, 2022. (Summary) Vaginal reconstruction using the posterior vaginal wall is required following radical cystectomy in women with resection of the uterus, adnexa, and anterior vaginal wall. Roll closure and clamshell closure are two widely known techniques. Of these, clamshell closure is recommended because roll closure has a high likelihood of breakdown or a resultant canal that is too narrow for sexual intercourse. In clamshell closure, however, folding the posterior vaginal wall anteriorly can be difficult. Therefore, we devised Mercedes-Benz closure, in which the vaginal wall is sutured from three directions to form a Mercedes-Benz shape, for anastomosis without tension on the vaginal wall. The present study was performed to investigate the efficacy of this alternative surgical technique for vaginal reconstruction. Twenty-six patients who underwent vaginal reconstruction following robot-assisted radical cystectomy were divided into two groups: 15 underwent clamshell closure and 11 underwent Mercedes-Benz closure. The patients' characteristics and surgical outcomes were compared between the two groups. There were no significant differences in clinical characteristics, including age, body mass index, and prior abdominal surgery between the two groups. The median vaginal reconstruction time tended to be longer in the Mercedes-Benz closure group than in the clamshell closure group (35.0 vs. 27.0 min, p = 0.102). No complications associated with vaginal reconstruction were identified. The surgical outcomes were comparable between Mercedes-Benz closure and clamshell closure. If vaginal reconstruction with clamshell closure is difficult, Mercedes-Benz closure is a valuable alternative technique. (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.13109 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35842843 ● Search Scopus @ Elsevier (PMID): 35842843 ● Search Scopus @ Elsevier (DOI): 10.1111/ases.13109 (DOI: 10.1111/ases.13109, PubMed: 35842843)
9.	Kyotaro Fukuta, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : High-Grade Renal Mucinous Tubular and Spindle Cell Carcinoma, Case Reports in Oncology, Vol.15, No.2, 580-585, 2022. (Summary) Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare subtype of renal cell carcinoma. Although usually indolent, high-grade MTSCC has been reported to exhibit an aggressive clinical course. Herein, we report a case of high-grade renal MTSCC. An 86-year-old man visited our hospital with fever and fatigue. Based on contrast-enhanced computed tomography findings, the patient was diagnosed with clinical stage T2aN0M0 right renal cell carcinoma and underwent laparoscopic radical nephrectomy. Histological examination showed tubular to tubulopapillary structures accompanied by mucinous stroma, suggesting high-grade renal MTSCC. He remained recurrence- and metastasis-free 6 months after nephrectomy. Since high-grade renal MTSCC may have an aggressive clinical course, such patients should be observed carefully after radical nephrectomy. (Tokushima University Institutional Repository) ● Metadata: 117428 (Link to Publication Site) ● Publication site (DOI): 10.1159/000524897 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35813692 ● Search Scopus @ Elsevier (PMID): 35813692 ● Search Scopus @ Elsevier (DOI): 10.1159/000524897 (Tokushima University Institutional Repository: 117428, DOI: 10.1159/000524897, PubMed: 35813692)
10.	Yusuke Fukatani, Kei Daizumoto, Fumiya Kadoriku, 山本拓, Yutaro Sasaki, 尾﨑啓介, 上野恵輝, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hiro-omi Kanayama, Mariko Niki and Hisanori Uehara : A Case of Pappilary Renal Cell Caircinoma which Responded Well to the Combination Therapy of Ipilimumab and Nivolumab --A CASE REPORT--, Acta Urologica Japonica, Vol.68, No.4, 107-111, 2022. (Summary) We report a case of papillary renal cell carcinoma that responded well to the combination of ipilimumab and nivolumab. The patient was a 68-year-old male who was being followed up for a small left renal mass without treatment. Two years later, computed tomography (CT) showed enlarged cervical and para-aortic lymph nodes, and lymph node biopsy suggested metastases of the cancer. After resection of the renal tumor, we performed pararenal aortic lymph node biopsy, and we diagnosed the case as papillary renal cell carcinoma type 1 with lymph node metastasis. The combination of ipilimumab and nivolumab each metastatic site showed regression on CT. Since immune-related adverse events occurred during the therapy nivolumab was discontinued, but partial response of the metastases was maintained. (Keyword) Papillary renal cell carcinoma / Ipilimumab and nivolumab / 494.9 (Link to Publication Site) ● Publication site (DOI): 10.14989/actauroljap_68_4_107 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390573715168780160 ● Search Scopus @ Elsevier (DOI): 10.14989/actauroljap_68_4_107 (DOI: 10.14989/actauroljap_68_4_107, CiNii: 1390573715168780160)
11.	Kyotaro Fukuta, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : Micropapillary Variant of Urothelial Carcinoma in a Hemodialysis Patient, Case Reports in Oncology, Vol.15, No.1, 462-468, 2022. (Summary) The micropapillary variant of urothelial carcinoma (MPUC) is an aggressive form of urothelial carcinoma with high metastatic potential and a poor prognosis. Although various therapies have been reported, there is still no established treatment strategy for MPUC due to its rarity. The incidence of urinary tract malignancies is higher in patients undergoing hemodialysis (HD) than in healthy individuals. Here, we report the case of an 82-year-old man on HD with end-stage kidney disease who visited our hospital for macrohematuria. Cystoscopy followed by computed tomography and urine cytology revealed a sessile papillary tumor around the left bladder wall. We performed transurethral resection of the bladder tumor. Based on histopathological and imaging findings indicative of clinical-stage T3N0M0 MPUC, we performed radical cystectomy. Histopathology revealed a pathological stage T4aN0M0 MPUC. Two months after the cystectomy, the patient complained of constipation and painful defecation due to local recurrence and rectal invasion. While colostomy was performed to improve defecation 3 months after cystectomy, he did not receive any chemotherapy due to his progressively worsening general condition. Six months after cystectomy, he died following rapid metastases. Our findings, in this case, confirm that bladder cancer in HD patients tends to be pathologically more advanced. Therefore, regular screening is recommended for its early detection in HD patients. (Tokushima University Institutional Repository) ● Metadata: 117427 (Link to Publication Site) ● Publication site (DOI): 10.1159/000524430 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35702563 ● Search Scopus @ Elsevier (PMID): 35702563 ● Search Scopus @ Elsevier (DOI): 10.1159/000524430 (Tokushima University Institutional Repository: 117427, DOI: 10.1159/000524430, PubMed: 35702563)
12.	Yutaro Sasaki, Masayuki Takahashi, Kei Daizumoto, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : The patient-side surgeon plays a key role in facilitating robot-assisted intracorporeal ileal conduit urinary diversion in men, Journal of Robotic Surgery, Vol.16, No.2, 437-444, 2022. (Summary) The influence of the console surgeon on the feasibility and outcome of various robot-assisted surgeries has been evaluated. These variables may be partially affected by the skills of the patient-side surgeon (PSS), but this has not been evaluated using objective data. This study aimed to describe the surgical techniques of the PSS in robot-assisted radical cystectomy (RARC) and intracorporeal ileal conduit (ICIC) urinary diversion and objectively examine the changes in surgical outcomes with increasing PSS experience. During a 3-year period, 28 men underwent RARC and ICIC urinary diversion. Clinical characteristics and surgical outcomes were compared between patients who underwent surgery early (first half group) or late in the study period (second half group). The pre-docking incision enabled easy specimen removal. The glove port technique widened the working space of the PSS. The stay suture allowed the PSS to control the distal portion of the conduit, facilitating the passage of the ureteral stents. During stoma creation, pneumoperitoneum pressure was lost by opening the abdominal cavity. To overcome this problem, the robotic arm was used to lift the abdominal wall to maintain the surgical field and facilitate the PSS procedure. Compared with the first half group, the second half group had significantly shorter times for urinary diversion (202 min vs 148 min, p < 0.001), ileal isolation and anastomosis (73 min vs 45 min, p < 0.001), and stenting (23.0 min vs 6.5 min, p < 0.001). As the experience of the PSS increased, the time of the PSS procedures decreased. (Keyword) Cystectomy / Humans / Male / Robotic Surgical Procedures / Robotics / Surgeons / Treatment Outcome / Urinary Bladder Neoplasms / Urinary Diversion (Tokushima University Institutional Repository) ● Metadata: 116363 (Link to Publication Site) ● Publication site (DOI): 10.1007/s11701-021-01256-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34081290 ● Search Scopus @ Elsevier (PMID): 34081290 ● Search Scopus @ Elsevier (DOI): 10.1007/s11701-021-01256-x (Tokushima University Institutional Repository: 116363, DOI: 10.1007/s11701-021-01256-x, PubMed: 34081290)
13.	Kyotaro Fukuta, Keito Shiozaki, Saki Kobayashi, Ryoichi Nakanishi, Hirofumi Izaki, Kazuya Kanda, Tohru Inai, Eiji Kudo, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : Poor Outcome due to the Plasmacytoid Variant of Urothelial Carcinoma, Case Reports in Oncology, Vol.15, No.1, 369-375, 2022. (Summary) A 72-year-old man visited our hospital due to pollakiuria and lower abdominal pain. Urinary cytology was positive, and cystoscopy revealed diffuse edematous nonpapillary tumor. We performed transurethral biopsy, and clinical stage T3 plasmacytoid variant of urothelial carcinoma (PUC) was diagnosed. Although we planned for radical cystectomy, peritoneal dissemination and lung and pelvic lymph node metastases appeared 3 weeks after the initial visit. We also planned for chemotherapy; however, the metastases rapidly progressed, and he died 7 weeks after the biopsy. PUC is rare and shows an aggressive clinical course and poor prognosis. (Tokushima University Institutional Repository) ● Metadata: 117426 (Link to Publication Site) ● Publication site (DOI): 10.1159/000524038 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35529298 ● Search Scopus @ Elsevier (PMID): 35529298 ● Search Scopus @ Elsevier (DOI): 10.1159/000524038 (Tokushima University Institutional Repository: 117426, DOI: 10.1159/000524038, PubMed: 35529298)
14.	Madoka Kohno, ANAYT ULLA, Rina Taniguchi, Akane Ohishi, Kako Hirayama, Yuma Takemura, Shoichiro Takao, Yuki Kanazawa, Yuki Matsumoto, Masafumi Harada, Tomoya Fukawa, Hiro-omi Kanayama, Takayuki Uchida, Toshio Suzuki and Takeshi Nikawa : Daily Dietary Supplementation with Steamed Soybean Improves Muscle Volume and Strength in Healthy People Lacking Exercise., Journal of Nutritional Science and Vitaminology, Vol.68, No.6, 521-526, 2022. (Summary) Various dietary protein supplements are used by the elderly and bedridden to maintain their skeletal muscle mass and functions. High-quality proteins act as an anabolic driver and help to improve muscle strength and performance. Previously, we reported that soy protein significantly attenuates denervation-induced loss of muscle mass and myofiber cross sectional area in mice with inhibition of ubiquitination and degradation of IRS-1 in tibialis anterior muscle. It also increased muscle volume and strength in bedridden patients. In the present study, we investigated the effects of dietary soybean supplementation on muscle functions in taxi drivers lacking vigorous physical exercise. We conducted a case-control study on 25 healthy, male taxi drivers between the ages of 36 and 71 y performing minimal physical exercise. They were divided into two dietary groups: the soybean diet group (n=13) who ate daily meals (dinner) supplemented with 50 g of steamed soybean for 30 d and the control diet group (n=12) who received no soybean supplement. Next, we measured the muscle cross-sectional area (CSA) and muscle strength and function in both the groups before and after 30 d of soybean intake. The body weights of both diet groups did not differ significantly over time. However, after 30 d of soybean supplementation, the soybean-fed group developed significantly higher muscle CSA and grip strength compared to the control groups. In conclusion, dietary soybean supplementation improved muscle function in taxi drivers who lacked exercise. (Keyword) Male / Animals / Mice / Soybeans / Case-Control Studies / Muscle, Skeletal / Dietary Supplements / Muscle Strength / Dietary Proteins (Link to Publication Site) ● Publication site (DOI): 10.3177/jnsv.68.521 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36596550 ● Search Scopus @ Elsevier (PMID): 36596550 ● Search Scopus @ Elsevier (DOI): 10.3177/jnsv.68.521 (DOI: 10.3177/jnsv.68.521, PubMed: 36596550)
15.	Kunihisa Yamaguchi, Yutaro Sasaki, Tomoya Fukawa, Masayuki Takahashi and Hiro-omi Kanayama : 腎移植後のリンパ漏にリンパ管造影が効果的であった3例, 日本臨床腎移植学会雑誌, Vol.1, No.19, 118-121, 2021. (Keyword) 腎移植 / リンパ漏 / リンパ管造影 / ジンイショク / リンパロウ / リンパカンゾウエイ (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1523388081028360448 (CiNii: 1523388081028360448)
16.	Yutaro Sasaki, 安宅真利花, 多田航生, 中西亮太, 橋本啓佑, 吉岡拓哉, Kei Daizumoto, Keisuke Ozaki, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hiro-omi Kanayama, Hideya Kashihara and Takuya Tokunaga : Two Cases of Robot-Assisted Total Pelvic Exenteration and Intracorporeal Ileal Conduit for Locally Advanced Rectal Cancer, Acta Urologica Japonica, Vol.68, No.5, 155-159, 2021. (Keyword) Robot-assisted total pelvic exenteration / Intracorporeal urinary diversion / Intracorporeal ileal conduit (Link to Publication Site) ● Publication site (DOI): 10.14989/actauroljap_68_5_155 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390855656035011840 ● Search Scopus @ Elsevier (DOI): 10.14989/actauroljap_68_5_155 (DOI: 10.14989/actauroljap_68_5_155, CiNii: 1390855656035011840)
17.	Yutaro Sasaki, 角陸文哉, 深谷友祐, 山本拓, Kei Daizumoto, Keisuke Ozaki, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : A Case of Robot-Assisted Radical Cystoprostatectomy for Locally Advanced Prostate Cancer with Bladder Infiltration, Acta Urologica Japonica, Vol.67, No.4, 163-166, 2021. (Summary) While robot-assisted radical cystoprostatectomy (RARC) for locally advanced prostate cancer (LAPC) may sometimes prove to be excessive treatment, it can significantly reduce the risk of positive surgical margins and lower urinary tract obstruction in some cases. Here, we report a case of LAPC treated with RARC in a patient with right hydronephrosis due to bladder infiltration and left hypoplastic kidney. A 71-year-old man presented with frequent urination in August 2019. Prostate-specific antigen (PSA) level was 8.633 ng/ml, and magnetic resonance imaging led to the suspicion that the prostate cancer extended beyond the prostate capsule without distant metastasis. Prostatic biopsy revealed Gleason score 10 (5+5) adenocarcinoma in 8 out of 8 specimens. We diagnosed left hypoplastic kidney and LAPC with right hydronephrosis due to bladder infiltration. We performed percutaneous right nephrostomy and started neoadjuvant hormone therapy. RARC and intracorporeal ileal conduit were performed in March 2020. The prostate was adherent to the anterior surface of the rectum and was difficult to remove. At present, five months after the surgery, the patient remains free of recurrence and metastasis with PSA level <0.003 ng/ml. RARC for LAPC with bladder infiltration can be an effective therapeutic strategy in some cases. (Keyword) Locally advanced prostate cancer / Bladder Invasion / Robot-assisted radical cystoprostatectomy (Link to Publication Site) ● Publication site (DOI): 10.14989/ActaUrolJap_67_4_163 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34107613 ● Summary page in Scopus @ Elsevier: 2-s2.0-85108011497 (DOI: 10.14989/ActaUrolJap_67_4_163, PubMed: 34107613, Elsevier: Scopus)
18.	Yutaro Sasaki, Masayuki Takahashi, Keisuke Ozaki, Kei Daizumoto, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : Efficacy of the direct grasping technique using pean forceps under fluoroscopy to replace ureteral stents in women, The Journal of Medical Investigation : JMI, Vol.3.4, No.68, 326-329, 2021. (Summary) Purpose : To evaluate the efficacy of the direct grasping technique using pean forceps under fluoroscopic guidance for ureteral stent replacement in women. Methods : Between April 2018 and September 2020, 28 female patients underwent ureteral stent replacements at our facility, and 184 stent replacement procedures were performed. A total of 127 stents were replaced using pean forceps under fluoroscopic guidance (pean forceps group), and 57 stents were replaced using the cystoscope (cystoscopy group). Clinical characteristics and surgical outcomes were compared between the groups. Results : All stents were successfully replaced. There was a statistically significant difference in the procedure time between the two groups (median [interquartile range], pean forceps group : 10.8 [8.2-13.9] minutes vs. cystoscopy group : 15.8 [11.1-20.9] minutes, P < 0.001). There were no intraoperative complications in either group and no difference in the incidence of postoperative complications (pean forceps group : 1.6% vs. cystoscopy group : 1.8%, P = 1.000). Fluoroscopy time was longer in the pean forceps group, although this difference was not statistically significant (pean forceps group : 38.9 [22.6-60.1] seconds vs. cystoscopy group : 33.0 [20.0-48.9] seconds, P = 0.0558). Conclusion : The direct grasping technique using pean forceps under fluoroscopy may be a beneficial alternative to cystoscopy for ureteral stent replacement in women. J. Med. Invest. 68 : 326-329, August, 2021. (Keyword) female / Fluoroscopy / Humans / Stents / Surgical Instruments / Ureter / Ureteral Obstruction (Tokushima University Institutional Repository) ● Metadata: 116511 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.326 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759153 ● Search Scopus @ Elsevier (PMID): 34759153 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.326 (Tokushima University Institutional Repository: 116511, DOI: 10.2152/jmi.68.326, PubMed: 34759153)
19.	Mitsuteru Yoshida, Akira Tangoku, Kousaku Higashino, Kazuya Kondo, Takashi Iwata, Masashi Akaike, Hiro-omi Kanayama and Yoshihiro Tsuruo : 【最先端医療を支える解剖学】呼吸器外科における最先端手術手技とCAL(Clinical Anatomy Laboratory), Shikoku Acta Medica, Vol.76, No.5-6, 225-234, 2020. (Summary) Recently, endoscopic surgery is the most common procedurein the field of thoracic surgery. The newestthoracic surgeryapproaches are the video-assisted thoracic surgery(VATS), the one-port video-assisted thoracic surgery, and the robotic surgery. The individual advantages and disadvantages of these procedures have been discussed. VATS covers a field of view of the surgical field from the leg to the head. The basic method in performing VATS is that the surgeon operates on the abdominal area of the patient and the assistant expands the surgical field from the patient's back. It is currently the standard surgical procedure. The advantage of one-port VATS is the one port itself and its cosmetic advantages and pain reduction. The advantage of robotic surgery is that it has a clear three-dimensional enlarged field of view and can be performed using the delicate moving robotic arm. However, a good surgical training system should be established for the familiarization of these procedures. The clinical anatomy laboratory is the most efficient surgical training in addition to dry and wet lab training. Our institution has fresh-frozen cadavers, which are rare in Japan. The participating thoracic surgeons underwent training for VATS lobectomy, subxiphoid extended thymectomy, and pleurectomy decortication. This training is beneficial for educational and clinical purposes. In the future, we must obtain consistent surgical education before and after graduation using fresh-frozen cadavers. At the same time, a good organ model for training is also necessary. The surgeon has to cooperate with anatomy doctors for the development of a good surgical organ model. For the development of future surgical medicine, surgical training programs should be implemented. (Keyword) thoracic surgery / fresh frozen cadaver / surgical training (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050005888447565312 (CiNii: 1050005888447565312)
20.	Yasuyo Yamamoto, Tomoya Fukawa, Megumi Tsuda, Tetsuhiro Yano, Kei Daizumoto, Yutaro Sasaki, Keisuke Ozaki, Yoshiteru Ueno, Yoshito Kusuhara, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : [A Case of Pelvic Organ Prolapse and Bladder Diverticulum Surgically Treated at the Same Time]., Acta Urologica Japonica, Vol.66, No.8, 269-272, 2020. (Summary) We report a case of bladder diverticulum presumably caused by lower urinary tract dysfunction due to pelvic organ prolapse (POP) simultaneously treated with transurethral coagulation (TUC) of the bladder diverticulum and laparoscopic sacrocolpopexy (LSC). A literature search showed this is the first report of bladder diverticulum and POP surgically treated at the same time. A 71-year-old woman was referred to our hospital for the treatment of cystocele. She had both storage and voiding symptoms. She had a POPQ stage III cystocele and stage I uterine prolapse. Ultrasonography and computed tomographic scan showed a large volume of residual urine along with a bladder diverticulum. Since urodynamic studies revealed a low compliance bladder and obstruction, we opined that the lower urinary tract symptoms were induced by the cystocele. TUC of the bladder diverticulum and LSC were performed at the same time. After the operation, clean intermittent catheterization (CIC) was needed once a day for one month. Gradually, residual urine decreased and CIC became unnecessary. The bladder diverticulum disappeared, and there has been no recurrence of POP. (Keyword) Aged / Diverticulum / female / Humans / Lower Urinary Tract Symptoms / Pelvic Organ Prolapse / Urinary Bladder / Urinary Bladder, Overactive (Link to Publication Site) ● Publication site (DOI): 10.14989/ActaUrolJap_66_8_269 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32882124 ● Summary page in Scopus @ Elsevier: 2-s2.0-85090318500 (DOI: 10.14989/ActaUrolJap_66_8_269, PubMed: 32882124, Elsevier: Scopus)
21.	Mitsuhiro Tsuboi, Mariko Aoyama, Hiromitsu Takizawa, Mitsuteru Yoshida, Takashi Iwata, Masashi Akaike, Hiro-omi Kanayama, Yoshihiro Tsuruo and Akira Tangoku : 内視鏡手術の教育システム, Official Journal of the Japan Association of Endocrine Surgeons and the Japanese Society of Thyroid Surgery, Vol.37, No.1, 22-26, 2020. (Link to Publication Site) ● Publication site (DOI): 10.11226/jaesjsts.37.1_22 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390848250117531136 ● Search Scopus @ Elsevier (DOI): 10.11226/jaesjsts.37.1_22 (DOI: 10.11226/jaesjsts.37.1_22, CiNii: 1390848250117531136)
22.	Maiko Sogawa, Kazutoshi Murao, Yoshiaki Kubo, Kei Daizumoto and Hiro-omi Kanayama : 顔面に皮疹を認めなかったBirt-Hogg-Dube症候群の1例, Japanese Journal of Clinical Dermatology, Vol.73, No.13, 1089-1094, 2019. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390565134811658112 (CiNii: 1390565134811658112)
23.	Yoshito Kusuhara, Kei Daizumoto, Kaichi Kawai, Kento Hirayama, Minoru Kowada, Terumichi Shintani, Yayoi Fukuhara, Tsogt-Ochir Dondoo, Keisuke Ozaki, Megumi Tsuda, Tomoya Fukawa, Hiroyoshi Nakatsuji, Yoshimi Bando, Hisanori Uehara, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : Low Expression of Toll-like Receptor 4 Is Associated With Poor Prognosis in Bladder Cancer., Anticancer Research, Vol.39, No.2, 703-711, 2019. (Summary) Low TLR4 expression was correlated with tumor progression. (Keyword) Aged / Biomarkers, Tumor / Cell Differentiation / Cell Line, Tumor / Computational Biology / Disease Progression / Female / Gene Expression Profiling / Gene Expression Regulation, Neoplastic / Humans / Immunohistochemistry / Male / Middle Aged / Neoplasm Invasiveness / Oligonucleotide Array Sequence Analysis / Prognosis / RNA, Small Interfering / Toll-Like Receptor 4 / Urinary Bladder Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.13166 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30711948 ● Search Scopus @ Elsevier (PMID): 30711948 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.13166 (DOI: 10.21873/anticanres.13166, PubMed: 30711948)
24.	Yoshito Kusuhara, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 腎摘除術, 副腎摘除術における血管処理のポイント, Japanese Journal of Endourology, Vol.32, No.1, 62-65, 2019. (Summary) <p> 腹腔鏡下腎摘除術や副腎摘除術は, 簡便な低侵襲手術として標準化され普及している. 本項では, 腎茎の血管処理を安全に遂行するための術前準備, 血管処理の基本について述べた. 術前に血管走行などの作図を行い, 手術手順を確認する準備が重要である. 術前に把握されていない構造物に遭遇した際には, 手技を中断し, 画像を見直すことで安全に手術を遂行できる. また, 手術後に手術動画を省みることで, 画像読影力や作図能力は向上していく.</p><p> 血管処理は, 「血管以外の組織を凝固切離した結果, 血管だけが残った」という考えで, 丁寧に基本に忠実に行う. 助手の術野展開と鏡の選定を行い, 処理に適した角度から良好な視野を得る. 血管は把持せず, 血管に垂直に鉗子を動かし剥離を行う. 微量な出血も放置せず, その都度止血し無血野を保つ. 各種デバイスの特性を理解し, 処理に最適なデバイスを選択する.</p> (Tokushima University Institutional Repository) ● Metadata: 115193 (Link to Publication Site) ● Publication site (DOI): 10.11302/jsejje.32.62 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390564238108124416 ● Search Scopus @ Elsevier (DOI): 10.11302/jsejje.32.62 (Tokushima University Institutional Repository: 115193, DOI: 10.11302/jsejje.32.62, CiNii: 1390564238108124416)
25.	Shinji Nagasaka, Yoshiro Abe, 佐々木健介, Masahiro Yamano, Hideki Nakanishi, Kunihisa Yamaguchi, Hiro-omi Kanayama and Ichiro Hashimoto : 皮島の一部を脱上皮した遊離前外側大腿皮弁で腹壁を再建した臍部尿膜管癌の1例, Journal of Japan Society of Plastic and Reconstructive Surgery, Vol.38, No.9, 496-503, 2018.
26.	Tomoya Fukawa and Hiro-omi Kanayama : Current knowledge of risk factors for testicular germ cell tumors., International Journal of Urology, Vol.25, No.4, 337-344, 2018. (Summary) The development of the human gonads is tightly regulated by the correct sequential expression of many genes and hormonal activity. Disturbance of this regulation does not only prevent proper development of the gonads, but it also contributes to the development of testicular germ cell tumors. Recent genetic studies, especially genome-wide association studies, have made great progress in understanding genetic susceptibility. Although there is strong evidence of inherited risks, many environmental factors also contribute to the development of testicular germ cell tumors. Histopathological studies have shown that most testicular germ cell tumors arise from germ cell neoplasia in situ, which is thought to be arrested and transformed primordial germ cells. Seminoma has features identical to germ cell neoplasia in situ or primordial germ cells, whereas non-seminoma shows varied differentiation. Seminomas and embryonic cell carcinomas have the feature of pluripotency, which is thought to be the cause of histological heterogeneity and mixed pathology in testicular germ cell tumors. Testicular germ cell tumors show high sensitivity to chemotherapies, but 20-30% of patients show resistance to standard chemotherapy. In the present review, the current knowledge of the epidemiological and genomic factors for the development of testicular germ cell tumors is reviewed, and the mechanisms of resistance to chemotherapies are briefly mentioned. (Keyword) oncology / Testicular tumor (Link to Publication Site) ● Publication site (DOI): 10.1111/iju.13519 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29345008 ● Search Scopus @ Elsevier (PMID): 29345008 ● Search Scopus @ Elsevier (DOI): 10.1111/iju.13519 (DOI: 10.1111/iju.13519, PubMed: 29345008)
27.	Satoru Shimochi, Kei Daizumoto, Keisuke Ozaki, Yoshito Kusuhara, Tomoya Fukawa, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : [Renal Angiomyolipoma Extending into the Renal Vein --A Case Report-]., Acta Urologica Japonica, Vol.64, No.5, 213-217, 2018. (Summary) We report a case of left renal angiomyolipoma extending into the renal vein. A 67-year-old woman showed a left renal tumor which was 6 cm in diameter and had density equal to fat tissue in computed tomography. We suspected liposarcoma and performed radical nephrectomy and resection of thrombus. The pathological diagnosis was angiomyolipoma with no malignancy. To our knowledge, renal angiomyolipoma with tumor thrombus has been reported in 62 cases, and pulmonary embolism developed in 9 of these cases. We conclude that surgical treatment is effective in treating angiomyolipoma with tumor thrombus. (Keyword) Aged / Angiomyolipoma / Female / Humans / Kidney Neoplasms / Nephrectomy / Renal Veins / Thrombosis / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.14989/ActaUrolJap_64_5_213 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30064160 ● Search Scopus @ Elsevier (PMID): 30064160 ● Search Scopus @ Elsevier (DOI): 10.14989/ActaUrolJap_64_5_213 (DOI: 10.14989/ActaUrolJap_64_5_213, PubMed: 30064160)
28.	Kei Daizumoto, Tetsuro Yoshimaru, Yosuke Matsushita, Tomoya Fukawa, Hisanori Uehara, Masaya Ono, Masato Komatsu, Hiro-omi Kanayama and Toyomasa Katagiri : A DDX31/mutant-p53/EGFR axis promotes multistep progression of muscle invasive bladder cancer, Cancer Research, Vol.78, No.9, 2233-2247, 2018. (Summary) The p53 and EGFR pathways are frequently altered in bladder cancer, yet their contributions to its progression remain elusive. Here we report that DEAD box polypeptide 31 (DDX31) plays a critical role in the multistep progression of muscle-invasive bladder cancer (MIBC) through its sequential interactions with mutant p53 (mutp53) and EGFR. In early MIBC cells, nuclear DDX31-bound mutp53/SP1 enhanced mutp53 transcriptional activation, leading to migration and invasion of MIBC. Cytoplasmic DDX31 also bound EGFR and phospho-nucleolin in advanced MIBC, leading to EGFR-Akt signaling activation. High expression of both cytoplasmic DDX31 and p53 proteins correlated with poor prognosis in patients with MIBC, and blocking the DDX31/NCL interaction resulted in downregulation of EGFR/Akt signaling, eliciting an antitumor effect against bladder cancer. These findings reveal that DDX31 cooperates with mutp53 and EGFR to promote progression of MIBC, and inhibition of DDX31/NCL formation may lead to potential treatment strategies for advanced MIBC. DDX31 cooperates with mutp53 and EGFR to promote progression of muscle invasive bladder cancer. . (Tokushima University Institutional Repository) ● Metadata: 111804 (Link to Publication Site) ● Publication site (DOI): 10.1158/0008-5472.CAN-17-2528 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29440146 ● Search Scopus @ Elsevier (PMID): 29440146 ● Search Scopus @ Elsevier (DOI): 10.1158/0008-5472.CAN-17-2528 (Tokushima University Institutional Repository: 111804, DOI: 10.1158/0008-5472.CAN-17-2528, PubMed: 29440146)
29.	Masayuki Takahashi and Hiro-omi Kanayama : 【小児腹腔内精巣-どう扱うか?】腹腔内精巣に対する腹腔鏡下二期的Fowler-Stephens法, Japanese Journal of Endourology, Vol.31, No.1, 51-54, 2018. (Link to Publication Site) ● Publication site (DOI): 10.11302/jsejje.31.51 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.11302/jsejje.31.51 (DOI: 10.11302/jsejje.31.51)
30.	Kunihisa Yamaguchi and Hiro-omi Kanayama : An in Vitro study of a new device : Evaluation of novel wide-angle lens flexible cystoscope using phantom bladder model, Journal of Endourology, Vol.31, No.10, 1073-1078, 2017. (Summary) The features and usefulness of a novel wide-angle lens flexible cystoscope were assessed with a view to its practical application. A phantom bladder model, on which a total of 12 markers that resemble lesions were arranged, was created for this study. Twenty-six urologists at three institutions observed this phantom bladder model using a conventional flexible cystoscope and a novel wide-angle lens flexible cystoscope, and they compared the observation time, marker detection rate, number of misidentified marker locations, overlooked locations, and misidentified location sites of both devices. Specific observation procedures that make use of the features of a wide-angle lens flexible cystoscope were also investigated. The observation time tended to be shorter with the wide-angle lens cystoscope than with a conventional cystoscope (104.9 seconds vs 113.6 seconds, p = 0.123). The marker detection rate was higher with the wide-angle lens cystoscope (90.2% vs 85.1%, p = 0.005). The number of marker location misidentifications did not differ between the two devices. Using a specifically designed observation procedure with the wide-angle lens cystoscope tended to further improve the marker detection rate (91.4% vs 88.1%, p = 0.157). Compared with a conventional cystoscope, a wide-angle lens cystoscope improved the lesion detection rate and has the potential to reduce observation time. The novel wide-angle lens flexible cystoscope is regarded as a useful device that offers advantages not available with a conventional cystoscope. (Keyword) Cystoscopes / Cystoscopy / Equipment Design / Humans / Lenses / Models, Biological / Phantoms, Imaging / Urinary Bladder Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1089/end.2017.0371 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28726499 ● Summary page in Scopus @ Elsevier: 2-s2.0-85031816821 (DOI: 10.1089/end.2017.0371, PubMed: 28726499, Elsevier: Scopus)
31.	Kojiro Nagai, Motokazu Matsuura, Kenji Tsuchida, Hiro-omi Kanayama, Toshio Doi and Jun Minakuchi : Prognostic factors for mortality in middle-aged and older hemodialysis patients: a 5-year observational study., Journal of Artificial Organs, Vol.21, No.1, 94-101, 2017. (Summary) -microglobulin and calcium concentration controlled by hemodialysis prescriptions were independent risk factors especially in older patients, not in middle-aged patients. In conclusion, hemodialysis prescriptions for lowering uremic toxins and managing mineral-bone disorder are important to decrease the risk of death even in older hemodialysis patients. (Keyword) Renal Dialysis / Retrospective Studies / Risk Factors (Link to Publication Site) ● Publication site (DOI): 10.1007/s10047-017-0993-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28918555 ● Search Scopus @ Elsevier (PMID): 28918555 ● Search Scopus @ Elsevier (DOI): 10.1007/s10047-017-0993-2 (DOI: 10.1007/s10047-017-0993-2, PubMed: 28918555)
32.	Hidehisa Mori, Tomoharu Fukumori, KEI DAIZUMOTO, MEGUMI TSUDA, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Hiro-omi Kanayama : Predictive Factors for Prolonged Urination Disorder After Permanent 125I Brachytherapy for Localized Prostate Cancer, In Vivo, Vol.31, No.4, 755-761, 2017. (Summary) We assessed the change in LUTS after prostate brachytherapy to reveal factors for prolonged urination disorder. Four hundred and four patients received prostate brachytherapy at our institution and were followed-up for at least 2 years. We evaluated the correlation of mean IPSS changes and clinical factors. Using multivariate analysis, we also evaluated clinical factors with potential to delay IPSS resolution. In cases with prostate volume more than 30 cm, radiation dose to 90% of prostate volume (D90) more than 160 Gy, and radiation dose to 30% of the urethral volume (UD30) more than 240 Gy, mean IPSS levels were significantly higher, even 30 months after treatment. On multivariate analysis, baseline IPSS more than 8 points and D90 more than 160 Gy were significant predictors for delayed IPSS resolution. Our data suggest that higher baseline IPSS and higher D90 were predictors for prolonged urination disorder. (Keyword) Aged / Aged, 80 and over / Brachytherapy / Humans / Iodine Radioisotopes / male / Middle Aged / Prostate / Prostate-Specific Antigen / Prostatic Neoplasms / Urination Disorders (Tokushima University Institutional Repository) ● Metadata: 113626 (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.11127 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28652453 ● Summary page in Scopus @ Elsevier: 2-s2.0-85028539877 (Tokushima University Institutional Repository: 113626, DOI: 10.21873/invivo.11127, PubMed: 28652453, Elsevier: Scopus)
33.	Kojiro Nagai, Kenji Tsuchida, Noriyuki Ishihara, Naoto Minagawa, Go Ichien, Satoshi Yamada, Daisuke Hirose, Hiroyuki Michiwaki, Hiro-omi Kanayama, Toshio Doi and Jun Minakuchi : Implications of Albumin Leakage for Survival in Maintenance Hemodialysis Patients: A 7-year Observational Study., Therapeutic Apheresis and Dialysis, 2017. (Summary) Albumin leakage during hemodialysis (HD) presents a clinical dilemma. However, protein-binding uremic toxins are suggested to be responsible for increased mortality. No one has investigated the relationship between albumin leakage and mortality. Therefore, the purpose of this observational study was to analyze the association of albumin leakage with mortality in 690 HD patients who survived one year after enrollment. They were divided to three groups who received HD with large (3 g or more per HD session), middle (1 to 3 g) or small (less than 1 g) amount of albumin leakage, respectively. A propensity score analysis minimizing indication bias was performed. Consequently, in a 7-year observation period, 212 patients died. Albumin leakage 3 g or more per HD session provided better prognosis than albumin leakage less than 3 g per HD session. In conclusion, clinically acceptable large albumin leakage provides beneficial effects on mortality in maintenance HD patients. (Link to Publication Site) ● Publication site (DOI): 10.1111/1744-9987.12526 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28452109 ● Search Scopus @ Elsevier (PMID): 28452109 ● Search Scopus @ Elsevier (DOI): 10.1111/1744-9987.12526 (DOI: 10.1111/1744-9987.12526, PubMed: 28452109)
34.	Terumichi Shintani, Yoshito Kusuhara, Kei Daizumoto, Tsogt-Ochir Dondoo, Yasuyo Yamamoto, Hidehisa Mori, Tomoya Fukawa, Hiroyoshi Nakatsuji, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells., Urology, Vol.101, 169.e7-169.e13, 2017. (Summary) To clarify the invasive mechanisms of muscle-invasive bladder cancer (BCa) would be useful for the determination of appropriate treatment strategies. We previously showed that hepatocyte growth factor (HGF)-MET signaling is correlated with invasiveness of BCa cells. Here, we investigated the effects of the MET inhibitor, cabozantinib (XL184), on BCa cells. We first conducted Western blot analysis to investigate MET expression in BCa cell lines. Next, we examined the effect of cabozantinib on their proliferation and invasive abilities using MTT and Matrigel invasion assays, respectively. Invasion assays were performed using the xCELLigence system. Additionally, to investigate the biological function of HGF-MET signaling, we analyzed gene expression profiles and performed real-time polymerase chain reaction analyses of 5637 cells that were cultivated with or without HGF stimulation, with or without cabozantinib. MET was highly expressed in 4 of 5 BCa cell lines, and 5637 and T24 cells showed especially high protein expression of MET. Cabozantinib suppressed cell proliferation and invasion (cell index; mock, 1.49 vs HGF, 2.26 vs HGF + XL184, 1.47, P < .05). Gene expression profile analysis indicated that matrix metalloproteinase 1 (MMP1) was significantly elevated at the mRNA level with addition of HGF. Moreover, cabozantinib suppressed HGF-induced MMP1 expression in 5637 T24 cells. These data indicate that cabozantinib suppressed MMP1 expression by blocking HGF-MET signaling and that HGF-MET-MMP1 signaling is involved in the invasiveness and proliferation of BCa cells. These results suggest that cabozantinib might prove useful for future treatment of muscle-invasive BCa. (Keyword) Anilides / Blotting, Western / Cell Count / Cell Line, Tumor / Cell Proliferation / Gene Expression Regulation, Neoplastic / Hepatocyte Growth Factor / Humans / Matrix Metalloproteinase 1 / Neoplasm Invasiveness / Protein Array Analysis / Proto-Oncogene Proteins c-met / Pyridines / RNA, Neoplasm / Receptor Protein-Tyrosine Kinases / Reverse Transcriptase Polymerase Chain Reaction / signal transduction / Urinary Bladder / Urinary Bladder Neoplasms (Tokushima University Institutional Repository) ● Metadata: 110112 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.urology.2016.12.006 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28013036 ● Summary page in Scopus @ Elsevier: 2-s2.0-85009932260 (Tokushima University Institutional Repository: 110112, DOI: 10.1016/j.urology.2016.12.006, PubMed: 28013036, Elsevier: Scopus)
35.	Michio Shimabukuro, H Sato, Hirofumi Izaki, Daiju Fukuda, E Uematsu, Y Hirata, Shusuke Yagi, Takeshi Soeki, Hiroshi Sakaue, Hiro-omi Kanayama, H Masuzaki and Masataka Sata : Depot- and gender-specific expression of NLRP3 inflammasome and toll-like receptors in adipose tissue of cancer patients., BioFactors, Vol.42, No.4, 397-406, 2016. (Keyword) obesity / inflammation / gender (Link to Publication Site) ● Publication site (DOI): 10.1002/biof.1287 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27086574 ● Summary page in Scopus @ Elsevier: 2-s2.0-84982113330 (DOI: 10.1002/biof.1287, PubMed: 27086574, Elsevier: Scopus)
36.	Kojiro Nagai, Kenji Tsuchida, Daisuke Hirose, Hiroyuki Michiwaki, Michael Hann, Hiro-omi Kanayama, Toshio Doi and Jun Minakuchi : The effect of albumin leakage in hemodialysis patients on redox status of serum albumin., Journal of Artificial Organs, 2016. (Summary) Human mercaptoalbumin (HMA) is a reduced form of albumin that is associated with cardiovascular disease in dialysis patients. Albumin-leaky hemodialysis (HD) is increasingly recognized as a gold standard therapy because it is correlated with better prognosis compared to conventional HD. However, albumin-leaky HD induces low serum albumin concentration because of albumin leakage, which is a classical risk factor for mortality. The aim of this study was to explain the preferable prognosis in patients undergoing albumin-leaky HD with low serum albumin concentration. Ten HD patients were enrolled. They were preconditioned with albumin-non-leaky HD (mean albumin leakage: 1.0 g) for 2 months. Subsequently, albumin-leaky HD (9.1 g) was performed for 6 months, followed by relatively non-leaky HD (within 3.0 g). The ratio and level of HMA were evaluated. The amount of albumin leakage was related to the ratio of HMA, and inversely correlated with serum albumin concentration. The level of HMA was maintained regardless of albumin leakage. Regarding HMA level, a moderate amount of albumin leakage was acceptable. A stably maintained HMA level in albumin-leaky HD patients can contribute to preferable prognosis even if they have low serum albumin concentration. (Link to Publication Site) ● Publication site (DOI): 10.1007/s10047-016-0900-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27086124 ● Search Scopus @ Elsevier (PMID): 27086124 ● Search Scopus @ Elsevier (DOI): 10.1007/s10047-016-0900-2 (DOI: 10.1007/s10047-016-0900-2, PubMed: 27086124)
37.	Masayuki Takahashi and Hiro-omi Kanayama : LAPAROSCOPIC PYELOPLASTY IN CHILDREN-ADVANCEMENT OF NEW TECHNIQUES, The Nishinihon Journal of Urology, Vol.78, No.4, 172-177, 2016. (Keyword) 腹腔鏡下腎盂形成術 / 経腹膜 / 後腹膜 / 経腸間膜 / 単孔式腹腔鏡下手術 / laparoscopic pyeloplasty / transperitoneal / retroperitoneal / transmesenteric / laparoendoscopic single-site (LESS) (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520572358445395200 ● Summary page in Scopus @ Elsevier: 2-s2.0-84973661387 (CiNii: 1520572358445395200, Elsevier: Scopus)
38.	Tomokazu Senzaki, Tomoharu Fukumori, Hidehisa Mori, Yoshito Kusuhara, Masatsugu Komori, Junichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Hiro-omi Kanayama : Clinical Significance of Neoadjuvant Combined Androgen Blockade for More Than Six Months in Patients with Localized Prostate Cancer Treated with Prostate Brachytherapy., Urologia Internationalis, Vol.95, No.4, 457-464, 2015. (Summary) The aim of this study is to clarify the clinical significance of neoadjuvant combined androgen blockade (CAB) for ≥ 6 months in patients with localized prostate cancer. A total of 431 patients with localized prostate cancer who underwent prostate brachytherapy (BT) with or without neoadjuvant CAB for ≥ 6 months with mean follow-up time of 64.6 months (range 24-108 months) were evaluated retrospectively. Of those 431, 232 patients received BT in combination with neoadjuvant CAB for ≥ 6 months. Biochemical recurrence-free rates (BRFRs) in 364 patients with at least 3 years of follow-up were evaluated by log-rank test. BRFR in patients with low-, intermediate- and high-risk prostate cancer were 98.1, 94.2 and 89.1%, respectively. In patients with intermediate-risk prostate cancer only, neoadjuvant CAB was significantly associated with BRFR (p = 0.0468). Especially in patients with intermediate-risk prostate cancer with radiation dose received by 90% of the prostate (D90) < 180 Gy, neoadjuvant CAB exerted a favorable impact on BRFR (p = 0.0429). On multivariate analyses, neoadjuvant CAB and D90 were independent predictors of BRFR (p = 0.0061 and p < 0.0001, respectively). Neoadjuvant CAB for ≥ 6 months has a favorable impact on BRFR in patients with intermediate-risk prostate cancer, particularly in patients with relatively low radiation doses of D90. (Link to Publication Site) ● Publication site (DOI): 10.1159/000439573 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26461847 ● Search Scopus @ Elsevier (PMID): 26461847 ● Search Scopus @ Elsevier (DOI): 10.1159/000439573 (DOI: 10.1159/000439573, PubMed: 26461847)
39.	Narushi Yokota, Kojiro Nagai, Daigo Okada, Yasuto Muromiya, Takehiro Suenaga, Yuka Ueda, Kana Kawahara, Hiro-omi Kanayama, Jun Minakuchi and Kenji Tsuchida : Vascular access for long-term hemodialysis/hemodiafiltration patients., The Journal of Vascular Access, Vol.16 Suppl 10, S18-21, 2015. (Summary) The present results suggest that the ratio of patients with AVG increased with prolonged HD/HDF treatment. AVG has a higher probability of complications and lower patency as compared to AVF, thus careful management is needed. On the other hand, AVG contributes more to a good long prognosis, as it offers efficient dialysis. In cases of vascular deterioration due to long-term hemodialysis, it is inevitable to change from AVF to AVG, thus the ratio of AVG patients is expected to increase in cases of long-term HD/HDF. (Link to Publication Site) ● Publication site (DOI): 10.5301/jva.5000427 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26429128 ● Search Scopus @ Elsevier (PMID): 26429128 ● Search Scopus @ Elsevier (DOI): 10.5301/jva.5000427 (DOI: 10.5301/jva.5000427, PubMed: 26429128)
40.	Yuka Ueda, Kenji Tsuchida, Daigo Okada, Yasuto Muromiya, Takehiro Suenaga, Narushi Yokota, Kana Kawahara, Kojiro Nagai, Hiro-omi Kanayama and Jun Minakuchi : Evaluation of sterilization using the MEH200® (cotton pack) in vascular access puncture., The Journal of Vascular Access, Vol.16 Suppl 10, S70-3, 2015. (Summary) In HD patients, the MEH200® may be effective for the prevention of bacteremia. (Link to Publication Site) ● Publication site (DOI): 10.5301/jva.5000414 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26349880 ● Search Scopus @ Elsevier (PMID): 26349880 ● Search Scopus @ Elsevier (DOI): 10.5301/jva.5000414 (DOI: 10.5301/jva.5000414, PubMed: 26349880)
41.	Kojiro Nagai, Kenji Tsuchida, Maki Sasada, Narushi Yokota, Masaaki Nishitani, Hiro-omi Kanayama and Jun Minakuchi : Reduction or discontinuation of antibiotic prophylaxis in vascular access surgery, tendon sheath incision and PD catheter placement., The Journal of Vascular Access, Vol.16 Suppl 10, S66-9, 2015. (Summary) Even in dialysis patients, neither pre- nor postoperative antibiotics are necessary for AVF and tendon sheath incision surgeries. AVG and PD catheter placement surgeries require only a small amount of antibiotics preoperatively. (Link to Publication Site) ● Publication site (DOI): 10.5301/jva.5000423 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26349895 ● Search Scopus @ Elsevier (PMID): 26349895 ● Search Scopus @ Elsevier (DOI): 10.5301/jva.5000423 (DOI: 10.5301/jva.5000423, PubMed: 26349895)
42.	Hiro-omi Kanayama, Tomoharu Fukumori, Hiroyuki Fujimoto, Hiroyuki Nakanishi, Chikara Ohyama, Kazuhiro Suzuki, Hiroyuki Nishiyama, Masatoshi Eto, Tsuneharu Miki, Kazumi Kamoi, Yoshinobu Kubota, Satoru Takahashi, Yukio Homma and Seiji Naito : Clinicopathological characteristics and oncological outcomes in patients with renal cell carcinoma registered in 2007: The first large-scale multicenter study from the Cancer Registration Committee of the Japanese Urological Association., International Journal of Urology, Vol.22, No.9, S1-7, 2015. (Summary) To describe the clinicopathological features and oncological outcomes of renal cell carcinoma diagnosed in Japan in 2007, the results of the large-scale renal cell carcinoma registration study carried out by the Japanese Urological Association are reported. The renal cell carcinoma survey was carried out by the Japanese Urological Association in 2012 to register newly diagnosed renal cell carcinoma cases in 2007 from 340 institutions nationwide. The survey included clinicopathological details, such as sex, age, family history, past history, smoking history, body mass index, reason for diagnosis, TNM classification, stage, histopathology, treatment and clinical outcomes. A total of 3663 cases diagnosed in 2007 were registered in this renal cell carcinoma registry program from 340 institutions. A total of 15 patients with a final diagnosis of oncocytoma were excluded, and 3648 cases of renal cell carcinoma were analyzed to evaluate oncological outcomes. The patients' median age was 63.9 years (range 5.9-95.1 years). Clear cell renal cell carcinoma was the most common histological subtype (77.2%), followed by papillary (5.0%) and chromophobe (3.2%) renal cell carcinoma. The most common initial treatment was radical nephrectomy (72.6%), and the most common secondary treatment was cytokine therapy (13.1%). Five-year overall survival rates in stages I, II, III, and IV were 94.8%, 90.2%, 78.8% and 39.6%, respectively. The 5-year overall survival rates for clear cell, papillary and chromophobe renal cell carcinomas, and carcinoma of the collecting ducts of Bellini were 88.6%, 79.8%, 93.0% and 40.0%, respectively. The present report is the first nationwide large-scale study to describe the clinicopathological characteristics and oncological outcomes of patients with renal cell carcinoma in Japan. Oncological outcomes depend on the clinical stage and histological subtype. Further investigations will be required to show improved oncological outcomes in the molecular targeted therapy era using the results of the present study as a baseline. (Keyword) Adolescent / Adult / Aged / Aged, 80 and over / Antineoplastic Agents / Carcinoma, Renal Cell / children / Child, Preschool / Female / Humans / Japan / Kidney Neoplasms / Male / Middle Aged / Neoplasm Staging / Nephrectomy / Registries / Survival Rate / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.1111/iju.12826 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26332059 ● Summary page in Scopus @ Elsevier: 2-s2.0-84940772132 (DOI: 10.1111/iju.12826, PubMed: 26332059, Elsevier: Scopus)
43.	Yasuto Muromiya, Kojiro Nagai, Narushi Yokota, Daigo Okada, Takehiro Suenaga, Yuka Ueda, Kana Kawahara, Hiro-omi Kanayama, Jun Minakuchi and Kenji Tsuchida : Factors associated with pain during vascular access intervention therapy., The Journal of Vascular Access, Vol.16 Suppl 10, S43-5, 2015. (Summary) The reason for severe pain with use of the semi-compliant balloon as compared with the other types might have been due to its characteristics during inflation, as increased diameter leads to an increase in pressure. Mismatching of balloon diameter to vascular diameter may also increase pain. (Link to Publication Site) ● Publication site (DOI): 10.5301/jva.5000425 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26429126 ● Search Scopus @ Elsevier (PMID): 26429126 ● Search Scopus @ Elsevier (DOI): 10.5301/jva.5000425 (DOI: 10.5301/jva.5000425, PubMed: 26429126)
44.	Kenji Tsuchida, Kojiro Nagai, Narushi Yokota, Daigo Okada, Yasuhito Muromiya, Takehiro Suenaga, Yuka Ueda, Kana Kawahara, Hiro-omi Kanayama and Jun Minakuchi : Simple surgical method for a native arteriovenous fistula of chronic hemodialysis patients and the patency rate., The Journal of Vascular Access, Vol.16 Suppl 10, S13-7, 2015. (Summary) The AVF is considered as the vascular access with the highest patency rate in the chronic hemodialysis patients. However, the factor influencing this rate is gender. In conclusion, female has a higher risk than male. (Link to Publication Site) ● Publication site (DOI): 10.5301/jva.5000408 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26349888 ● Search Scopus @ Elsevier (PMID): 26349888 ● Search Scopus @ Elsevier (DOI): 10.5301/jva.5000408 (DOI: 10.5301/jva.5000408, PubMed: 26349888)
45.	Akira Yokomizo, Yusuke Kanimoto, Takehiko Okamura, Seiichiro Ozono, Hirofumi Koga, Masatsugu Iwamura, Hiroshi Tanaka, Satoru Takahashi, Tomoyasu Tsushima, Hiro-omi Kanayama, Hideyuki Akaza, Nobuo Shinohara, Soichi Mugiya, Koichiro Nomata, Tsuyoshi Nakamura and Seiji Naito : Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer., The Journal of Urology, Vol.195, No.1, 41-46, 2015. (Summary) The optimal dose of intravesical bacillus Calmette-Guérin for the treatment of nonmuscle invasive bladder cancer is controversial. We investigated if induction therapy with low dose bacillus Calmette-Guérin could achieve a complete response rate similar to that of standard dose bacillus Calmette-Guérin, with less toxicity and higher quality of life. After transurethral resection, patients with unresectable multiple nonmuscle invasive bladder cancer and/or carcinoma in situ were randomized to receive standard (80 mg) or low dose (40 mg) bacillus Calmette-Guérin instillation induction therapy (weekly, 8 times). The primary end point was noninferiority of low dose bacillus Calmette-Guérin with a null hypothesis of a 15% decrease in complete response rate. Secondary end points were recurrence-free survival, progression-free survival, overall survival, patient compliance, adverse events and quality of life using the EORTC QLQ-C30. In an intent to treat analysis of 166 patients the complete response rates for low dose and standard dose bacillus Calmette-Guérin were 79% (95% CI 0.70-0.88) and 85% (95% CI 0.77-0.92), respectively. Dunnett-Gent analysis revealed that the null hypothesis of inferiority of low dose bacillus Calmette-Guérin in terms of complete response could not be rejected (p = 0.119). However, there were no significant differences between the groups in terms of recurrence, progression and overall survival. Low dose bacillus Calmette-Guérin was associated with significantly less fever (p = 0.001) and micturition pain (p = 0.047), and significantly higher quality of life scores for global quality of life, role functioning and functional impairment. The noninferiority of low dose bacillus Calmette-Guérin was not proven. However, low dose bacillus Calmette-Guérin was associated with lower toxicity and higher quality of life compared to standard dose bacillus Calmette-Guérin in patients with nonmuscle invasive bladder cancer. (Keyword) Adjuvants, Immunologic / Administration, Intravesical / Aged / BCG Vaccine / Female / Humans / Male / Neoplasm Invasiveness / Quality of Life / Treatment Outcome / Urinary Bladder Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1016/j.juro.2015.08.075 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26307162 ● Search Scopus @ Elsevier (PMID): 26307162 ● Search Scopus @ Elsevier (DOI): 10.1016/j.juro.2015.08.075 (DOI: 10.1016/j.juro.2015.08.075, PubMed: 26307162)
46.	小居浩之, 大豆本圭, Yasuyo Yamamoto, Jun-ichiro Kagawa, Masatsugu Komori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Hirofumi Izaki : RETROPERITONEAL SCHWANNOMA WITH INCREASED F18-FLUORODEOXYGLUCOSE UPTAKE ON POSITRON EMISSION TOMOGRAPHY : A CASE REPORT, The Nishinihon Journal of Urology, Vol.77, No.8, 297-301, 2015. (Keyword) 後腹膜神経鞘腫 / ¹⁸F-FDGPET-CT / retroperitoneal schwannoma (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520853833143993344 ● Summary page in Scopus @ Elsevier: 2-s2.0-84941121427 (CiNii: 1520853833143993344, Elsevier: Scopus)
47.	Kenji Yoshida, Akira Yokomizo, Tadashi Matsuda, Tsutomu Hamasaki, Yukihiro Kondo, Kunihisa Yamaguchi, Hiro-omi Kanayama, Yoshiaki Wakumoto, Shigeo Horie and Seiji Naito : The Advantage of a Ureteroscopic Navigation System with Magnetic Tracking in Comparison with Simulated Fluoroscopy in a Phantom Study., Journal of Endourology, Vol.29, No.9, 1059-1064, 2015. (Summary) To assess whether our ureteroscopic real-time navigation system has the possibility to reduce radiation exposure and improve performance of ureteroscopic maneuvers in surgeons of various ages and experience levels. Our novel ureteroscopic navigation system used a magnetic tracking device to detect the position of the ureteroscope and display it on a three-dimensional image. We recruited 31 urologists from five institutions to perform two tasks. Task 1 consisted of finding three internal markings on the phantom calices. Task 2 consisted of identifying all calices by ureteroscopy. In both tasks, participants performed with simulated fluoroscopy first, followed by our navigation system. Accuracy rates (AR) for identification, required time (T) for completing the task, migration length (ML), and time exposed to simulated fluoroscopy were recorded. The AR, T, and ML for both tasks were significantly better with the navigation system than without it (Task 1 with simulated fluoroscopy vs with navigation: AR 87.1 % vs 98.9%, P=0.003; T 355 s vs 191 s, P<0.0001; ML 4627 mm vs 2701 mm, P<0.0001. Task 2: AR 88.2% vs 96.7%, P=0.011; T 394 s vs 333 s, P=0.027; ML 5966 mm vs 5299 mm, P=0.0006). In both tasks, the participants used the simulated fluoroscopy about 20% of the total task time. Our navigation system, while still under development, could help surgeons of all levels to achieve better performances for ureteroscopic maneuvers compared with using fluoroscopic guidance. It also has the potential to reduce radiation exposure during fluoroscopy. (Keyword) Computer Simulation / Female / Fluoroscopy / Humans / Imaging, Three-Dimensional / Magnetic Resonance Imaging / Magnetics / Male / Phantoms, Imaging / Reproducibility of Results / Surgery, Computer-Assisted / Ureteroscopes / Ureteroscopy / Urology (Link to Publication Site) ● Publication site (DOI): 10.1089/end.2015.0054 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25793540 ● Search Scopus @ Elsevier (PMID): 25793540 ● Search Scopus @ Elsevier (DOI): 10.1089/end.2015.0054 (DOI: 10.1089/end.2015.0054, PubMed: 25793540)
48.	Masatsugu Komori, Hirofumi Izaki, Kei Daizumoto, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Junichiro Kagawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama, Manabu Sakaki, Hiroyoshi Nakatsuji, Takumi Hamao and Hiroyasu Miura : Complications of Flexible Ureteroscopic Treatment for Renal and Ureteral Calculi during the Learning Curve., Urologia Internationalis, Vol.95, No.1, 26-32, 2015. (Summary) The flexible ureterorenoscope (URS) and associated devices have developed rapidly. However, despite its therapeutic benefits, URS may be associated with some complications. To the best of our knowledge, there are no studies discussing the complications of flexURS during the learning curve. A retrospective review of the records of patients who underwent flexURS from January 2005 to June 2013 was performed. To compare the complications after the introduction of flexURS, patients were divided into four groups based on the surgeon's training experience, that is, based on the number of cases performed by the surgeon. A total of 219 cases underwent flexURS. Groups 1, 2, 3, and 4 included 35, 50, 50, and 84 cases, respectively. The complications were classified using the Clavien system (I-IV). The mean operation time and stone-free rate were significantly different (p < 0.001, p = 0.013, respectively). The total complication rates were 13.6, 10, 8.3, and 3.2%, respectively (p = 0.068). The more the surgeon's experience, the less was the complication rate. Despite our best efforts, the incidence of urosepsis was not reduced (p = 0.902). To reduce severe complications, it is necessary to have performed about 100 cases. Increased surgeon experience tended to decrease the risk of severe complications, but the incidence of urosepsis was not reduced. (Keyword) Adolescent / Adult / Aged / Aged, 80 and over / children / Female / Humans / Kidney Calculi / Learning Curve / Male / Middle Aged / Operative Time / Retrospective Studies / risk / Sepsis / Ureter / Ureteral Calculi / Ureteroscopes / Ureteroscopy / Urology / Young Adult (Tokushima University Institutional Repository) ● Metadata: 112031 (Link to Publication Site) ● Publication site (DOI): 10.1159/000368617 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25833730 ● Summary page in Scopus @ Elsevier: 2-s2.0-84939651848 (Tokushima University Institutional Repository: 112031, DOI: 10.1159/000368617, PubMed: 25833730, Elsevier: Scopus)
49.	Masayuki Takahashi, Yoshito Kusuhara, Hidehisa Mori, Masatsugu Komori, Junichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Long-Term Administration of Docetaxel Over 70 Cycles for Castration-Resistant Prostate Cancer., Clinical Genitourinary Cancer, Vol.13, No.4, e337-40, 2015. (Keyword) Aged / Antineoplastic Agents / Bone Neoplasms / Drug Administration Schedule / Fatal Outcome / Humans / Maintenance Chemotherapy / Male / Middle Aged / Prostatic Neoplasms, Castration-Resistant / Taxoids (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clgc.2015.01.012 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25770768 ● Summary page in Scopus @ Elsevier: 2-s2.0-84936985299 (DOI: 10.1016/j.clgc.2015.01.012, PubMed: 25770768, Elsevier: Scopus)
50.	Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Masaaki Nishitani, Yasushi Sutou, Kenzou Uema, Akira Kawano, Takumi Hamao and Hiro-omi Kanayama : Changes in levels of prostate-specific antigen and testosterone following discontinuation of long-term hormone therapy for non-metastatic prostate cancer., The Journal of Medical Investigation : JMI, Vol.61, No.1-2, 35-40, 2014. (Summary) We evaluated changes in levels of prostate-specific antigen (PSA) and testosterone following discontinuation of long-term hormone therapy for non-metastatic prostate cancer. Treatment was discontinued in 31 patients with non-metastatic prostate cancer (clinical stage B-C) after ≥ 5 years of hormone therapy, during which time PSA level had been maintained less than 0.5 ng/ml. PSA and testosterone levels were measured after discontinuation of therapy. PSA > 4.0 ng/ml was defined as PSA relapse in this study. Mean age at discontinuation of hormone therapy was 78.7 years (range, 66-90). Mean duration of follow-up after discontinuation of therapy was 25.5 months. PSA non-relapse rate was quite high (87.1%). 4 of the 31 patients showed PSA relapse, after 12-24 months. Testosterone level exceeded castration level (< 1.0 ng/ml) in 3 patients, each of whom developed PSA relapse. During follow-up, the PSA relapse rate was relatively low. These results suggest that treatment may be safely discontinued in many prostate cancer patients. In addition, rate of testosterone recovery after treatment discontinuation may be associated with PSA relapse. When considered the adaptation of discontinued, or intermittent hormone therapy for aged people, these findings may be useful. (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.61.35 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24705746 ● Summary page in Scopus @ Elsevier: 2-s2.0-84897929249 (DOI: 10.2152/jmi.61.35, PubMed: 24705746, Elsevier: Scopus)
51.	Yasuyo Yamamoto and Hiro-omi Kanayama : Clinical development of treatment for female pelvic organ prolapse and urinary incontinence, Shikoku Acta Medica, Vol.69, No.5,6, 207-210, 2013. (Summary) Pelvic organ prolapse (POP) and urinary incontinence are not rare among the middle and advance aged woman. Although these diseases don't cause life threatening, decrease the QOL (Quality of life) of patients. The patients of POP or urinary incontinence were hesitated to tell to another person so far, the opportunities to consult a medical institution increase by the enlightenment activity such as media. In this review, we describe the latest treatment for female POP and urinary incontinence. (Keyword) pelvic organ prolapse / urinary incontinence (Tokushima University Institutional Repository) ● Metadata: 109727 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050845762395117568 (Tokushima University Institutional Repository: 109727, CiNii: 1050845762395117568)
52.	Masayuki Takahashi and Hiro-omi Kanayama : Updated systemic therapy for advanced/metastatic renal cell carcinoma and prostate cancer, Shikoku Acta Medica, Vol.69, No.5,6, 201-206, 2013. (Summary) As advanced renal cell carcinoma (RCC) shows resistance to anti-cancer drugs, immunotherapy had been the mainstay of systemic therapy. Recently, molecular targeted agents including VEGF and mTOR inhibitors have been introduced, and so systemic therapy for advanced RCC has been significantly altered. VEGF inhibitors show marked efficacy in regard to tumor size reduction, and the representative adverse events include hypertension, hand-foot syndrome, and hypothyroidism. mTOR inhibitors have modest effects for tumor size reduction, and the specific adverse events include stomatitis, hyperglycemia, hyperlipidemia, and interstitial pneumonia. The introduction of molecular targeted agents has improved survival in advanced RCC patients. Hormonal therapy is at the center of systemic therapy for advanced prostate cancer patients. Castration or LH-RH analogues suppress the proliferation of prostate cancer cells by decreasing androgen production in the testes. Anti-androgens inhibit the binding of testosterone to androgen receptors, and combination therapy of castration or LH-RH analogues and anti-androgens, called maximum androgen blockade, shows enhanced efficacy for advanced prostate cancer. Docetaxel is administered for castration-resistant prostate cancer, and prolongs survival compared to previously used anti-cancer drugs. Regarding new drugs for prostate cancer, an LH-RH antagonist, a CYP17 inhibitor of androgen production in the adrenal glands, and new anti-androgens with a higher affinity for androgen receptors have been developed for clinical use. (Keyword) renal cell carcinoma / prostate cancer / molecular targeted therapy / hormonal therapy / docetaxel (Tokushima University Institutional Repository) ● Metadata: 109726 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050564287418406400 (Tokushima University Institutional Repository: 109726, CiNii: 1050564287418406400)
53.	Hiroyuki Fujimoto, Hiroyuki Nakanishi, Tsuneharu Miki, Hiro-omi Kanayama, Chikara Ohyama, Kazuhiro Suzuki, Hiroyuki Nishiyama, Masatoshi Eto, Seiji Naito, Tomoharu Fukumori, Yoshinobu Kubota, Satoru Takahashi, Yukio Homma and Kazumi Kamoi : Oncological outcomes of renal pelvic and ureteral cancer patients registered in 2005: The first large population report from the Cancer Registration Committee of the Japanese Urological Association., International Journal of Urology, Vol.21, No.5, 527-534, 2013. (Summary) To describe the clinical and pathological characteristics and the outcomes of renal pelvic and ureteral cancer patients diagnosed in 2005 in Japan. In 2011, data were collected from renal pelvic and ureteral cancer patients diagnosed in 2005. A total of 1509 registered patients from 348 institutions were analyzed. Epidemiology and survival were analyzed based on each cancer location and on cancer multiplicity. The 5-year overall survival of the 1509 patients was estimated at 0.64. Open surgery was carried out in 409 renal pelvic cancer cases (66.9%) and 315 ureteral cancer cases (63.0%). The retroperitoneal approach was common, and lymph node dissection was carried out in approximately one-third of open surgery cases and one-fifth of laparoscopic cases. Approximately 60% of the operated unilateral renal pelvic or ureteral cancer was diagnosed as invasive, and just 14.6% was diagnosed as stage pTa. Distribution of the estimated worst tumor grade was significantly different for renal pelvic cancer and ureteral cancer. This article presents the first large population report of survival data in Japanese renal pelvic and ureteral cancer patients. In comparison with the Japanese bladder cancer database report in 1999-2001 from the Cancer Registration Committee of the Japanese Urological Association, the pathological characteristics of renal pelvic and ureteral cancer were diagnosed as aggressive. (Keyword) Aged / Aged, 80 and over / Female / Humans / Japan / Kidney Neoplasms / Kidney Pelvis / Male / Middle Aged / Registries / Survival Rate / Ureteral Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1111/iju.12367 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24372688 ● Summary page in Scopus @ Elsevier: 2-s2.0-84899491743 (DOI: 10.1111/iju.12367, PubMed: 24372688, Elsevier: Scopus)
54.	Jun-ichiro Kagawa, Hiro-omi Kanayama, 大谷正樹 and 河野明 : A PATIENT WITH INFLAMMATORY PSEUDOTUMOR OF THE URINARY BLADDER : A CASE REPORT, The Nishinihon Journal of Urology, Vol.75, No.11, 572-575, 2013. (Keyword) 炎症性偽腫瘍 / 炎症性筋線維芽細胞性腫瘍 / 膀胱腫瘍 / inflammatory pseudotumor / inflammatory myofibroblastic tumor / bladder tumor (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520290883033566720 ● Summary page in Scopus @ Elsevier: 2-s2.0-84892405347 (CiNii: 1520290883033566720, Elsevier: Scopus)
55.	佐々木雄太郎, 小居浩之, 大山拓郎, Jun-ichiro Kagawa, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Hisaya Takahashi, Masahiko Takemura, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : NON-MUSCLE INVASIVE BLADDER CANCER WITH MULTIPLE BONE METASTASIS WITHOUT LOCAL INVASION : A CASE REPORT, Acta Urologica Japonica, Vol.59, No.10, 669-672, 2013. (Summary) A 66-year-old man with superficial bladder cancer was treated with transurethral resection (TURBT) in October 2011. The pathological diagnosis was urothelial carcinoma (UC), grade 2, T1. A second TURBT was performed one month later. The pathological diagnosis was UC, grade 3, T1. He was treated with intravesical bacillus Calmette-Guerin (BCG) after TURBT. His progress was satisfactory, but a small superficial bladder cancer was found on cystoscopy in August 2012. He was going to be treated with TURBT, but the serum alkaline phosphatase level was abnormally high on preoperative evaluation. Bone scintigraphy showed multiple bone metastases from non-muscle invasive bladder cancer (NMIBC) without local invasion. He was started on combined chemotherapy with 1,000 mg/m2 gemcitabine on days 1, 8 and 15 and 70 mg/m2 cisplatin on day 2 every four weeks. He received denosumab for multiple bone metastases at the same time. Although he subsequently developed severe hypocalcemia, treatment was continued, and he completed four courses of chemotherapy. Bone scintigraphy and contrast-enhanced computed tomography showed reduction of the multiple bone metastases, and alkaline phosphatase decreased to the normal range. It is rare for NMIBC without local invasion to metastasize to other organs. Thus, it is necessary to consider distant metastases in patients with NMIBC. (Keyword) Non-muscle invasive / Bladder cancer / Bone metastasis (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24262709 ● CiNii @ National Institute of Informatics (CRID): 1050845760708113920 ● Summary page in Scopus @ Elsevier: 2-s2.0-84888314282 (PubMed: 24262709, CiNii: 1050845760708113920, Elsevier: Scopus)
56.	Nozawa Masahiro, Nonomura Norio, Ueda Takeshi, Nishimura Kazuo, Hiro-omi Kanayama, Miki Tsunehara, Nakatani Tatsuya, Tomita Yoshihiko, Azuma Haruhito, Yoshioka Toshiaki, Tsujihata Masao and Uemura Hirotsugu : Adverse Event Profile and Dose Modification of Everolimus for Advanced Renal Cell Carcinoma in Real-world Japanese Clinical Practice, Japanese Journal of Clinical Oncology, Vol.43, No.11, 1132-1138, 2013. (Summary) The aim of the study was to assess the safety and efficacy of everolimus therapy for advanced renal cell carcinoma in Japanese patients receiving real-world care. Patients who had been treated with everolimus for advanced renal cell carcinoma at 39 Japanese medical centers between January 2010 and November 2011 were retrospectively investigated to assess adverse events and the time to treatment failure. A total of 180 patients were identified. Their median age was 65 years (range 23-93). The median time to treatment failure was 2.9 months (95% confidence interval 2.4-3.4). The median time to treatment failure was significantly longer in patients with dose modification (4.2 months; 95% confidence interval 3.4-5.0) than in patients without dose modification (1.7 months; 95% confidence interval 1.0-2.3; P < 0.01) after experiencing adverse events. Stomatitis (44%) was the most frequent adverse event, followed by thrombocytopenia (31%), anemia (22%), interstitial pneumonia (22%) and hyperglycemia (17%). Interstitial pneumonia was the most frequent cause of discontinuation in patients who discontinued everolimus due to intolerability regardless of the dose modification status. None of the patients with dose modification of everolimus discontinued everolimus due to thrombocytopenia or leukopenia. The adverse event profile of everolimus may differ between Japanese and Caucasian patients. Dose modification of everolimus might be associated with longer treatment duration in patients with advanced renal cell carcinoma. Further studies are required to clarify this association. Interstitial pneumonia may be difficult to overcome by dose modification. (Keyword) Adult / Aged / Aged, 80 and over / Antineoplastic Agents / Carcinoma, Renal Cell / Drug Administration Schedule / Female / Humans / Hyperglycemia / Japan / Kaplan-Meier Estimate / Kidney Neoplasms / Lung Diseases, Interstitial / Male / Middle Aged / Retrospective Studies / Sirolimus / Stomatitis / Thrombocytopenia / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1093/jjco/hyt121 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23999768 ● Summary page in Scopus @ Elsevier: 2-s2.0-84887108900 (DOI: 10.1093/jjco/hyt121, PubMed: 23999768, Elsevier: Scopus)
57.	Masayuki Takahashi, Masatsugu Komori, Jun-ichiro Kagawa, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Hisaya Takahashi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 小児低形成腎/機能低下腎に対する腹腔鏡下腎摘除術の臨床的検討, Japanese Journal of Endourology, Vol.26, No.2, 263-269, 2013. (Summary) We reviewed the results of laparoscopic nephrectomy for children with a hypoplastic or poorly functioning kidney in our department. Laparoscopic nephrectomy was performed in 10 patients including 1 boy and 9 girls. The patients' median age was 5.5 years old. There were 8 patients with a hypoplastic kidney and an ectopic ureter, and 2 patients with a poorly functioning kidney and a megaureter or vesicoureteral reflux. Laparoscopic nephrectomy was conducted transperitoneally in 5 and retroperitoneally in 5 patients. The median operative time was 167 minutes. There was no intraoperative complication. Postoperatively, subcutaneous emphysema and fever developed in one patient each. 7 patients used an analgesic suppository once or several times, and 3 patients received no analgesics. Oral intake was started at a median of 1 day postoperatively. The median hospital stay after surgery was 4.5 days. Laparoscopic nephrectomy for a hypoplastic and poorly functioning kidney in children is a minimally invasive surgery. (Keyword) 小児 / 鏡視下腎摘除術 / 尿管異所開口 (Link to Publication Site) ● Publication site (DOI): 10.11302/jsejje.26.263 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205509695360 ● Search Scopus @ Elsevier (DOI): 10.11302/jsejje.26.263 (DOI: 10.11302/jsejje.26.263, CiNii: 1390001205509695360)
58.	Masayuki Takahashi, Kawabata Rumi, Kawano Akira, Murakami Yoshihide, Sutou Yasushi, Inai Tohru, Akazawa Seiji, Hamao Takumi, Hayashi Hideki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : Substitution of antiandrogens and tegafur-uracil combination therapy for castration-resistant prostate cancer: results of a multi-center randomized phase II study, International Journal of Oncology, Vol.43, No.3, 713-720, 2013. (Summary) We conducted this study to determine whether substitution with anti-androgen (SOA) and tegafur-uracil (a pro-drug of 5-FU) combination therapy is more effective than SOA alone after relapse from initial hormonal therapy. Patients who were histologically confirmed and relapsed after initial hormonal therapy were included. All patients were randomly allocated into two groups: SOA alone (group A) or SOA combined with tegafur-uracil (group B). The mRNA expression of four enzymes, including thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phospho-ribosyltransferase (OPRT) and thymidine phosphorylase (TP), in prostate cancer cells was analyzed by quantitative reverse-transcription polymerase chain reaction. Fifty-two patients were enrolled in this study. The median age was 77 (range: 47-92) years. The PSA response rate in group B (61.5%) tended to be higher compared to that in group A (34.6%) (p=0.095). Group B (median: 15.9 months) had a significantly longer time to PSA progression (TTP) compared to group A (6.4 months) (p=0.014). In patients with a lower TS expression or a higher OPRT expression, group B demonstrated a higher PSA response rate compared to group A (p=0.019 and p=0.041, respectively). In addition, in the patients with a lower TS expression, group B demonstrated a significantly longer TTP compared to group A (p=0.018). There were no severe adverse events in either treatment group. After relapse from initial hormonal therapy, SOA combined with tegafur-uracil is effective and well tolerated. The TS mRNA expression level may be a predictive factor for this combination therapy. (Keyword) Aged / Aged, 80 and over / Androgen Antagonists / Antineoplastic Combined Chemotherapy Protocols / Dihydrouracil Dehydrogenase (NADP) / Gene Expression Regulation, Neoplastic / Humans / Male / Middle Aged / Orotate Phosphoribosyltransferase / Prostatic Neoplasms, Castration-Resistant / RNA, Messenger / Tegafur / Thymidine Phosphorylase / Thymidylate Synthase / Uracil (Link to Publication Site) ● Publication site (DOI): 10.3892/ijo.2013.1997 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23817692 ● Summary page in Scopus @ Elsevier: 2-s2.0-84880578556 (DOI: 10.3892/ijo.2013.1997, PubMed: 23817692, Elsevier: Scopus)
59.	Hisaya Takahashi, Yasuyo Yamamoto, 小居浩之, 大山拓郎, 佐々木雄太郎, Masatsugu Komori, Jun-ichiro Kagawa, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : CLINICAL EXPERIENCE OF INTERSTITIAL CYSTITIS TREATED WITH HYDRODISTENSION, The Nishinihon Journal of Urology, Vol.75, No.8, 413-417, 2013. (Keyword) 間質性膀胱炎 / 水圧拡張術 / interstitial cystitis (IC) hydrodistension (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520290882119498752 ● Summary page in Scopus @ Elsevier: 2-s2.0-84884299458 (CiNii: 1520290882119498752, Elsevier: Scopus)
60.	Kojiro Nagai, Masashi Miyoshi, Takei Kake, Naoshi Fukushima, Motokazu Matsuura, Eriko Shibata, Satoshi Yamada, Kazuhiro Yoshikawa, Hiro-omi Kanayama, Tomoya Fukawa, Kunihisa Yamaguchi, Hirofumi Izaki, Akira Mima, Naoko Abe, Toshikazu Araoka, Taichi Murakami, Fumi Kishi, Seiji Kishi, Tatsuya Tominaga, Tatsumi Moriya, Hideharu Abe and Toshio Doi : Dual Involvement of Growth Arrest-specific Gene 6 in the Early Phase of Human IgA Nephropathy, PLoS ONE, Vol.8, No.6, e66759, 2013. (Summary) Gas6 is a growth factor that causes proliferation of mesangial cells in the development of glomerulonephritis. Gas6 can bind to three kinds of receptors; Axl, Dtk, and Mer. However, their expression and functions are not entirely clear in the different glomerular cell types. Meanwhile, representative cell cycle regulatory protein p27 has been reported to be expressed in podocytes in normal glomeruli with decreased expression in proliferating glomeruli, which inversely correlated with mesangial proliferation in human IgA nephropathy (IgAN). The aim of this study is to clarify Gas6 involvement in the progression of IgAN. Expression of Gas6/Axl/Dtk was examined in 31 biopsy proven IgAN cases. We compared the expression levels with histological severity or clinical data. Moreover, we investigated the expression of Gas6 and its receptors in cultured podocytes. In 28 of 31 cases, Gas6 was upregulated mainly in podocytes. In the other 3 cases, Gas6 expression was induced in endothelial and mesangial cells, which was similar to animal nephritis models. Among 28 podocyte type cases, the expression level of Gas6 correlated with the mesangial hypercellularity score of IgAN Oxford classification and urine protein excretion. It also inversely correlated with p27 expression in glomeruli. As for the receptors, Axl was mainly expressed in endothelial and mesangial cells, while Dtk was expressed in podocytes. In vitro, Dtk was expressed in cultured murine podocytes, and the expression of p27 was decreased by Gas6 stimulation. Gas6 was uniquely upregulated in either endothelial/mesangial cells or podocytes in IgAN. The expression pattern can be used as a marker to classify IgAN. Gas6 has a possibility to be involved in not only mesangial proliferation via Axl, but also podocyte injury via Dtk in IgAN. (Keyword) Cells, Cultured / Endothelial Cells / Glomerulonephritis, IGA / Humans / Immunohistochemistry / Intercellular Signaling Peptides and Proteins / Mesangial Cells / Podocytes (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0066759 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23826128 ● Summary page in Scopus @ Elsevier: 2-s2.0-84879474790 (DOI: 10.1371/journal.pone.0066759, PubMed: 23826128, Elsevier: Scopus)
61.	Jun-ichiro Kagawa, Hirofumi Izaki, Hiro-omi Kanayama, 大谷正樹 and 河野明 : NON-SPECIFIC REGIONAL URETERITIS WHERE PREOPERATIVE DIAGNOSIS WAS DIFFICULT : A CASE REPORT, The Nishinihon Journal of Urology, Vol.75, No.6, 328-330, 2013. (Keyword) ureteritis / ureteral tumor (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520853834286004224 ● Summary page in Scopus @ Elsevier: 2-s2.0-84879628077 (CiNii: 1520853834286004224, Elsevier: Scopus)
62.	Hirofumi Izaki and Hiro-omi Kanayama : THE FUTURE OUTLOOK OF SURGERY IN THE FIELD OF UROLOGY : STANDARD AND ADVANCED MEDICAL CARE FOR LAPAROSCOPIC SURGERY, The Nishinihon Journal of Urology, Vol.75, No.6, 293-299, 2013. (Keyword) laparoscopic surgery / robot-assisted laparoscopic surgery (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520290883466761344 ● Summary page in Scopus @ Elsevier: 2-s2.0-84879673795 (CiNii: 1520290883466761344, Elsevier: Scopus)
63.	Masayuki Takahashi and Hiro-omi Kanayama : TREATMENT ALGORITHM FOR ADVANCED/METASTATIC RENAL CELL CARCINOMA : AVAILABILITY OF NEW CANDIDATE AGENTS FOR USE IN THE NEAR FUTURE, The Nishinihon Journal of Urology, Vol.75, No.5, 218-224, 2013. (Keyword) renal cell carcinoma / molecular targeted agent / treatment algorithm / near future (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520572358200310272 ● Summary page in Scopus @ Elsevier: 2-s2.0-84879205280 (CiNii: 1520572358200310272, Elsevier: Scopus)
64.	Tomohiro Soga, Shinji Kawahito, Nami Kakuta, Tosiko Katayama, Narutomo Wakamatsu, Kazumi Takaishi, Kunihisa Yamaguchi, Hirofumi Izaki, Hiro-omi Kanayama, Hiroshi Kitahata and Shuzo Oshita : Recent less-invasive circulatory monitoring during renal transplantation., The Journal of Medical Investigation : JMI, Vol.60, No.1, 2, 159-163, 2013. (Summary) For anesthetic management during renal transplantation, it is necessary to maintain the blood flow and function of the transplanted kidney by performing massive fluid management and stabilizing blood pressure. We report anesthetic management for renal transplantation with a less-invasive circulatory monitoring system (Edwards Life Sciences Co., Ltd., Irvine, California, U.S.A.). In November 2010, renal transplantation was started in our hospital, and performed in 6 patients. In the first patient, fluid/circulatory management was conducted by connecting a standard arterial line and a standard central venous (CV) line. In the second patient, a FloTrac(TM) system and a standard CV line were used. In the third patient, a standard arterial line and a PreSep(TM) CV Oximetry Catheter were used. In the fourth and fifth patients, a FloTrac(TM) and a PreSep(TM) were used. In the latest patient, FloTrac(TM) and PreSep(TM) were connected to an EV1000(TM) Clinical Platform for fluid/circulatory management. The establishment of high-visibility monitors was useful for evaluating the condition and confirming the effects. As there are marked changes in hemodynamics, the CV pressure, which has been used as a parameter of fluid management, is not reliable in renal failure patients with a high incidence of cardiovascular complications. Advances in noninvasive circulatory monitoring with dynamic indices may improve the safety of anesthetic management during renal transplantation. (Keyword) Adolescent / Adult / anesthesia / Cardiac Output / Central Venous Pressure / Humans / Kidney Transplantation / Middle Aged / Monitoring, Physiologic / Oxygen (Tokushima University Institutional Repository) ● Metadata: 106058 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.60.159 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23614926 ● CiNii @ National Institute of Informatics (CRID): 1390282679221800704 ● Summary page in Scopus @ Elsevier: 2-s2.0-84876046292 (Tokushima University Institutional Repository: 106058, DOI: 10.2152/jmi.60.159, PubMed: 23614926, CiNii: 1390282679221800704, Elsevier: Scopus)
65.	Tomoteru Kishimoto, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : Mineralocorticoid receptor expression in human penile corpus cavernosum, The Journal of Medical Investigation : JMI, Vol.60, 21-26, 2013. (Summary) Mineralocorticoid receptor (MR) is known to play physiological and pathophysiological roles in the cardiovascular system, and MR activation directly damages these organs. The aim of this study was to evaluate the expression of MR and 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) in the human penile corpus cavernosum. MR and 11β-HSD2 expression was assayed in human penile tissues, and also in human renal tissues as a positive control. Expressions of MR mRNA and 11β-HSD2 mRNA were evaluated using reverse transcription polymerase chain reaction (RT-PCR). MR and 11β-HSD2 were visually identified using immunofluorescence analysis. MR mRNA expression in human penis was confirmed by RT-PCR. On quantitative RT-PCR analysis, 11β-HSD2 mRNA expression was detected at minimal levels in penile tissue. Immunofluorescence analysis revealed positive staining for MR and negative staining for 11β-HSD2 in smooth muscle cells of the corpus cavernosum. This study demonstrated the presence of MR and the absence of 11β-HSD2 in human penile corpus cavernosum. Considering that MR activation causes various organ damages, MR blockade in human penile corpus cavernosum may have therapeutic benefits. Investigations for the penile effects of MR activation have the potential to provide new treatment approaches for erectile dysfunction. (Keyword) 11-beta-Hydroxysteroid Dehydrogenase Type 2 / Adult / Aged / Erectile Dysfunction / Fluorescent Antibody Technique / Humans / Male / Middle Aged / Mineralocorticoid Receptor Antagonists / Penis / RNA, Messenger / Receptors, Mineralocorticoid (Tokushima University Institutional Repository) ● Metadata: 106037 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.60.21 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23614907 ● Summary page in Scopus @ Elsevier: 2-s2.0-84876057957 (Tokushima University Institutional Repository: 106037, DOI: 10.2152/jmi.60.21, PubMed: 23614907, Elsevier: Scopus)
66.	Hisaya Takahashi, 津田恵, 大豆本圭, 三宅毅志, 塩﨑啓登, Masatsugu Komori, Jun-ichiro Kagawa, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : CLINICAL EXPERIENCE OF REITER'S SYNDROME FOLLOWING BCG INTRAVESICAL THERAPY, The Nishinihon Journal of Urology, Vol.76, 10-14, 2013. (Keyword) Reiter症候群 / BCG膀胱内注入療法 / 膀胱癌 / Reiter's syndrome / intravesical BCG therapy / bladder cancer (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520853832090604416 ● Summary page in Scopus @ Elsevier: 2-s2.0-84894647903 (CiNii: 1520853832090604416, Elsevier: Scopus)
67.	Masayuki Takahashi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 分子標的薬投与中に腸管穿孔をきたした2例, 泌尿器外科, Vol.26, 106-108, 2013.
68.	Tomoya Fukawa, Masaya Ono, Taisuke Matsuo, Hisanori Uehara, Tsuneharu Miki, Yusuke Nakamura, Hiro-omi Kanayama and Toyomasa Katagiri : DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through its interaction with NPM1 in renal cell carcinomas, Cancer Research, Vol.72, No.22, 5867-5877, 2012. (Summary) Studies of renal cell carcinoma (RCC) have led to the development of new molecular-targeted drugs but its oncogenic origins remain poorly understood. Here, we report the identification and critical roles in renal carcinogenesis for DDX31, a novel nucleolar protein upregulated in the vast majority of human RCC. Immunohistochemical overexpression of DDX31 was an independent prognostic factor for patients with RCC. RNA interference (RNAi)-mediated attenuation of DDX31 in RCC cells significantly suppressed outgrowth, whereas ectopic DDX31 overexpression in human 293 kidney cells drove their proliferation. Endogenous DDX31 interacted and colocalized with nucleophosmin (NPM1) in the nucleoli of RCC cells, and attenuation of DDX31 or NPM1 expression decreased pre-ribosomal RNA biogenesis. Notably, in DDX31-attenuated cells, NPM1 was translocated from nucleoli to the nucleoplasm or cytoplasm where it bound to HDM2. As a result, HDM2 binding to p53 was reduced, causing p53 stablization with concomitant G(1) phase cell-cycle arrest and apoptosis. Taken together, our findings define a mechanism through which control of the DDX31-NPM1 complex is likely to play critical roles in renal carcinogenesis. (Keyword) Animals / COS Cells / Carcinoma, Renal Cell / Cell Nucleolus / DEAD-box RNA Helicases / HEK293 Cells / Humans / immunohistochemistry / Kidney Neoplasms / Nuclear Proteins / Prognosis / Proto-Oncogene Proteins c-mdm2 / RNA, Ribosomal / signal transduction / Transcription, Genetic / Transfection / Tumor Suppressor Protein p53 / Up-Regulation (Link to Publication Site) ● Publication site (DOI): 10.1158/0008-5472.CAN-12-1645 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23019224 ● Search Scopus @ Elsevier (PMID): 23019224 ● Search Scopus @ Elsevier (DOI): 10.1158/0008-5472.CAN-12-1645 (DOI: 10.1158/0008-5472.CAN-12-1645, PubMed: 23019224)
69.	Takuya Tsujioka, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : BCG膀胱内注入療法後に発症した結核性精巣上体炎の1例, 泌尿器外科, Vol.25, No.11, 2217-2220, 2012.
70.	Masayuki Takahashi, Kosuke Seto, Takuya Tsujioka, Ryotaro Tomita, Megumi Tsuda, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : SEQUENTIAL THERAPY WITH MOLECULAR TARGETED AGENTS FOR ADVANCED RENAL CELL CARCINOMA, The Nishinihon Journal of Urology, Vol.74, No.5, 258-263, 2012. (Keyword) renal cell carcinoma / molecular targeted agent / sequential therapy (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520572357422341632 ● Summary page in Scopus @ Elsevier: 2-s2.0-84861809136 (CiNii: 1520572357422341632, Elsevier: Scopus)
71.	Yasuharu Watanabe, Tomoya Nakamura, Sho Ishikawa, Shiho Fujisaka, Isao Usui, Koichi Tsuneyama, Yoshinori Ichihara, Tsutomu Wada, Yoichiro Hirata, Takayoshi Suganami, Hirofumi Izaki, Shizuo Akira, Kensuke Miyake, Hiro-omi Kanayama, Michio Shimabukuro, Masataka Sata, Toshiyasu Sasaoka, Yoshihiro Ogawa, Kazuyuki Tobe, Kiyoshi Takatsu and Yoshinori Nagai : The Radioprotective 105/MD-1 complex contributes to diet-induced obesity and adipose tissue inflammation., Diabetes, Vol.61, No.5, 1199-1209, 2012. (Summary) Recent accumulating evidence suggests that innate immunity is associated with obesity-induced chronic inflammation and metabolic disorders. Here, we show that a Toll-like receptor (TLR) protein, radioprotective 105 (RP105)/myeloid differentiation protein (MD)-1 complex, contributes to high-fat diet (HFD)-induced obesity, adipose tissue inflammation, and insulin resistance. An HFD dramatically increased RP105 mRNA and protein expression in stromal vascular fraction of epididymal white adipose tissue (eWAT) in wild-type (WT) mice. RP105 mRNA expression also was significantly increased in the visceral adipose tissue of obese human subjects relative to nonobese subjects. The RP105/MD-1 complex was expressed by most adipose tissue macrophages (ATMs). An HFD increased RP105/MD-1 expression on the M1 subset of ATMs that accumulate in eWAT. Macrophages also acquired this characteristic in coculture with 3T3-L1 adipocytes. RP105 knockout (KO) and MD-1 KO mice had less HFD-induced adipose tissue inflammation, hepatic steatosis, and insulin resistance compared with wild-type (WT) and TLR4 KO mice. Finally, the saturated fatty acids, palmitic and stearic acids, are endogenous ligands for TLR4, but they did not activate RP105/MD-1. Thus, the RP105/MD-1 complex is a major mediator of adipose tissue inflammation independent of TLR4 signaling and may represent a novel therapeutic target for obesity-associated metabolic disorders. (Keyword) Adipocytes / Adipose Tissue / Animals / Antigens, CD / Antigens, Surface / Coculture Techniques / Dietary Fats / Epididymis / Fatty Liver / Gene Expression Regulation / Humans / inflammation / insulin resistance / Macrophages / Male / Membrane Glycoproteins / Mice / Mice, Inbred C57BL / knockout mice / obesity / Palmitic Acid / Stearic Acids / Toll-Like Receptor 4 (Link to Publication Site) ● Publication site (DOI): 10.2337/db11-1182 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22396206 ● Summary page in Scopus @ Elsevier: 2-s2.0-84860555433 (DOI: 10.2337/db11-1182, PubMed: 22396206, Elsevier: Scopus)
72.	Hisaya Takahashi, Hiroyoshi Nakatsuji, Masayuki Takahashi, Avirmed Shiirevnyamba, Tomoya Fukawa, Masahiko Takemura, Tomoharu Fukumori and Hiro-omi Kanayama : Up-regulation of Plakophilin-2 and Down-regulation of Plakophilin-3 are Correlated With Invasiveness in Bladder Cancer, Urology, Vol.79, No.1, 240e1-240e8, 2012. (Summary) To examine plakophilin proteins (Pkp) and 3 expression levels in bladder cancer, in particular their levels during cellular growth and invasion. Pkp is associated with the binding of cadherin to intermediate filaments of the cytoskeleton. The relative mRNA and protein expression levels of Pkp2 and 3 in bladder cancer cell lines were determined using quantitative real-time polymerase chain reaction and Western blot analyses. The cellular localization of Pkp2 and 3 proteins in bladder cancer cells was also assayed using immunohistochemistry. The proliferation and invasive activities of bladder cancer cells were evaluated using cell growth and in vitro cell invasion assays, and were compared with those of bladder cancer cells treated with Pkp2 and 3 small interfering RNAs. Pkp2 mRNA and protein levels were elevated, and those of Pkp3 were reduced, in bladder cancer cells that are known to exhibit increased proliferation and invasive activity. Pkp2/3 protein expression was predominantly observed in the cytoplasm of invasive bladder cancer cells and tissues. Pkp2 knockdown inhibited, and Pkp3 knockdown enhanced, invasion of bladder cancer cells, but these knockdowns did not alter cell proliferation. We conclude that high Pkp2, and low Pkp3, expression is associated with bladder cancer cell invasion and that neither Pkp2 nor Pkp3 is associated with cell proliferation. We further hypothesize that accumulation of Pkp2 and 3 in the cell cytoplasm, rather than their recruitment to the cell membrane, is related to an increased ability of the tumor to invade and metastasize. (Keyword) Blotting, Western / Cell Line, Tumor / Cell Proliferation / Down-Regulation / Gene Expression Regulation, Neoplastic / Humans / Immunohistochemistry / Microscopy, Fluorescence / Neoplasm Invasiveness / Plakophilins / RNA, Messenger / Real-Time Polymerase Chain Reaction / Sensitivity and Specificity / Up-Regulation / Urinary Bladder Neoplasms (Tokushima University Institutional Repository) ● Metadata: 106137 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.urology.2011.08.049 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22119253 ● Search Scopus @ Elsevier (PMID): 22119253 ● Search Scopus @ Elsevier (DOI): 10.1016/j.urology.2011.08.049 (Tokushima University Institutional Repository: 106137, DOI: 10.1016/j.urology.2011.08.049, PubMed: 22119253)
73.	Tomonori Habuchi, Toshiro Terachi, Hiromitsu Mimata, Yukihiro Kondo, Hiro-omi Kanayama, Tomohiko Ichikawa, Kikuo Nutahara, Tsuneharu Miki, Yoshinari Ono, Shiro Baba, Seiji Naito and Tadashi Matsuda : Evaluation of 2,590 urological laparoscopic surgeries undertaken by urological surgeons accredited by an endoscopic surgical skill qualification system in urological laparoscopy in Japan., Surgical Endoscopy, Vol.26, No.6, 1656-1663, 2011. (Summary) In 2003, the Japanese Urological Association (JUA) and Japanese Society of Endourology (JSE) established a urological laparoscopic skill qualification system, called the Endoscopic Surgical Skill Qualification System in Urological Laparoscopy of JUA and JSE (ESSQSJJ). The main goal of the system is to decrease the prevalence of complications associated with laparoscopic surgery. To validate the qualification system, perioperative outcome and the prevalence of complications in different types of urological laparoscopic surgery performed by accredited surgeons were evaluated. One hundred thirty-six surgeons who obtained the qualification in 2004 were prospectively asked to submit intraoperative and postoperative data of their latest 20 cases at the end of 2009, along with the number of laparoscopic urological surgeries performed in each year for a 5-year period (2004-2009). Intraoperative and postoperative complications were graded according to the Satava classification and modified Clavien classification, respectively. Data of 2,590 urological laparoscopic surgeries of 130 surgeons, including 904 laparoscopic radical nephrectomies, 430 laparoscopic nephroureterectomies, 390 laparoscopic adrenalectomies, 320 laparoscopic radical prostatectomies, and 170 laparoscopic partial nephrectomies, were analyzed. Complications were noted in 97 (3.7%) patients. Major intraoperative complications (grade II or III) occurred in 32 (1.2%) patients, and major postoperative complications (grade III or higher) occurred in 24 (0.9%) patients. The prevalence of conversion to open surgery, allogeneic transfusion, and perioperative mortality was 2.5%, 1.6%, and 0%, respectively. The number of surgeries performed by each qualified surgeon or the role of the surgeon (main operator vs. mentor/instructor) in the surgery did not affect the prevalence of intraoperative complications or postoperative complications. The open conversion rate was significantly higher in surgeons with a low surgical volume. ESSQSJJ can ensure urological laparoscopic surgeons who can perform various types of urological laparoscopic surgeries with a low prevalence of perioperative complications and reasonable outcomes. (Keyword) Analysis of Variance / Clinical Competence / Endoscopy / Humans / Intraoperative Complications / Japan / Laparoscopy / Length of Stay / Postoperative Complications / Prospective Studies / Urology (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-011-2088-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22179473 ● Search Scopus @ Elsevier (PMID): 22179473 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-011-2088-0 (DOI: 10.1007/s00464-011-2088-0, PubMed: 22179473)
74.	Rumi Kawabata, Shinji Oie, Masayuki Takahashi, Hiro-omi Kanayama, Toshinori Oka and Kouji Itou : Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines., International Journal of Oncology, Vol.38, No.6, 1489-1500, 2011. (Summary) In this study, we investigated the synergistic mechanism of anti-androgen and 5-fluorouracil (5-FU) combination therapy against castration-resistant prostate cancer (CRPC). Four prostate cancer cell lines, LNCaP, 22Rv1, DU145 and PC3, were examined for their growth dependency on androgens and the insulin-like growth factor 1 (IGF1). We assessed the expression changes of certain growth factor receptors and regulating proteins when treated with 5-FU, and found that 5-FU increased the expression of the IGF-binding protein 3 (IGFBP3). Furthermore, 5-FU inhibited the phosphorylation of Akt and p70 S6K, while the knockdown of IGFBP3 reduced the levels of poly (ADP-ribose) polymerase cleaved by 5-FU in PC3 cells. Therefore, the up-regulation of IGFBP3 by 5-FU not only inhibits cell growth by reducing the IGF1 signal but also induces apoptosis in PC3 cells. The synergistic effect of bicalutamide and 5-FU on 22Rv1 cells was reduced by IGFBP3 gene silencing using small-interfering RNA. These results suggest that the up-regulation of IGFBP3 induced by 5-FU plays an important role in the potent anti-tumor effect of 5-FU combined with anti-androgens on CRPC. Androgen-deprivation therapy combined with 5-FU could therefore be an appropriate therapy for CRPC patients. (Keyword) Androgen Antagonists / Androgens / Anilides / Antineoplastic Agents / apoptosis / Cell Line, Tumor / Cell Proliferation / Drug Synergism / Fluorouracil / Gene Expression Profiling / Gene Expression Regulation, Neoplastic / Humans / Insulin-Like Growth Factor Binding Protein 3 / Insulin-Like Growth Factor I / Male / Nitriles / Prostatic Neoplasms / RNA Interference / Receptors, Growth Factor / Signal Transduction / Tosyl Compounds / Up-Regulation (Link to Publication Site) ● Publication site (DOI): 10.3892/ijo.2011.991 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21455575 ● Search Scopus @ Elsevier (PMID): 21455575 ● Search Scopus @ Elsevier (DOI): 10.3892/ijo.2011.991 (DOI: 10.3892/ijo.2011.991, PubMed: 21455575)
75.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Shunsuke Furutani, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 中間リスク群，高リスク群前立腺癌に対するI-125密封小線源療法の治療成績, Japanese Journal of Endourology, Vol.24, No.1, 131-135, 2011. (Keyword) prostate cancer / brachytherapy / risk group classification (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205509858560 (CiNii: 1390001205509858560)
76.	羽渕友則, 寺地敏郎, 三股浩光, 近藤幸尋, Hiro-omi Kanayama, 市川智彦, 奴田原紀久雄, 三木恒治, 小野佳成, 馬場志郎, 内藤誠二 and 松田公志 : 泌尿器腹腔鏡技術認定取得医の手術成績:初回技術認定医のアンケート調査の解析報告, Japanese Journal of Endourology, Vol.24, No.1, 69-82, 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282680486547200 (CiNii: 1390282680486547200)
77.	安積麻衣, 山口真司, Yoshifumi Mizobuchi, Motohiro Hirasawa, 影治照善, Shinji Nagahiro, Kunihisa Yamaguchi and Hiro-omi Kanayama : 小脳血管芽腫と褐色細胞腫を合併したvon Hippel-Lindau病に対する手術の1例, Shikoku Acta Medica, Vol.67, No.1-2, 99, 2011. (Keyword) *von Hippel-Lindau病(合併症,外科的療法)
78.	Rumi Kawabata, Shinji Oie, Toshinori Oka, Masayuki Takahashi, Hiro-omi Kanayama and Kouji Itou : Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells, International Journal of Oncology, Vol.38, No.3, 665-676, 2011. (Summary) We investigated the antitumor effects of combination therapy with anti-androgens and 5-fluorouracil (5-FU), and examined the underlying mechanism of the treatment. Initially, we established the bicalutamide-resistant subline CDX25R from the androgen receptor (AR)-positive human prostate cancer cell line LNCaP through continuous exposure to bicalutamide. CDX25R cells lost the ability to respond to androgens, but still expressed AR. They showed significant resistance to bicalutamide, but had high sensitivity to hydroxyflutamide (OH-flutamide) compared with LNCaP cells. The CDX25R subline was thus considered to be a suitable model for prostate cancer that has developed resistance to first-line hormonal therapy but shows sensitivity to an alternative approach. Combined treatment with 5-FU and OH-flutamide had a synergistic effect on CDX25R cells. OH-flutamide decreased expression of the transcription factor E2F1, and subsequently of thymidylate synthase (TS), in CDX25R cells but not in AR-negative DU145 cells. This suggested that OH-flutamide enhanced the growth-inhibitory activity of 5-FU in CDX25R cells by reducing TS expression through the AR pathway. Combined therapy with 5-FU and OH-flutamide may, therefore, be appropriate for patients with prostate cancer that has acquired resistance to initial hormone therapy including bicalutamide. (Keyword) Androgen Antagonists / Anilides / Antimetabolites, Antineoplastic / Carcinoma / Cell Line, Tumor / Drug Evaluation, Preclinical / Drug Resistance, Neoplasm / Drug Synergism / Fluorouracil / Flutamide / Gene Expression Regulation, Enzymologic / Gene Expression Regulation, Neoplastic / Humans / Male / Models, Biological / Neoplasms, Hormone-Dependent / Nitriles / Prostatic Neoplasms / Thymidylate Synthase / Tosyl Compounds (Link to Publication Site) ● Publication site (DOI): 10.3892/ijo.2011.909 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21243325 ● Search Scopus @ Elsevier (PMID): 21243325 ● Search Scopus @ Elsevier (DOI): 10.3892/ijo.2011.909 (DOI: 10.3892/ijo.2011.909, PubMed: 21243325)
79.	Avirmed Shiirevnyamba, Tetsuyuki Takahashi, Hongchao Shan, Hirohisa Ogawa, Seiji Yano, Hiro-omi Kanayama, Keisuke Izumi and Hisanori Uehara : Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts, British Journal of Cancer, Vol.104, No.3, 505-513, 2011. (Summary) The interaction between prostate cancer cells and osteoblasts is critical for the development of bone metastasis. Metastatic cancer cells may physically contact osteoblasts in the bone microenvironment; however, the biological significance of this interaction is not fully understood. Human prostate cancer cells (the osteolytic cell line PC-3 and the osteoblastic cell line MDA-PCa 2b) and human osteoblasts (hFOB1.19) were cocultured under two different conditions (bilayer and contact conditions). Differential gene expression profiles of prostate cancer cells were then investigated using microarray analysis. Differentially expressed genes were analysed using RT-PCR and western blotting, and the effect of anti-cadherin neutralising antibodies on their expression was assayed. The osteoclastogenic activity of cells grown under these different conditions was also investigated using an in vitro assay. When PC-3 or MDA-PCa 2b cells were cocultured with hFOB1.19 cells under contact conditions, the expression of eight genes was upregulated and that of one gene was downregulated in PC-3 cells compared with gene expression in bilayer culture. No differentially expressed genes were detected in MDA-PCa 2b cells. Four of the eight upregulated genes (interleukin-1β (IL-1β), cyclooxygenase-2 (COX-2), IL-6 and the third component of complement (C3)) have already been reported to participate in osteoclastogenesis. Indeed, a cell lysate of PC-3 cells grown under contact coculture conditions significantly enhanced osteoclastogenesis in vitro (P<0.005). neutralisation of cadherin-11 with a specific antibody inhibited upregulation of COX-2 and C3 mRNA in PC-3 cells. In contrast, neutralisation of N-cadherin induced upregulation of COX-2 mRNA. Physical contact between osteolytic prostate cancer cells and osteoblasts may upregulate osteoclastogenesis-related gene expression in prostate cancer cells and enhance osteoclastogenesis. Additionally, cadherin-11 and N-cadherin are involved in this process. These data provide evidence supporting new therapies of prostate cancer bone metastasis that target direct cancer-cell-osteoblast cell-cell contact. (Keyword) Animals / Antigens, CD / Bone Resorption / Cadherins / Cell Line, Tumor / Gene Expression Profiling / Humans / Male / Mice / Mice, Nude / Osteoblasts / Osteoclasts / Osteolysis / Prostatic Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1038/sj.bjc.6606070 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21206493 ● Search Scopus @ Elsevier (PMID): 21206493 ● Search Scopus @ Elsevier (DOI): 10.1038/sj.bjc.6606070 (DOI: 10.1038/sj.bjc.6606070, PubMed: 21206493)
80.	Nobuo Shinohara, Masayuki Takahashi and Hiro-omi Kanayama : The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma, British Journal of Cancer, Vol.104, No.2, 241-247, 2011. (Summary) To elucidate the incidence and mechanisms of sunitinib-induced thyroid atrophy, we investigated serial volumetric and functional changes, and evaluated histological changes of the thyroid gland in metastatic renal cell carcinoma patients who received sunitinib. Thyroid volume (by computed tomography volumetry) and thyroid function were measured at baseline, during the treatment, and at post-treatment periods. Histological evaluation of the thyroid gland was performed in four autopsied patients. The median reduction rate in thyroid volume at last evaluation during sunitinib treatment was 30% in all 17 patients. The incidence of hypothyroidism during sunitinib treatment was significantly higher in the high reduction rate group (n=8; more than 50% reduction in volume) than in the low reduction rate group (n=9; less than 50% reduction in volume). Half of the patients in the high reduction rate group exhibited a transient thyroid-stimulating hormone suppression, suggesting thyrotoxicosis during sunitinib treatment. Histological evaluation demonstrated atrophy of thyroid follicles and degeneration of follicular epithelial cells without critical diminution of vascular volume in the thyroid gland. Thyroid atrophy is frequently observed following sunitinib treatment and may be brought about by sunitinib-induced thyrotoxicosis or the direct effects of sunitinib that lead to degeneration of thyroid follicular cells. (Keyword) Adult / Aged / Antineoplastic Agents / Carcinoma, Renal Cell / Cohort Studies / Female / Humans / Indoles / Kidney Neoplasms / Male / Neoplasm Metastasis / Pyrroles / Thyroid Function Tests / Thyroid Gland / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1038/sj.bjc.6606029 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21157447 ● Search Scopus @ Elsevier (PMID): 21157447 ● Search Scopus @ Elsevier (DOI): 10.1038/sj.bjc.6606029 (DOI: 10.1038/sj.bjc.6606029, PubMed: 21157447)
81.	Masayuki Takahashi, HIROYUKI YAMAMOTO, AKIHITO YUASA, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : CLINICAL REVIEW OF ELDERLY PATIENTS WITH RENAL TUMORS IN OUR HOSPITAL, The Nishinihon Journal of Urology, Vol.72, No.7, 363-370, 2010. (Summary) 初診時80歳以上の腎腫瘍患者24例(男17例・女7例・中央値81.5歳)の成績を報告した．ECOG performance status(PS)は0:9例，1:7例，2:3例，3:1例，4:3例，不明:1例，臨床病期はstage I:11例，II:2例，III:5例，IV:6例であった．腎摘出術を施行したのは6例で，PSは0:4例，1:1例，2:1例，病期はstage I:4例，II:1例，III:1例であった．非手術の理由は，本人・家族が希望しない，手術適応外，合併症の存在などであった．全生存期間の中央値は25ヵ月で，stage I:44ヵ月，II:10ヵ月，III:9ヵ月，IV:25ヵ月であった．癌特異生存期間の中央値はstage I:44ヵ月，II:10ヵ月，III:15ヵ月，IV:18ヵ月であった．stage I・IIの13例を手術施行5例と非手術8例に分け比較したが，全生存率，癌特異生存率ともに有意差はなかった．また，stage III・IVを治療介入7例と無治療3例に分けて行った比較でも，同様に有意差はなかった． (Keyword) RCC / elderly patients / survival / 腎細胞癌 / 高齢者 / 生存率 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520290883090281344 ● Summary page in Scopus @ Elsevier: 2-s2.0-77955855677 (CiNii: 1520290883090281344, Elsevier: Scopus)
82.	Tomoharu Fukumori, Natsuo Oka, Yukinori Takenaka, Pratima Nangia-Makker, Essam Elsammam, Toshinori Kasai, Masayuki Shono, Hiro-omi Kanayama, Julie Ellerhorst, Reuben Lotan and Avraham Raz : Galectin-3 regulates Mitochondrial Stability and Antiapoptotic Function in Response to Anticancer Drug in Prostate Cancer, Cancer Research, Vol.66, No.6, 3114-3119, 2006. (Summary) Prostate cancer is one of the malignant tumors which exhibit resistance to anticancer drugs, at least in part due to enhanced antiapoptotic mechanisms. Therefore, the understanding of such mechanisms should improve the design of chemotherapy against prostate cancer. Galectin-3 (Gal-3), a multifunctional oncogenic protein involved in the regulation of tumor proliferation, angiogenesis, and apoptosis has shown antiapoptotic effects in certain cell types. Here, we show that the expression of exogenous Gal-3 in human prostate cancer LNCaP cells, which do not express Gal-3 constitutively, inhibits anticancer drug-induced apoptosis by stabilizing the mitochondria. Thus, Gal-3-negative cells showed 66.31% apoptosis after treatment with 50 micromol/L cis-diammine-dichloroplatinum for 48 hours, whereas two clones of Gal-3-expressing cells show only 2.92% and 1.42% apoptotic cells. Similarly, Gal-3-negative cells showed 43.8% apoptosis after treatment with 300 micromol/L etoposide for 48 hours, whereas only 15.38% and 14.51% of Gal-3-expressing LNCaP cells were apoptotic. The expression of Gal-3 stimulated the phosphorylation of Ser(112) of Bcl-2-associated death (Bad) protein and down-regulated Bad expression after treatment with cis-diammine-dichloroplatinum. Gal-3 also inhibited mitochondrial depolarization and damage after translocation from the nuclei to the cytoplasm, resulting in inhibition of cytochrome c release and caspase-3 activation. These findings indicate that Gal-3 inhibits anticancer drug-induced apoptosis through regulation of Bad protein and suppression of the mitochondrial apoptosis pathway. Therefore, targeting Gal-3 could improve the efficacy of anticancer drug chemotherapy in prostate cancer. (Keyword) Galectin-3 / mitochondria / Anticancer Drug (Link to Publication Site) ● Publication site (DOI): 10.1158/0008-5472.CAN-05-3750 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16540661 ● Search Scopus @ Elsevier (PMID): 16540661 ● Search Scopus @ Elsevier (DOI): 10.1158/0008-5472.CAN-05-3750 (DOI: 10.1158/0008-5472.CAN-05-3750, PubMed: 16540661)
83.	Natsuo Oka, Susumu Nakahara, Yukinori Takenaka, Tomoharu Fukumori, Victor Hogan, Hiro-omi Kanayama, Takashi Yanagawa and Avraham Raz : Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells, Cancer Research, Vol.65, No.17, 7546-7553, 2005. (Summary) The antiapoptotic molecule galectin-3 was previously shown to regulate CD95, a member of the tumor necrosis factor (TNF) family of proteins in the apoptotic signaling pathway. Here, we question the generality of the phenomenon by studying a different member of this family of proteins [e.g., TNF-related apoptosis-inducing ligand (TRAIL), which induces apoptosis in a wide variety of cancer cells]. Overexpression of galectin-3 in J82 human bladder carcinoma cells rendered them resistant to TRAIL-induced apoptosis, whereas phosphatidylinositol 3-kinase (PI3K) inhibitors (wortmannin and LY-294002) blocked the galectin-3 protecting effect. Because Akt is a major downstream PI3K target reported to play a role in TRAIL-induced apoptosis, we questioned the possible relationship between galectin-3 and Akt. Parental J82 and the control vector-transfected J82 cells (barely detectable galectin-3) exhibit low level of constitutively active Akt, resulting in sensitivity to TRAIL. On the other hand, J82 cells overexpressing galectin-3 cells expressed a high level of constitutively active Akt and were resistant to TRAIL. Moreover, the blockage of TRAIL-induced apoptosis in J82 cells seemed to be mediated by Akt through the inhibition of BID cleavage. These results suggest that galectin-3 involves Akt as a modulator molecule in protecting bladder carcinoma cells from TRAIL-induced apoptosis. (Keyword) Apoptosis / Apoptosis Regulatory Proteins / Caspase 3 / Caspase 9 / Caspases / Cell Line, Tumor / Down-Regulation / Enzyme Activation / Galectin 3 / Humans / Intracellular Membranes / Membrane Glycoproteins / Membrane Potentials / Mitochondria / Phosphatidylinositol 3-Kinases / Protein-Serine-Threonine Kinases / Proto-Oncogene Proteins / Proto-Oncogene Proteins c-akt / Signal Transduction / TNF-Related Apoptosis-Inducing Ligand / Transfection / Tumor Necrosis Factor-alpha / Urinary Bladder Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1158/0008-5472.CAN-05-1197 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16140916 ● Search Scopus @ Elsevier (PMID): 16140916 ● Search Scopus @ Elsevier (DOI): 10.1158/0008-5472.CAN-05-1197 (DOI: 10.1158/0008-5472.CAN-05-1197, PubMed: 16140916)
84.	Yoshio Inoue, Hiroko Segawa, Ichiro Kaneko, Setsuko Yamanaka, Kenichiro Kusano, Eri Kawakami, Junya Furutani, Mikiko Ito, Masashi Kuwahata, Hitoshi Saito, Naoshi Fukushima, Shigeaki Kato, Hiro-omi Kanayama and Ken-ichi Miyamoto : Role of the vitamin D receptor in FGF23 action on phosphate metabolism, The Biochemical Journal, Vol.390, No.1, 325-331, 2005. (Summary) FGF23 (fibroblast growth factor 23) is a novel phosphaturic factor that influences vitamin D metabolism and renal re-absorption of Pi. The goal of the present study was to characterize the role of the VDR (vitamin D receptor) in FGF23 action using VDR(-/-) (VDR null) mice. Injection of FGF23M (naked DNA encoding the R179Q mutant of human FGF23) into VDR(-/-) and wildtype VDR(+/+) mice resulted in an elevation in serum FGF23 levels, but had no effect on serum calcium or parathyroid hormone levels. In contrast, injection of FGF23M resulted in significant decreases in serum Pi levels, renal Na/Pi co-transport activity and type II transporter protein levels in both groups when compared with controls injected with mock vector or with FGFWT (naked DNA encoding wild-type human FGF23). Injection of FGF23M resulted in a decrease in 25-hydroxyvitamin D 1a-hydroxylase mRNA levels in VDR(-/-) and VDR(+/+) mice, while 25-hydroxyvitamin D 24-hydroxylase mRNA levels were significantly increased in FGF23M-treated animals compared with mock vector control- or FGF23WT-treated animals. The degree of 24-hydroxylase induction by FGF23M was dependent on the VDR, since FGF23M significantly reduced the levels of serum 1,25(OH)2D3 [1,25-hydroxyvitamin D3] in VDR(+/+) mice, but not in VDR(-/-) mice. We conclude that FGF23 reduces renal Pi transport and 25-hydroxyvitamin D 1a-hydroxylase levels by a mechanism that is independent of the VDR. In contrast, the induction of 25-hydroxyvitamin D 24-hydroxylase and the reduction of serum 1,25(OH)2D3 levels induced by FGF23 are dependent on the VDR. (Keyword) fibroblast growth factor 23 / kidney / phosphate transport / vitamin D receptor (Link to Publication Site) ● Publication site (DOI): 10.1042/BJ20041799 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15885032 ● Search Scopus @ Elsevier (PMID): 15885032 ● Search Scopus @ Elsevier (DOI): 10.1042/BJ20041799 (DOI: 10.1042/BJ20041799, PubMed: 15885032)
85.	Masayuki Takahashi, X J Yang, S McWhinney, Nobuya Sano, C Eng, Susumu Kagawa, B T Teh and Hiro-omi Kanayama : cDNA microarray analysis assists in diagnosis of malignant intrarenal pheochromocytoma originally masquerading as a renal cell carcinoma, Journal of Medical Genetics, Vol.42, 48, 2005. (Summary) Intrarenal pheochromocytoma (paraganglioma) is a very rare tumour. Its diagnosis is often difficult to establish because of its rarity and its histological similarity to renal cell carcinoma (RCC). Recently, we examined the molecular signatures of different subtypes of kidney tumours by using cDNA microarray. The signature pattern for one tumour, which was originally diagnosed as granular cell RCC, was clearly distinct from that of any other subtype of kidney tumour, and led us to re-evaluate the case. Haematoxylin and eosin staining revealed histological features suggestive of pheochromocytoma, and immunohistochemical studies showed positive staining for neuroendocrine markers but not for keratin. A germline missense mutation, D119E, in the familial paraganglioma related gene succinate dehydrogenase subunit D (SDHD), was subsequently identified. The treatment modality was revised and radiotherapy was given, to which the patient responded, leading to a reduction in tumour size of 25% within the first month. To our knowledge, this is the first report of an intrarenal pheochromocytoma that was diagnosed with the assistance of cDNA microarray analysis. (Keyword) intrarenal pheochromocytoma / paraganglioma (Link to Publication Site) ● Publication site (DOI): 10.1136/jmg.2005.031708 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16061554 ● Search Scopus @ Elsevier (PMID): 16061554 ● Search Scopus @ Elsevier (DOI): 10.1136/jmg.2005.031708 (DOI: 10.1136/jmg.2005.031708, PubMed: 16061554)
86.	Ximing J. Yang, Min-Han Tan, Hyung L. Kim, Jonathon A. Ditlev, Mark W. Betten, Carolina E. Png, Eric J. Kort, Kunihiko Futami, Kyle A. Furge, Masayuki Takahashi, Hiro-omi Kanayama, Puay Hoon Tan, Bin Sing Teh, Chunyan Luan, Kim Wang, Michael Pins, Maria Tretiakova, John Anema, Richard Kahnoski, Theresa Nicol, Walter Stadler, Nicholas G. Vogelzang, Robert Amato, David Seligson, Robert Figlin, Arie Belldegrun, Craig G. Rogers and Bin Tean Teh : A Molecular Classification of Papillary Renal Cell Carcinoma, Cancer Research, Vol.65, No.13, 5628-5637, 2005. (Summary) Despite the moderate incidence of papillary renal cell carcinoma (PRCC), there is a disproportionately limited understanding of its underlying genetic programs. There is no effective therapy for metastatic PRCC, and patients are often excluded from kidney cancer trials. A morphologic classification of PRCC into type 1 and 2 tumors has been recently proposed, but its biological relevance remains uncertain. We studied the gene expression profiles of 34 cases of PRCC using Affymetrix HGU133 Plus 2.0 arrays (54,675 probe sets) using both unsupervised and supervised analyses. Comparative genomic microarray analysis was used to infer cytogenetic aberrations, and pathways were ranked with a curated database. Expression of selected genes was validated by immunohistochemistry in 34 samples with 15 independent tumors. We identified two highly distinct molecular PRCC subclasses with morphologic correlation. The first class, with excellent survival, corresponded to three histologic subtypes: type 1, low-grade type 2, and mixed type 1/low-grade type 2 tumors. The second class, with poor survival, corresponded to high-grade type 2 tumors (n = 11). Dysregulation of G1-S and G2-M checkpoint genes were found in class 1 and 2 tumors, respectively, alongside characteristic chromosomal aberrations. We identified a seven-transcript predictor that classified samples on cross-validation with 97% accuracy. Immunohistochemistry confirmed high expression of cytokeratin 7 in class 1 tumors and of topoisomerase IIalpha in class 2 tumors. We report two molecular subclasses of PRCC, which are biologically and clinically distinct and may be readily distinguished in a clinical setting. (Keyword) Adult / Aged / Carcinoma, Papillary / Carcinoma, Renal Cell / Chromosome Aberrations / Female / Gene Expression Profiling / Humans / Immunohistochemistry / Kidney Neoplasms / Male / Middle Aged / Oligonucleotide Array Sequence Analysis (Link to Publication Site) ● Publication site (DOI): 10.1158/0008-5472.CAN-05-0533 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15994935 ● Search Scopus @ Elsevier (PMID): 15994935 ● Search Scopus @ Elsevier (DOI): 10.1158/0008-5472.CAN-05-0533 (DOI: 10.1158/0008-5472.CAN-05-0533, PubMed: 15994935)
87.	Masayuki Takahashi, VERONICA PAPAVERO, JASON YUHAS, ERIC KORT, Hiro-omi Kanayama, Susumu Kagawa, ROBERT C. BAXTER, XIMING J. YANG, STEVEN G. GRAY and BIN TEAN TEH : Altered expression of members of the IGF-axis in clear cell renal cell carcinoma, International Journal of Oncology, Vol.26, No.4, 923-931, 2005. (Summary) Renal cell carcinoma (RCC) is a heterogeneous disease and its biology is poorly understood. The commonest subtype identified is clear cell RCC. The insulin-like growth factor axis is intimately involved with many cellular roles including that of renal development. Dysregulation of this axis has frequently been demonstrated in cancer. In this study, we examine the expression of several IGF-axis components, including receptors, ligands, and binding proteins in clear cell renal cell carcinoma. A series of clear cell RCCs with matched normal kidney from the same individuals were obtained. Total RNA was extracted and expression levels of genes examined using RNase protection analysis. We confirm the dysregulation of the IGF-axis within clear cell renal cell carcinoma including the upregulation of IGFBP-3, which is further validated by immunohistochemical staining on a tissue array containing 50 RCC: positive staining in 29/30 clear cell; 1/10 papillary and 0/10 chromophobe. In addition, we demonstrate that the expression of the A isoform of the insulin receptor is significantly upregulated, while that of IGFBP-5 are significantly downregulated in this tumour subtype. (Keyword) Carcinoma, Renal Cell / Case-Control Studies / Down-Regulation / Female / Gene Expression Regulation, Neoplastic / Humans / Immunohistochemistry / Insulin-Like Growth Factor Binding Protein 3 / Insulin-Like Growth Factor Binding Protein 5 / Male / RNA / Receptor, Insulin / Ribonucleases / Somatomedins / Up-Regulation (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15753986 ● Summary page in Scopus @ Elsevier: 2-s2.0-22844443822 (PubMed: 15753986, Elsevier: Scopus)
88.	Tomoharu Fukumori, Natsuo Oka, Toshinori Kasai, Tatsunori Tyubachi, Masayuki Takahashi, Masa-aki Nishitani, Susumu Kagawa and Hiro-omi Kanayama : Expression of galectin-3 is Associated With Resistance to Anticancer Drug-Induced Apoptosis in prostate Cancer, The Journal of Urology, Vol.173, No.4, 60, 2005.
89.	Natsuo Oka, Yasuyo Yamamoto, Masayuki Takahashi, Masaaki Nishitani, Hiro-omi Kanayama and Susumu Kagawa : Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer, BJU International, Vol.95, No.4, 660-663, 2005. (Summary) To investigate the relationship between angiopoietin-1 and -2 expression and the clinicopathological variables and clinical outcome in patients with bladder cancer treated by surgical resection, as both have been recently identified as antagonistic angiogenic factors which regulate tumour growth. The expression of angiopoietin-1 and -2 were assessed by immunohistochemistry in tissue sections from 52 transitional cell carcinomas of the bladder (33 grade 1, 15 grade 2, four grade 3, including two associated with carcinoma in situ; 22 were stage Ta, 19 T1 and 11 T2 tumours). Normal bladder specimens were also resected during each operation as controls. The expression angiopoietins were related to the clinicopathological variables of the tumours. Positive immunostaining was detected in 18 samples (35%) for angiopoietin-1 and in 23 (44) for angiopoietin-2. There was no significant difference in survival according to tumour angiopoietin-1 status in the patients, but in contrast the overall survival of patients with angiopoietin-2-positive tumours was significantly lower than for those with angiopoietin-2-negative tumours (P < 0.05). Positive angiopoietin-2 expression was significantly correlated with histological grade (P = 0.026), histological stage (P = 0.009) and poor prognosis (P < 0.05). On multivariate analysis, positive angiopoietin-2 expression was an independent negative predictor for survival (P = 0.042). These results suggest that angiopoietin-2 overexpression is associated with tumour progression, thereby indicating a poor prognosis for some patients treated by surgical resection for bladder carcinoma. (Keyword) Aged / Angiopoietin-1 / Carcinoma, Transitional Cell / Female / Humans / Immunohistochemistry / Male / Middle Aged / Prognosis / Survival Analysis / Urinary Bladder Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1464-410X.2005.05358.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15705099 ● Search Scopus @ Elsevier (PMID): 15705099 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1464-410X.2005.05358.x (DOI: 10.1111/j.1464-410X.2005.05358.x, PubMed: 15705099)
90.	Kyle A. Furge, Kerry A. Lucas, Masayuki Takahashi, Jun Sugimura, Eric J. Kort, Hiro-omi Kanayama, Susumu Kagawa, Philip Hoekstra, John Curry, Ximing J. Yang and Bin T Teh : Robust Classification of Renal Cell Carcinoma Based on Gene Expression Data and Predicted Cytogenetic Profiles, Cancer Research, Vol.64, No.12, 4117-4121, 2004. (Summary) Renal cell carcinoma (RCC) is a heterogeneous disease that includes several histologically distinct subtypes. The most common RCC subtypes are clear cell, papillary, and chromophobe, and recent gene expression profiling studies suggest that classification of RCC based on transcriptional signatures could be beneficial. Traditionally, however, patterns of chromosomal alterations have been used to assist in the molecular classification of RCC. The purpose of this study was to determine whether it was possible to develop a classification model for the three major RCC subtypes that utilizes gene expression profiles as the bases for both molecular genetic and cytogenetic classification. Gene expression profiles were first used to build an expression-based RCC classifier. The RCC gene expression profiles were then examined for the presence of regional gene expression biases. Regional expression biases are genetic intervals that contain a disproportionate number of genes that are coordinately up- or down-regulated. The presence of a regional gene expression bias often indicates the presence of a chromosomal abnormality. In this study, we demonstrate an expression-based classifier can distinguish between the three most common RCC subtypes in 99% of cases (n = 73). We also demonstrate that detection of regional expression biases accurately identifies cytogenetic features common to RCC. Additionally, the in silico-derived cytogenetic profiles could be used to classify 81% of cases. Taken together, these data demonstrate that it is possible to construct a robust classification model for RCC using both transcriptional and cytogenetic features derived from a gene expression profile. (Keyword) Carcinoma, Renal Cell / Gene Expression Profiling / Humans / Kidney Neoplasms / Oligonucleotide Array Sequence Analysis / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1158/0008-5472.CAN-04-0534 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15205321 ● Search Scopus @ Elsevier (PMID): 15205321 ● Search Scopus @ Elsevier (DOI): 10.1158/0008-5472.CAN-04-0534 (DOI: 10.1158/0008-5472.CAN-04-0534, PubMed: 15205321)
91.	Natsuo Oka, Yuushi Okumura, Hiro-omi Kanayama, Hirofumi Izaki, Masumi Okamoto, Hiroshi Kido and Susumu Kagawa : Amiloride and Urinary Trypsin Inhibitor Inhibit Urothelial Cancer Invasion, European Urology, Vol.44, No.6, 737-741, 2003. (Summary) To determine the contribution of urokinase-type plasminogen activator (uPA) and plasmin in the invasion of highly invasive urothelial cancer cells. We compared expression levels of mRNA and protease activity of uPA and plasmin formation in primary cultures of the noninvasive transitional cell carcinoma, UCT-1, and in the highly invasive type, UCT-2. By using in vitro cell invasion assay system, we evaluated the effects of amiloride and urinary trypsin inhibitor (UTI), which inhibit uPA and plasmin, respectively, on invasion by both cell lines. Expression levels of mRNA, protein, and activities of uPA were significantly higher (p<0.005) and resulted in more plasminogen activation in UCT-2 than in UCT-1. Amiloride and UTI significantly inhibited plasmin formation and the invasion of both cell lines (p<0.001). High expression levels of mRNA, activities of uPA and high plasmin formation significantly potentiated the invasiveness of urothelial cancer cells. Thus, inhibitors of uPA and plasmin, such as amiloride and UTI, respectively, could be useful therapeutic tools with which to treat urothelial cancer. (Keyword) Amiloride / Carcinoma, Transitional Cell / Cell Line, Tumor / Enzyme-Linked Immunosorbent Assay / Female / Humans / Male / Neoplasm Invasiveness / RNA, Messenger / Sensitivity and Specificity / Trypsin Inhibitors / Urokinase-Type Plasminogen Activator / Urothelium (Link to Publication Site) ● Publication site (DOI): 10.1016/S0302-2838(03)00383-X (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14644129 ● Search Scopus @ Elsevier (PMID): 14644129 ● Search Scopus @ Elsevier (DOI): 10.1016/S0302-2838(03)00383-X (DOI: 10.1016/S0302-2838(03)00383-X, PubMed: 14644129)
92.	Jindong Chen, Weng-Onn Lui, Michele D. Vos, Geoffrey J. Clark, Masayuki Takahashi, Jacqueline Schoumans, Sok Kean Khoo, David Petillo, Todd Lavery, Jun Sugimura, Dewi Astuti, Chun Zhang, Susumu Kagawa, Eamonn R. Maher, Catharina Larsson, Arthur S. Alberts, Hiro-omi Kanayama and Bin Tean Teh : The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas, Cancer Cell, Vol.4, No.5, 405-413, 2003. (Summary) By positional cloning, we identified two breakpoint-spanning genes in a familial clear cell renal cell carcinoma (CCRCC)-associated t(1;3)(q32.1;q13.3): LSAMP and NORE1 (RASSF1 homolog). Both genes are downregulated in 9 of 9 RCC cell lines. While the NORE1A promoter predominantly presents partial methylation in 6 of the cell lines and 17/53 (32%) primary tumors, the LSAMP promoter is completely methylated in 5 of 9 cell lines and in 14/53 (26%) sporadic and 4 familial CCRCCs. Expression of LSAMP and NORE1A proteins in CCRCC cell lines inhibited cell proliferation. These characteristics indicate that LSAMP and NORE1A may represent new candidate tumor suppressors for CCRCC. (Keyword) Adenocarcinoma, Clear Cell / Animals / Base Sequence / Carcinoma, Renal Cell / Cell Adhesion Molecules, Neuronal / Cell Division / Cells, Cultured / Cloning, Molecular / DNA Methylation / GPI-Linked Proteins / Gene Expression Regulation, Neoplastic / Humans / Molecular Sequence Data / Monomeric GTP-Binding Proteins (Link to Publication Site) ● Publication site (DOI): 10.1016/S1535-6108(03)00269-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14667507 ● Search Scopus @ Elsevier (PMID): 14667507 ● Search Scopus @ Elsevier (DOI): 10.1016/S1535-6108(03)00269-1 (DOI: 10.1016/S1535-6108(03)00269-1, PubMed: 14667507)
93.	Yasuyo Yamamoto, Noriyuki Nishimura, Shinya Morimoto, Hiroko Kitamura, Shinji Manabe, Hiro-omi Kanayama, Susumu Kagawa and Takuya Sasaki : Distinct roles of Rab3B and Rab13 in the polarized transport of apical, basolateral, and tight junctional membrane proteins to the plasma membrane, Biochemical and Biophysical Research Communications, Vol.308, No.2, 270-275, 2003. (Summary) Regulated transport of proteins to distinct plasma membrane domains is essential for the establishment and maintenance of cell polarity in all eukaryotic cells. The Rab family small G proteins play a crucial role in determining the specificity of vesicular transport pathways. Rab3B and Rab13 localize to tight junction in polarized epithelial cells and cytoplasmic vesicular structures in non-polarized fibroblasts, but their functions are poorly understood. Here we examined their roles in regulating the cell-surface transport of apical p75 neurotrophin receptor (p75NTR), basolateral low-density lipoprotein receptor (LDLR), and tight junctional Claudin-1 using transport assay in non-polarized fibroblasts. Overexpression of Rab3B mutants inhibited the cell-surface transport of LDLR, but not p75NTR and Claudin-1. In contrast, overexpression of Rab13 mutants impaired the transport of Claudin-1, but not LDLR and p75NTR. These results suggest that Rab3B and Rab13 direct the cell-surface transport of LDLR and Claudin-1, respectively, and may contribute to epithelial polarization. (Keyword) Rab3B / Rab13 / Polarized transport / Tight junction / Claudins (Link to Publication Site) ● Publication site (DOI): 10.1016/S0006-291X(03)01358-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12901864 ● Search Scopus @ Elsevier (PMID): 12901864 ● Search Scopus @ Elsevier (DOI): 10.1016/S0006-291X(03)01358-5 (DOI: 10.1016/S0006-291X(03)01358-5, PubMed: 12901864)
94.	Yasushi Kurokawa, Masayuki Takahashi, Hiro-omi Kanayama and Susumu Kagawa : Strategy for treating pediatreic urological disease in the department of urology, The Nishinihon Journal of Urology, Vol.65, No.7, 433-436, 2003. (Keyword) strategy for pediatric disease / hypospadias / urethrocutaneous fistula / phimosis / undescended testis (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572543025429482496 ● Summary page in Scopus @ Elsevier: 2-s2.0-0042155842 (CiNii: 1572543025429482496, Elsevier: Scopus)
95.	AHMED ANWAR, YASUSHI KUROKAWA, Masayuki Takahashi, YASUYO YAMAMOTO, Hiro-omi Kanayama and Susumu Kagawa : Functional evaluation of one-stage urethroplasty with parameatal foreskin flaps repair of hypospadias using uroflowmetry, International Journal of Urology, Vol.10, No.6, 297-301, 2003. (Summary) Uroflowmetry is a simple, accurate and non-invasive test. In the present study, we aimed to determine the role of uroflowmetry in the evaluation of the functional results of one-stage urethroplasty with parameatal foreskin flaps (OUPF) technique. Twenty-one children who had undergone OUPF repair at our clinic were selected. Selection criteria were that patients were toilet trained and had no fistula. Uroflowmetry was performed using a rotating disk sensor. The maximum flow rate (Qmax) and average flow rate (Qave) were plotted against body surface related flow rate nomograms. The upper 95% tolerance limits for the 5th, 10th, 15th, 20th and 25th percentiles of the normal population were used for comparison. The flow pattern was classified as bell ring, plateau or intermittent. The median age at the first uroflowmetry was 4.7 years (range 2.5-8.6) and the mean postoperative follow-up period was 25 months (range 1-58). Twelve children had Qmax above the 25th, six between the 5th and 25th and three less than the 5th percentiles of the normal population. A normal bell-shaped flow curve was obtained in 17 (80.6%) of the children. Of the three children with Qmax below the 5th percentile, two children had a plateau flow pattern and were found to have a urethal stricture. Dilation was performed successfully, after which the Qmax returned to the normal range and the symptoms disappeared. The OUPF technique provided satisfactory functional results for hypospadias repair. We advocate the use of uroflowmetry for routine postoperative follow-up. (Keyword) hypospadias / uroflowmetry / OUPF (Link to Publication Site) ● Publication site (DOI): 10.1046/j.1442-2042.2003.00636.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12757597 ● Search Scopus @ Elsevier (PMID): 12757597 ● Search Scopus @ Elsevier (DOI): 10.1046/j.1442-2042.2003.00636.x (DOI: 10.1046/j.1442-2042.2003.00636.x, PubMed: 12757597)
96.	Yasushi Kurokawa, Hiro-omi Kanayama, Ahmed Anwar, Tomoharu Fukumori, Yasuyo Yamamoto, Masayuki Takahashi, Susumu Kagawa, Yosihide Murakami and Toshiro Terachi : Laparoscopic nephroureterectomy for dysplastic kidney in children: an initial experience, International Journal of Urology, Vol.9, No.11, 613-617, 2002. (Summary) Laparoscopic nephroureterectomy for dysplastic kidney is now becoming a widely accepted procedure. We report here our initial experience with laparoscopic nephroureterectomy in four girls. Between 1993 and 1999, laparoscopic nephroureterectomy was performed in four girls (mean age 5.3 years). Three patients had an ectopic dysplastic kidney with ectopic ureter, and one patient had hydronephrosis with megaureter due to distal ureteral atresia of the upper moiety in a duplicated dysplastic kidney. The transperitoneal approach was used in all cases. Mean operative time was 195 min (range 150-266). Blood loss was minimal. All operations were completed successfully and there were no intraoperative or postoperative complications except for subcutaneous emphysema in one patient (case 4). Postoperative analgesia was used in three patients and administered in the form of diclofenac sodium suppositories 12.5 mg (cases 1 and 2) or acetaminophen suppositories 50 mg (case 3) for 1-2 days. One patient did not require any analgesia (case 4). Oral fluid intake was resumed on the first postoperative day and ambulation began within 1-3 days (mean 1.6, cases 1, 2 and 3) and 6 days (case 4). All children returned to normal activity within 3-6 days of surgery. Mean postoperative hospital stay was 7.3 days. All cases had uneventful courses after discharge. Laparoscopic nephroureterectomy can be performed safely, with minimal postoperative pain, excellent cosmetic results and early ambulation. We advocate the use of laparoscopy for the diagnosis and treatment of dysplastic kidney with ectopic ureter. (Keyword) children / dysplastic kidney / laparoscopic nephroureterectomy (Link to Publication Site) ● Publication site (DOI): 10.1046/j.1442-2042.2002.00534.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12534902 ● Search Scopus @ Elsevier (PMID): 12534902 ● Search Scopus @ Elsevier (DOI): 10.1046/j.1442-2042.2002.00534.x (DOI: 10.1046/j.1442-2042.2002.00534.x, PubMed: 12534902)
97.	Masayuki Takahashi, Daniel R. Rhodes, Kyle A. Furge, Hiro-omi Kanayama, Susumu Kagawa, Brian B. Haab and Bin Tean Teh : Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification, Proceedings of the National Academy of Sciences of the United States of America, Vol.98, No.17, 9754-9759, 2001. (Summary) To better understand the molecular mechanisms that underlie the tumorigenesis and progression of clear cell renal cell carcinoma (ccRCC), we studied the gene expression profiles of 29 ccRCC tumors obtained from patients with diverse clinical outcomes by using 21,632 cDNA microarrays. We identified gene expression alterations that were both common to most of the ccRCC studied and unique to clinical subsets. There was a significant distinction in gene expression profile between patients with a relatively nonaggressive form of the disease [100% survival after 5 years with the majority (15/17 or 88%) having no clinical evidence of metastasis] versus patients with a relatively aggressive form of the disease (average survival time 25.4 months with a 0% 5-year survival rate). Approximately 40 genes most accurately make this distinction, some of which have previously been implicated in tumorigenesis and metastasis. To test the robustness and potential clinical usefulness of this molecular distinction, we simulated its use as a prognostic tool in the clinical setting. In 96% of the ccRCC cases tested, the prediction was compatible with the clinical outcome, exceeding the accuracy of prediction by staging. These results suggest that two molecularly distinct forms of ccRCC exist and that the integration of expression profile data with clinical parameters could serve to enhance the diagnosis and prognosis of ccRCC. Moreover, the identified genes provide insight into the molecular mechanisms of aggressive ccRCC and suggest intervention strategies. (Keyword) Adenocarcinoma, Clear Cell / Carcinoma, Renal Cell / Follow-Up Studies / Gene Expression Profiling / Gene Expression Regulation, Neoplastic / Humans / Image Processing, Computer-Assisted / Japan / Kidney Neoplasms / Neoplasm Proteins / Oligonucleotide Array Sequence Analysis / Prognosis / Risk / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1073/pnas.171209998 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11493696 ● Search Scopus @ Elsevier (PMID): 11493696 ● Search Scopus @ Elsevier (DOI): 10.1073/pnas.171209998 (DOI: 10.1073/pnas.171209998, PubMed: 11493696)
98.	Natsuo Oka, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Susumu Kagawa : Secondary amyloidosis of the bladder causing macroscopic hematuria, International Journal of Urology, Vol.8, No.6, 330-332, 2001. (Summary) Bladder involvement in amyloidosis is unusual. The case of an 80-year-old man with macroscopic hematuria caused by secondary amyloidosis of the bladder is described. Cystoscopic examination revealed only a diffuse edematous area and bleeding. No tumor-like lesions were identified. Transurethral biopsy revealed amyloid deposits. Macroscopic hematuria disappeared spontaneously after cystoscopy and bladder biopsy. The patient has been followed up without treatment and is currently free of symptoms. (Keyword) Aged / Aged, 80 and over / Amyloidosis / Hematuria / Humans / Male / Urinary Bladder (Link to Publication Site) ● Publication site (DOI): 10.1046/j.1442-2042.2001.00309.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11389752 ● Search Scopus @ Elsevier (PMID): 11389752 ● Search Scopus @ Elsevier (DOI): 10.1046/j.1442-2042.2001.00309.x (DOI: 10.1046/j.1442-2042.2001.00309.x, PubMed: 11389752)
99.	Hiro-omi Kanayama, Weng-Onn Lui, Masayuki Takahashi, Takushi Naroda, Darek Kedra, Fung Ki Wong, Yoko Kuroki, Yutaka Nakahori, Catharina Larsson, Susumu Kagawa and Bin Tean Teh : Association of a novel constitutional translocation t(1q;3q) with familial renal cell carcinoma, Journal of Medical Genetics, Vol.38, No.3, 165-170, 2001. (Summary) Four cases of late onset clear cell renal cell carcinoma (RCC), a case of gastric cancer, and a case of exocrine pancreatic cancer were identified in a Japanese family. In order to elucidate the underlying mechanism for tumorigenesis in this family, extensive genetic studies were performed including routine and spectral karyotyping (SKY), fluorescence in situ hybridisation (FISH), comparative genomic hybridisation (CGH), loss of heterozygosity studies (LOH), and VHL mutation analysis. A germline translocation t(1;3)(q32-q41;q13-q21) was identified by karyotyping in five members of the family including all three RCC cases tested. The translocation was refined to t(1;3)(q32;q13.3) by FISH analysis using locus specific genomic clones, and the two breakpoints were mapped to a 5 cM region in 3q13.3 and a 3.6 cM region in 1q32. Both CGH and allelotyping using microsatellite markers showed loss of the derivative chromosome 3 carrying a 1q segment in the three familial RCCs analysed. Additional chromosomal imbalances were identified by CGH, including amplifications of chromosomes 5 and 7 and loss of 8p and 9. No germline VHL mutation was found but two different somatic mutations, a splice (IVS1-2A>C) and a frameshift (726delG), were identified in two RCCs from the same patient confirming their distinct origin. Taken together, these results firmly support a three step model for tumorigenesis in this family. A constitutional translocation t(1q;3q) increased the susceptibility to loss of the derivative chromosome 3 which is then followed by somatic mutations of the RCC related tumour suppressor gene VHL located in the remaining copy of chromosome 3. (Keyword) familial renal cell carcinoma / translocation / von Hippel-Lindau disease / loss of heterozygosity (Link to Publication Site) ● Publication site (DOI): 10.1136/jmg.38.3.165 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11238683 ● Search Scopus @ Elsevier (PMID): 11238683 ● Search Scopus @ Elsevier (DOI): 10.1136/jmg.38.3.165 (DOI: 10.1136/jmg.38.3.165, PubMed: 11238683)
100.	Yasushi Kurokawa, Ahmed Anwar, Masayuki Takahashi, Lee Kyung Soo, Yasuyo Yamamoto, Hiro-omi Kanayama, Susumu Kagawa, Tohru Inai and Masaharu Kan : De-epithelialized flap for closure of urethrocutaneous fistula after hypospadias repair, Japanese Journal of Pediatric Urology, Vol.10, No.2, 19(129)-23(133), 2001. (Keyword) urethrocutaneous fistula / de-epithelialized flap / hypospadias (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572261550132603776 (CiNii: 1572261550132603776)
101.	Hiro-omi Kanayama, Masayuki Takahashi, Masa-aki Nishitani and Susumu Kagawa : Analysis of serum soluble interferon α/β receptor levels in patients with urological diseases, The Japanese Journal of Urology, Vol.91, No.9, 630-636, 2000. (Summary) (Purpose)In order to define the clinical significance of serum soluble Interferon α/βreceptor(sIFN/α/βR)levels, we determined sIFNα/βR concentrations in serum of patients with urological benign and malignant diseases. (Materials and Methods)Serum sIFNα/βR levels were measured in normal control(n=22), patients with benign diseases(n=50)included urolithiasis(n=16), prostatic hypertrophy(n=13), and malignant diseases included bladder cancer(n=49), renal cell carcinoma(n=30)and prostate cancer(n=36)by the enzyme linked immunosolbent assay(ELISA)using monoclonal and pliyclonal antibodies. The levels of serum sIFNα/βR was correlated with the results of other hematoserological examinations, and clinical or pathological characters of each urological malignancies. (Results)The serum sIFNα/βR levels(pg/ml)of patients with urolithiasis(2,370.6±640.6, p=0.0002), benign prostatic hypertrophy(2,121.1±55.06, p=0.0103), bladder cancer(2,512.3±1,012.3,p=0.0006), renal cell carcinoma(2,686.4±1,510.9, p=0.0046), prostate cancer(3,188.7±1,788.0, P=0.0003)showed significantly higher values than those of controls(1,790.5±346.7). Moreover, we found statistically significant correlations among serum creatinine(Cr)levels and sIFNα/βR levels. However, there were no correlations between the sIFNα/βR levels and clinical stage, or histological grade in the patients with bladder cancer or prostate cancer, whenever the levels of sIFNα/βR were corrected by serum Cr levels. On the other hand, high level of corrected serum sIFNα/βR was observed in patients with high stage or high grade renal cell carcinoma, but not significant statistically. (Conclusion)Elevated serum sIFNα/βR was observed in patients with urological decease. Further examinations should be necessary to determine the clinical usefulness of serum sIFNα/βR. (Keyword) serum soluble Interferon α/β receptor / urological disease / clinical usefulness (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11068427 ● CiNii @ National Institute of Informatics (CRID): 1390001205057788288 ● Summary page in Scopus @ Elsevier: 2-s2.0-0033792143 (PubMed: 11068427, CiNii: 1390001205057788288, Elsevier: Scopus)
102.	K Kanda, Masayuki Takahashi, Yoshihide Murakami, Hiro-omi Kanayama and Susumu Kagawa : The role of the activated form of matrix metalloproteinase-2 in urothelial cancer, BJU International, Vol.86, No.4, 553-557, 2000. (Summary) To investigate the expression of matrix metalloproteinase-2 (MMP-2, reportedly associated with cancer cell invasion and metastasis in many human cancers) in urothelial tumours and thus define its role in this disease. Materials and methods The expression of both the activated form of MMP-2 and total MMP-2 (activated + latent form) was measured using gelatine zymography in tissue obtained surgically from 61 patients with urothelial cancer. The correlation between the level of the activated form of MMP-2 and clinical and histological variables was assessed. The expression of activated and total MMP-2 were significantly higher in invasive tumour tissue and both levels were correlated with histological grade. In particular, the level of activated MMP-2 was more closely correlated than that of total MMP-2 in invasive tumour tissue. Moreover, high levels of activated MMP-2 were strongly associated with shorter disease-specific survival (P = 0.0016). These findings suggest that activated MMP-2 plays a significant role in invasion of urothelial cancer and that the level of activated MMP-2 expression is a useful prognostic indicator. (Keyword) Matrix metalloproteinase-2 / urothelial cancer / gelatine zymography / invasion / prognostic indicator (Link to Publication Site) ● Publication site (DOI): 10.1046/j.1464-410X.2000.00734.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10971291 ● Search Scopus @ Elsevier (PMID): 10971291 ● Search Scopus @ Elsevier (DOI): 10.1046/j.1464-410X.2000.00734.x (DOI: 10.1046/j.1464-410X.2000.00734.x, PubMed: 10971291)
103.	Li NC, Kazaya Kanda, Tomoharu Fukumori, Yoshio Inoue, Masa-aki Nishitani, Hiro-omi Kanayama and Susumu Kagawa : The role of expression of vascular endothelial growth factor isoforms and platelet-derived endothelial cell growth factor in bladder cancer., Urologic Oncology, Vol.5, 1-6, 2000.

Academic Paper (Unrefereed Paper):

1.	Yutaro Sasaki, 安宅真利花, 多田航生, 中西亮太, 橋本啓佑, 吉岡拓哉, Kei Daizumoto, 尾崎啓介, 上野恵輝, Megumi Tsuda, 楠原義人, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hiro-omi Kanayama, Hideya Kashihara and Takuya Tokunaga : Two Cases of Robot-Assisted Total Pelvic Exenteration and Intracorporeal Ileal Conduit for Locally Advanced Rectal Cancer, Acta Urologica Japonica, Vol.68, No.5, 155-159, 2022. (Summary) We describe two cases of locally advanced rectal cancer (LARC) treated with robot-assisted total pelvic exenteration (Ra-TPE) and intracorporeal ileal conduit (ICIC). The first case was in a 71-year-old man with LARC (RbP, T4bN2bM0, cStage IIIc). He was started on bevacizumab+S-1/oxaliplatin therapy in July 2019. In April 2020, he developed Fournier's gangrene due to subcutaneous penetration of rectal cancer. Emergency drainage and colostomy were performed simultaneously, and a percutaneous vesical fistula was created. In May 2020, Ra-TPE and ICIC were performed. Histopathological analysis revealed moderately differentiated tubular adenocarcinoma (ypT3N0, RM0). At postoperative 9 months, thoracoscopic right upper lobectomy was performed for a right metastatic lung tumor. At present, ie, at postoperative 12 months, the patient has been free of recurrence and metastasis, with a carcinoembryonic antigen (CEA) level of 1.4 ng/ml and carcinoma antigen (CA) 19-9 level of 11 U/ml. The second case was in a 61-year-old man with fistula-associated anal cancer (PRb, T4N3M1b, cStage IVb). In April 2019, he was started on FOLFOXIRI+cetuximab therapy. In August 2020, Ra-TPE, ICIC, and transperineal total mesenteric excision were performed. Histopathological analysis revealed adenocarcinoma (ypT4N0, RM0). At postoperative 11 months, thoracoscopic left lower lobectomy was performed for a left metastatic lung tumor. At present, ie, at postoperative 12 months, the patient remains free of recurrence and metastasis, with a CEA level of 7.3 ng/ml and CA19-9 level of 12 U/ml. Ra-TPE, which allows transperineal removal of a specimen, can be performed as a minimally invasive surgery in combination with ICIC. (Keyword) 腫瘍多剤併用療法骨盤内臓器全摘術生検腺癌(X線診断,病理学,治療) X線CT 直腸腫瘍(X線診断,病理学,治療) 尿路変更術膀胱造瘻術ネオアジュバント療法 Oxaliplatin(治療的利用) TS-1(治療的利用) Bevacizumab(治療的利用) 放射線化学療法結腸造瘻術ロボット手術ヒト中年(45∼64) 高齢者(65∼79) 男 (Link to Publication Site) ● Publication site (DOI): 10.14989/actauroljap_68_5_155 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390855656035011840 ● Summary page in Scopus @ Elsevier: 2-s2.0-85132908756 (DOI: 10.14989/actauroljap_68_5_155, CiNii: 1390855656035011840, Elsevier: Scopus)
2.	Masayuki Takahashi and Hiro-omi Kanayama : Injury of spleen, pancreas, and bowel during laparoscopic adrenalectomy or nephrectomy, Japanese Journal of Clinical Urology, Vol.70, No.11, 868-874, 2016. (Keyword) pancreatic injury / 腸管損傷 (Link to Publication Site) ● Publication site (DOI): 10.11477/mf.1413205799 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390846634843361024 ● Search Scopus @ Elsevier (DOI): 10.11477/mf.1413205799 (DOI: 10.11477/mf.1413205799, CiNii: 1390846634843361024)
3.	井内俊輔, Hidehisa Mori, 大豆本圭, 津田恵, Yoshito Kusuhara, Jun-ichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 徳島大学泌尿器科におけるBCG膀胱内注入療法の臨床検討, 泌尿器外科, Vol.28, No.3, 330-331, 2015.
4.	Kunihisa Yamaguchi and Hiro-omi Kanayama : 後期研修医がおさえておきたい泌尿器疾患TOP30 尿路造影, 泌尿器外科, Vol.Vol.26, 2013.
5.	Masahiko Takemura, Hirofumi Izaki, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 子宮頸癌副腎転移との識別が困難であった18F-FDG PET/CT陽性副腎皮質線種の1例, 泌尿紀要, Vol.59, 91-95, 2013.
6.	Tomoharu Fukumori, Shunsuke Furutani, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 限局性前立腺癌に対する密封小線源療法のリスク分類別治療成績, 泌尿器外科, Vol.27, No.8, 1651-1654, 2012.
7.	Tomoteru Kishimoto, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Hiro-omi Kanayama and Susumu Kagawa : 射精障害を契機に発見されたトルコ鞍空洞症を伴う汎下垂体機能低下症の1例, The Japanese Journal of Sexual Medicine, Vol.26, No.1, 21-26, 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572543024868809472 (CiNii: 1572543024868809472)
8.	Hiro-omi Kanayama : Symposium: Next generation surgical treatment, The Nishinihon Journal of Urology, Vol.73, No.5, 207-227, 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520853834309704576 (CiNii: 1520853834309704576)
9.	津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : BCG膀胱内注入療法後に生じたReiter症候群の1例, The Nishinihon Journal of Urology, Vol.73, No.10, 559-561, 2011. (Keyword) *BCGワクチン(治療的利用,毒性・副作用) (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-82055207262 (Elsevier: Scopus)
10.	Noriomi Miyao, Seiji Naito, Seiichiro Ozono, Nobuo Shinohara, Naoya Masumori, Tatsuo Igarashi, Masahiro Nakao, Tomoyasu Tsushima, Yutaka Senga, Shigeo Horie, Hiro-omi Kanayama, Noriaki Tokuda and Mikio Kobayashi : Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer., Urology, Vol.77, No.2, 379-384, 2010. (Summary) To evaluate in collaboration the clinical features of late recurrence of renal cell carcinoma (RCC). Late recurrence is one of the specific biologic behaviors of RCC; however, the clinical and pathologic features of the late recurrence of RCC are not fully understood. (Keyword) Adolescent / Adult / Aged / Aged, 80 and over / Carcinoma, Renal Cell / Female / Humans / Japan / Kidney Neoplasms / Male / Middle Aged / Neoplasm Recurrence, Local / Retrospective Studies / Societies, Medical / Time Factors / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.1016/j.urology.2010.07.462 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20970828 ● Search Scopus @ Elsevier (PMID): 20970828 ● Search Scopus @ Elsevier (DOI): 10.1016/j.urology.2010.07.462 (DOI: 10.1016/j.urology.2010.07.462, PubMed: 20970828)
11.	Taiji Tsukamoto, Nobuo Shinohara, Norihiko Tsuchiya, Yasuo Hamamoto, Masayuki Maruoka, Hiroyuki Fujimoto, Masashi Niwakawa, Hirotsugu Uemura, Michiyuki Usami, Akito Terai, Hiro-omi Kanayama, Yoshiteru Sumiyoshi, Masatoshi Eto and Hideyuki Akaza : Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1., Japanese Journal of Clinical Oncology, Vol.41, No.1, 17-24, 2010. (Summary) To assess the efficacy and safety of everolimus in Japanese patients with metastatic renal cell carcinoma. (Keyword) Adult / Aged / Antineoplastic Agents / Carcinoma, Renal Cell / Disease-Free Survival / Double-Blind Method / Drug Administration Schedule / Female / Humans / Immunosuppressive Agents / Incidence / International Cooperation / Japan / Kidney Neoplasms / Male / Middle Aged / Odds Ratio / Pneumonia / Prospective Studies / Sirolimus / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1093/jjco/hyq166 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20965941 ● Search Scopus @ Elsevier (PMID): 20965941 ● Search Scopus @ Elsevier (DOI): 10.1093/jjco/hyq166 (DOI: 10.1093/jjco/hyq166, PubMed: 20965941)
12.	Yasuo Kawanishi, Kazuyoshi Izumi, Hiroshi Muguruma, Tomohiro Mashima, Masatsugu Komori, Masahito Yamanaka, Akira Yamamoto, Akira Numata, Tomoteru Kishimoto and Hiro-omi Kanayama : Three-dimensional CT cavernosography: reconsidering venous ligation surgery on the basis of the modern technology., BJU International, Vol.107, No.9, 1442-1446, 2010. (Summary) To examine the feasibility of three-dimensional (3D) CT cavernosography in the diagnosis of corporal veno-occlusive dysfunction. (Keyword) Adolescent / Adult / Aged / Feasibility Studies / Humans / Impotence, Vasculogenic / Ligation / Male / Middle Aged / Penis / Phosphodiesterase 5 Inhibitors / Regional Blood Flow / Tomography, X-Ray Computed / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1464-410X.2010.09644.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20868388 ● Search Scopus @ Elsevier (PMID): 20868388 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1464-410X.2010.09644.x (DOI: 10.1111/j.1464-410X.2010.09644.x, PubMed: 20868388)
13.	Tomoharu Fukumori, Takahiro Koizumi, 山本洋之, 湯浅明人, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : Training system of laparoscopic surgery for young urologists in the university of Tokushima, The Nishinihon Journal of Urology, Vol.72, No.6, 285-288, 2010. (Keyword) laparoscopic surgery / training / 腎臓摘出術 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520009408512732416 ● Summary page in Scopus @ Elsevier: 2-s2.0-77954345645 (CiNii: 1520009408512732416, Elsevier: Scopus)
14.	Manabu Sakaki, Tomoharu Fukumori, Tomoya Fukawa, Essam Elsamman, Avirmed Shiirevnyamba, Hiroyoshi Nakatsuji and Hiro-omi Kanayama : Clinical significance of Galectin-3 in clear cell renal cell carcinoma., The Journal of Medical Investigation : JMI, Vol.57, No.1-2, 152-157, 2010. (Summary) Overexpression of galectin-3 in a variety of cancer cell lines has been shown to correlate with tumor progression and metastasis. In this study, we investigated the expression of galectin-3 in clear cell renal cell carcinoma (CC-RCC) and evaluated the relationship between galectin-3 expression levels and the clinicopathological features of CC-RCC. Expression of galectin-3 in the kidney cancer cell lines Caki-1, Caki-2, A704, ACHN and KPK-1 were evaluated using western blot analysis, while galectin-3 expression in CC-RCC tissues and normal parenchyma were measured by real-time PCR and immunohistochemistry. We found that galectin-3 was overexpressed in the Caki-1, Caki-2, A704, ACHN and KPK-1 cell lines and that the expression level in CC-RCC was also significantly higher than that in renal parenchyma obtained from the same patient samples (p=0.039). Galectin-3 expression in CC-RCC with distant metastasis was also significantly higher than that in CC-RCC without distant metastasis (p=0.045). In conclusion, we revealed that galectin-3 is highly expressed in CC-RCC, especially in CC-RCC with distant metastasis, suggesting that galectin-3 may serve as a novel target molecule for predicting CC-RCC metastasis. (Keyword) Adult / Aged / Aged, 80 and over / Carcinoma, Renal Cell / Cell Line, Tumor / Female / galectin-3 / Humans / Kidney Neoplasms / Male / Middle Aged / Neoplasm Metastasis / Prognosis (Tokushima University Institutional Repository) ● Metadata: 78648 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.57.152 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20299755 ● Search Scopus @ Elsevier (PMID): 20299755 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.57.152 (Tokushima University Institutional Repository: 78648, DOI: 10.2152/jmi.57.152, PubMed: 20299755)
15.	Hirofumi Izaki, Masayuki Takahashi, Avirmed Shiirevnyamba, Ryuichi Taue, Hiroyuki Furumoto, Yoshimi Bando, Yoshihide Murakami, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Tomoharu Fukumori and Hiro-omi Kanayama : Long-term recurrence-free survivor after laparoscopic removal of solitary adrenal metastasis from endometrial adenocarcinoma., The Journal of Medical Investigation : JMI, Vol.57, No.1-2, 174-177, 2010. (Summary) Solitary adrenal metastasis from endometrial adenocarcinoma is extremely rare. We report herein the case of a laparoscopically resected solitary adrenal metastasis originating from endometrial adenocarcinoma. The patient was a 55-year-old woman who had undergone total abdominal hysterectomy for stage IIIc endometrial carcinoma, followed by 7 courses of adjuvant chemotherapy comprising carboplatin and paclitaxel. However, the patient developed an isolated right adrenal metastasis 15 months postoperatively. The solitary adrenal metastasis (diameter, 5.7 cm) was removed laparoscopically. The patient has now been in good health without recurrence for 5 years and 7 months after laparoscopic surgery. To the best of our knowledge, this is the first case of solitary adrenal metastasis originating from endometrial adenocarcinoma that is controlled for the long term by successful laparoscopic resection. (Keyword) Adenocarcinoma / Adrenal Gland Neoplasms / Endometrial Neoplasms / Female / Humans / Laparoscopy / Middle Aged / Survivors / Tomography, X-Ray Computed (Tokushima University Institutional Repository) ● Metadata: 77529 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.57.174 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20299759 ● Search Scopus @ Elsevier (PMID): 20299759 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.57.174 (Tokushima University Institutional Repository: 77529, DOI: 10.2152/jmi.57.174, PubMed: 20299759)
16.	Takahiro Koizumi, Hiroyoshi Nakatsuji, Tomoya Fukawa, Shiirevnyamba Avirmed, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : The role of actinin-4 in bladder cancer invasion., Urology, Vol.75, No.2, 357-364, 2009. (Summary) To examine actinin-4 expression levels in bladder cancer, in particular its levels during cellular growth and invasion. Actinin-4 is an actin-binding protein that is associated with cell motility and cancer metastasis. (Keyword) Actinin / Cell Proliferation / Humans / Neoplasm Invasiveness / RNA, Messenger / Tumor Cells, Cultured / Urinary Bladder Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1016/j.urology.2009.09.037 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19969329 ● Search Scopus @ Elsevier (PMID): 19969329 ● Search Scopus @ Elsevier (DOI): 10.1016/j.urology.2009.09.037 (DOI: 10.1016/j.urology.2009.09.037, PubMed: 19969329)
17.	Hiro-omi Kanayama, Susumu Kagawa, Utsunomiya Masato, Kawashima Shu, Sumitani Haruo and Yokozeki Hideaki : Mass screening for prostate cancer in Tokushima city - Analysis of the 3 year results from 2001 to 2003 -, Japanese journal of urological surgery, Vol.18, No.8, 916-920, 2005. (Keyword) 検診 / 前立腺癌 / PSA

Review, Commentary:

1.	Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : 排尿障害・女性泌尿器;Next 10 Years 尿失禁手術で女性の健康長寿を目指す(解説), The Nishinihon Journal of Urology, Vol.85, No.5, 277-283, Jun. 2023. (Keyword) 女性泌尿器 / 尿失禁手術 (Tokushima University Institutional Repository) ● Metadata: 118514 (Tokushima University Institutional Repository: 118514)
2.	Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : 【ここだけは押さえておきたい間質性膀胱炎・膀胱痛症候群診療のポイント】<治療> 膀胱水圧拡張術(解説), Japanese Journal of Clinical Urology, Vol.77, No.6, 460-464, May 2023. (Keyword) 間質性膀胱炎・膀胱痛症候群 / 膀胱水圧拡張術
3.	Masayuki Takahashi and Hiro-omi Kanayama : 【腎臓症候群(第3版)-その他の腎臓疾患を含めて-】腫瘍性腎疾患腎細胞癌, Nihon Rinsho. Japanese Journal of Clinical Medicine, 340-348, Sep. 2022.
4.	Yasuyo Yamamoto and Hiro-omi Kanayama : 【LUTS治療にリハビリテーションは重要だ!】排尿ケアの要,リハビリテーションに望むこと泌尿器科医の立場から(総説), 日本排尿機能学会誌, Vol.32, No.2, 348-351, Jul. 2022. (Keyword) 排尿ケア / rehabilitation / LUTS
5.	Masayuki Takahashi and Hiro-omi Kanayama : 【高齢者の泌尿器疾患update-病態に基づく診断・治療上の問題点-】高齢者泌尿器疾患の特徴と問題点外科治療の実際と問題点, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.80, No.6, 932-941, Jun. 2022.
6.	Masayuki Takahashi and Hiro-omi Kanayama : 【ここまで進んだ鏡視下手術】泌尿器領域腎・副腎, The Japanese journal of clinical and experimental medicine, Vol.99, No.6, 720-726, Jun. 2022.
7.	Masayuki Takahashi and Hiro-omi Kanayama : CHANGING ROLE OF CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA, The Nishinihon Journal of Urology, Vol.82, No.2, 224-233, Jun. 2020. (Keyword) 転移性腎癌 / 腫瘍縮小腎摘除術 / サイトカイン療法 / 分子標的治療 / 免疫チェックポイント阻害剤 / metastatic renal cell carcinoma / cytoreductive nephrectomy / cytokine therapy / molecular targeted therapy / immune checkpoint inhibitor (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520853832939214080 ● Summary page in Scopus @ Elsevier: 2-s2.0-85096340463 (CiNii: 1520853832939214080, Elsevier: Scopus)
8.	Mototsugu Oya, Hiro-omi Kanayama, Norihiko Tsuchiya, Hiroshi Kitamura, Takashi Arakawa and Masayuki Takahashi : 地域包括ケアシステムの中での泌尿器科医のあり方, The Japanese Journal of Urology, Vol.109, No.Suppl, S64-S69, Nov. 2018.
9.	Masayuki Takahashi and Hiro-omi Kanayama : 【腎癌に対する薬物療法-最新エビデンスを実臨床に活かす】腎癌に対する二次薬物療法各薬剤の特徴とその選択指針, Japanese Journal of Clinical Urology, Vol.72, No.1, 26-33, Jan. 2018. (Link to Publication Site) ● Publication site (DOI): 10.11477/mf.1413206167 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.11477/mf.1413206167 (DOI: 10.11477/mf.1413206167)
10.	Masayuki Takahashi and Hiro-omi Kanayama : 膀胱尿管逆流症に対する気膀胱下Cohen法の導入時期におけるトラブルシューティング, 泌尿器外科, Vol.30, No.11, 1635-1637, Nov. 2017.
11.	Masayuki Takahashi and Hiro-omi Kanayama : 【まるごと泌尿器がんの化学療法・分子標的療法・免疫療法】腎がんチロシンキナーゼ阻害薬の副作用コントロール, Uro-Lo: 泌尿器Care & Cure, Vol.22, No.5, 556-561, Oct. 2017.
12.	Masayuki Takahashi, Tomoya Fukawa and Hiro-omi Kanayama : 【新腎・泌尿器癌(上)-基礎・臨床研究の進歩-】腎癌腎癌の分子生物学と発癌機序遺伝子異常, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.75, No.6, 39-46, Aug. 2017.
13.	Masayuki Takahashi and Hiro-omi Kanayama : 泌尿器がん疾患に関する投与のポイント副作用のマネージメント, 腎臓内科・泌尿器科, Vol.4, No.1, 97-108, Jul. 2016.
14.	Masayuki Takahashi and Hiro-omi Kanayama : 【進行性腎細胞癌に対する治療の最前線】高齢に左右される進行性腎癌の治療について, 泌尿器外科, Vol.29, No.6, 985-994, Jun. 2016.
15.	Masayuki Takahashi, Hiro-omi Kanayama and 田岡寛之 : 腎がんに用いる薬 (特集切り取って使える保存版泌尿器科薬剤ノート(2)泌尿器がんの薬), Urological Nursing, Vol.18, No.10, 1056-1060, Oct. 2013. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1522262180578132864 (CiNii: 1522262180578132864)
16.	Yasuyo Yamamoto and Hiro-omi Kanayama : 骨盤臓器脱はなぜ起きる?, Urological Nursing, Vol.18, No.5, 76-78, May 2013. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1521980704816225792 (CiNii: 1521980704816225792)
17.	Kunihisa Yamaguchi and Hiro-omi Kanayama : 後期研修医がおさえておきたい泌尿器疾患TOP30, 泌尿器外科, Vol.Vol.26, Apr. 2013.
18.	Yasuyo Yamamoto and Hiro-omi Kanayama : 高齢者の術前アセスメント (心機能，腎機能，呼吸機能，肝機能，糖尿病など), 新版泌尿器科周術期管理のすべて, 2013.
19.	Hirofumi Izaki and Hiro-omi Kanayama : "遊走腎 ", 今日の臨床サポート, 2013.
20.	冨田善彦, Hiro-omi Kanayama, 上村天受 and 篠原信雄 : 有転移症例の集学的治療, Year Book of RCC 2013, 15-41, 2013. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1521417756103561856 (CiNii: 1521417756103561856)
21.	Kunihisa Yamaguchi and Hiro-omi Kanayama : 5 尿路造影 Urography, 後期研修医がおさえておきたい泌尿器科疾患TOP30(泌尿器外科), Vol.26, 29-43, 2013.
22.	Hiro-omi Kanayama : 特集泌尿器科疾患の最新治療と腎疾患・がんの栄養管理(巻頭言), Shikoku Acta Medica, Vol.69, No.5,6, 193, 2013.
23.	Hiro-omi Kanayama : 褐色細胞腫, ベッドサイド泌尿器科学, 792-799, 2013.
24.	Hiro-omi Kanayama : "Cushing症候群 ", ベッドサイド泌尿器科学, 784-791, 2013.
25.	Hiro-omi Kanayama : 男性生殖器がん(精巣がん)患者の術式決定とインフォームドコンセント, がん介護手術をめぐるがん介護, 145-150, 2013.
26.	Masayuki Takahashi and Hiro-omi Kanayama : 肺転移 (Topics of RCC : 転移巣に対する治療戦略), Year book of RCC, 65-77, 2013. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1524232505867284864 (CiNii: 1524232505867284864)
27.	Masayuki Takahashi and Hiro-omi Kanayama : Topics of RCC 併存症のある患者に対する分子標的治療糖尿病・代謝障害, Year Book of RCC 2012, 127-136, Dec. 2012. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520010381216654592 (CiNii: 1520010381216654592)
28.	Masayuki Takahashi and Hiro-omi Kanayama : 【ナースがかかわる泌尿器がん薬物療法の副作用対策】副作用の予防法と発症時の対応悪心・嘔吐, Vol.17, No.9, 930-931, Sep. 2012.
29.	Masayuki Takahashi and Hiro-omi Kanayama : 【ナースがかかわる泌尿器がん薬物療法の副作用対策】副作用の予防と発症時の対応下痢・便秘, 泌尿器ケア, Vol.17, No.9, 932-933, Sep. 2012.
30.	Shunsuke Furutani, Tomoharu Fukumori, Hitoshi Ikushima and Hiro-omi Kanayama : リアルタイムプランニングによる辺縁配置法の実践, Interplant ver. 3.3を用いた術中計画ハンドブック, Jun. 2012.
31.	Yasuyo Yamamoto and Hiro-omi Kanayama : 骨盤臓器脱はなぜ起こる, 日本老年泌尿器科学会誌, Jun. 2012.
32.	Masayuki Takahashi and Hiro-omi Kanayama : 【知っておきたい内科症候群】内分泌《性腺の症候群》ミューラー管遺残症候群, 内科, Vol.109, No.6, 1314-1315, Jun. 2012.
33.	Masayuki Takahashi and Hiro-omi Kanayama : 【進行性腎癌の臨床:分子標的治療薬 up-to-date】新規薬物(候補)について, 泌尿器外科, Vol.25, No.5, 1181-1188, May 2012.
34.	Masayuki Takahashi and Hiro-omi Kanayama : 【泌尿器科ベッドサイドマニュアル】全身合併症を有する患者の管理肺疾患の既往を有する患者の管理, 臨床泌尿器科, Vol.66, No.4, 310-315, Apr. 2012.
35.	Masayuki Takahashi and Hiro-omi Kanayama : 【ここが変わった，腎癌診療ガイドライン-改訂版について-】腎癌の手術療法の変遷, 泌尿器外科, Vol.25, No.2, 165-170, Feb. 2012.
36.	Tomoharu Fukumori and Hiro-omi Kanayama : Which is the best molecular target drug for cytokine-refractory metastatic renal cell carcinoma?, Japanese Journal of Clinical Urology, Vol.66, No.1, 27-31, Jan. 2012. (Keyword) 進行性腎細胞癌 / サイトカイン治療 / 分子標的薬 / セカンドライン治療 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390283684890510592 ● Summary page in Scopus @ Elsevier: 2-s2.0-84856159260 (CiNii: 1390283684890510592, Elsevier: Scopus)
37.	Masayuki Takahashi and Hiro-omi Kanayama : 【腎臓症候群(第2版)上-その他の腎臓疾患を含めて-】腫瘍性腎疾患腎細胞癌, Nihon Rinsho. Japanese Journal of Clinical Medicine, 639-645, Jan. 2012.
38.	Tomoharu Fukumori and Hiro-omi Kanayama : 膀胱癌・前立腺癌治療薬, 新薬展望, 185-191, 2012.
39.	Tomoharu Fukumori and Hiro-omi Kanayama : Problems in PSA screening: distinction from false positives, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.69, No.5, 259-263, Jun. 2011. (Keyword) PSAcutoff値 / age-adjusted PSA / PSA density / PSAD / PSA velocity / PSAV / PSA doubling time / PSADT (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22207982 ● CiNii @ National Institute of Informatics (CRID): 1523951029733649024 ● Summary page in Scopus @ Elsevier: 2-s2.0-84857495334 (PubMed: 22207982, CiNii: 1523951029733649024, Elsevier: Scopus)
40.	Hiro-omi Kanayama : VEGF/VEGFR標的治療薬-腎細胞癌での治療成績と今後の治療戦略, Experimental Medicine, Vol.29, No.2, 215-222, 2011.
41.	Tomoharu Fukumori and Hiro-omi Kanayama : 泌尿器科で扱う主な疾患, Urological Nursing, Vol.15, No.4, 26, Oct. 2010.
42.	Hiro-omi Kanayama : 分子標的薬:今後の展望, Urology View, Vol.8, No.5, 86-96, Sep. 2010.
43.	Masayuki Takahashi and Hiro-omi Kanayama : 【小径腎腫瘍の診断と治療Update】多発小径腎腫瘍の生物学的特徴, Urology View, Vol.8, No.4, 88-93, Jul. 2010. (Keyword) von Hippel-Lindau病(遺伝学)
44.	Hiro-omi Kanayama : Molecular targeted therapy for advanced renal cell carcinoma, Japanese Journal of Cancer and Chemotherapy, Vol.37, No.7, 1208, Jul. 2010. (Summary) Two molecular targeted drugs, sorafenib and sunitinib, were approved for treatment against advanced renal cell carcinoma in 2008 in Japan. These two drugs can be orally administered as different from interferon-alpha administered subcutaneously or interleukin-2 intravenously. In the near future, everolimus will also be approved in Japan. Moreover, other vascular endothelial growth factor receptor inhibitors will be up available. Molecular targeted drugs are associated with different adverse events from classical anticancer drugs. Control of adverse events is important to obtain maximum effectiveness of these molecular targeted drugs. Neoadjuvant therapy with these drugs for unresectable primary tumor or large tumor in solitary kidney may also be effective to complete nephrectomy or nephron spearing surgery. Treatment strategy for advanced renal cell carcinoma has been changing dramatically after introduction of these molecular targeted drugs. (Keyword) Antineoplastic Agents / Carcinoma, Renal Cell / Clinical Trials as Topic / Humans / Kidney Neoplasms / Neoadjuvant Therapy / Neoplasm Staging (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20647700 ● Summary page in Scopus @ Elsevier: 2-s2.0-79961104813 (PubMed: 20647700, Elsevier: Scopus)
45.	Hiro-omi Kanayama : Treatment for T1G3 bladder cancer, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.68, 357-362, Apr. 2010. (Keyword) T1G3膀胱癌 / CIS / 膀胱上皮内癌 / repeat TUR / BCG膀胱内注入療法 / 膀胱全摘除術 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520854804960400512 (CiNii: 1520854804960400512)
46.	Masayuki Takahashi and Hiro-omi Kanayama : Gene alterations of renal cell carcinoma, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.68, 17-24, Apr. 2010. (Keyword) 網羅的遺伝子解析 / マイクロアレイ / 予後 / pathway analysis (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1521417754981288576 (CiNii: 1521417754981288576)
47.	Hiro-omi Kanayama : エベロリムス(アフィニトール)による腎細胞癌の治療戦略(前編), 泌尿器外科, Vol.23, No.11, 1519-1599, 2010.
48.	Hiro-omi Kanayama : 転移性腎細胞がんの新しい治療戦略-mTOR阻害剤:エベロリムスー, Mebio, Vol.27, No.6, 6-14, 2010.
49.	Hiro-omi Kanayama : 組織内照射療法前のネオアジュバントホルモン療法は治療後のPSA非再発率や生存率を向上させますか?, 前立腺癌診療こんなときどうするQ&A, 154-157, 2010.
50.	Kunihisa Yamaguchi and Hiro-omi Kanayama : 泌尿器科疾患とCKD-高齢者に対するnephron-sparing surgeryの意義, Geriatric Medicine, Vol.48, 1047-1051, 2010.
51.	Masayuki Takahashi, Hiro-omi Kanayama and Susumu Kagawa : GENE EXPRESSION PROFILING OF RENAL CELL CARCINOMA, The Nishinihon Journal of Urology, Vol.64, No.12, 679-686, Dec. 2002. (Keyword) マイクロアレイ / 腎細胞癌 / 予後 / cDNA microarray / gene expression profiling / RCC / prognosis (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1570572700592871936 (CiNii: 1570572700592871936)

Proceeding of International Conference:

1.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Examination of Mid-Urethral Sling (MUS) for elderly patients over 75 years old, Athens, Oct. 2019.
2.	Masayuki Takahashi, Kei Daizumoto, Tomoya Fukawa, Yayoi Fukuhara, Ozaki Keisuke, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : The significance of insulin receptor expression to predict the resistance to VEGFR-TKIs and induce PD-L1 expression in advanced clear cell renal cell carcinoma, 2019 ASCO Genitourinary Cancers Symposium, Feb. 2019.
3.	Yasuyo Yamamoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama, Yoshihiro Tsuruo, Kei Daizumoto and Hidehisa Mori : Usefulness of Fresh Frozen Cadaver and Animal Models for Surgical Training in Laparoscopic Sacrocolpopexy, The 36th World Congress of Endourology, Paris, Sep. 2018.
4.	Masayuki Takahashi, Kei Daizumoto, Yayoi Fukuhara, Ozaki Keisuke, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Correlation of the insulin receptor expression changes by the administration of VEGFR-TKI and the resistance to the VEGFR-TKI in clear cell renal cell carcinoma, 113th American Urological Association Annual meeting, May 2018.
5.	Hidehisa Mori, Tomoharu Fukumori, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : What is an appropriate definition of IPSS resolution that correlates closely with QOL recovery after prostate brachytherapy?, The Journal of Urology, Vol.199, No.4, e274, San Francisco, May 2018. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.juro.2018.02.718 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.juro.2018.02.718 (DOI: 10.1016/j.juro.2018.02.718)
6.	Toyomasa Katagiri, Kei Daizumoto, Tetsuro Yoshimaru, Yosuke Matsushita, Tomoya Fukawa, Ono Masaya and Hiro-omi Kanayama : DDX31 cooperates with mutant p53 and EGFR to promote the multistep progression of invasive bladder cancer, American Association For Cancer Research ANNUAL MEETING 2018, Chicago, Apr. 2018.
7.	Kunihisa Yamaguchi and Hiro-omi Kanayama : An in vitro study of the new device ; wide-angle lens cystoscopy, WCE 2017, Nov. 2017.
8.	Hidehisa Mori, Tomoharu Fukumori, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Safety and efficacy of low-dose-rate brachytherapy for localized prostate cancer in elderly patients, Lisbon, Oct. 2017.
9.	T Shintani, K Daizumoto, Tomoya Fukawa, H Nakatsuji, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : HGF-MET-MMP and VEGF-C signaling as a potential target for invasive bladder cancer therapy, 2017 European association of Urology, London, Mar. 2017.
10.	Tomoharu Fukumori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Galectin-3 is involved in the progression of castration-resistant prostate cancer through the regulation of tumor invasion, angiogenesis and androgen receptor signaling., 2017 European association of Urology, London, Mar. 2017.
11.	Masayuki Takahashi, Kei Daizumoto, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Terumichi Shintani, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Correlation of insulin receptor expression with efficacy of axitinib in patients with advanced renal cell carcinoma, 2017 Genitourinary Cancers Symposium, Feb. 2017.
12.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : Clinical characteristics differ in ulcerative and non-ulcerative subtypes of interstitial cystitis/ bladder pain syndrome, International Continence Society, Tokyo, Sep. 2016.
13.	Terumichi Shintani, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : Low expression of Toll like receptor 4 is associated with squamous differentiation in bladder cancer., The American Urological Association, Inc. 111th Annual Meeting, May 2016.
14.	Tomoharu Fukumori, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Galectin-3 is implicated in the progression of castration-resistant prostate cancer through the regulation of angiogenesis and androgen receptor signaling., The American Urological Association, Inc. 111th Annual Meeting, San Diego, May 2016.
15.	Yasuyo Yamamoto, Hidehisa Mori, Terumichi Shintani, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : Evaluation of Urinary tract inection after mid-urethral sling, International Continence Society, Oct. 2015.
16.	Tomoharu Fukumori, Dondoo Tsogt-Ochir, K Daizumoto, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Galectin-3 is a therapeutic target for castration-resistant prostate cancer., The American Urological Association, Inc. 110th Annual Meeting, New Orleans, May 2015.
17.	Masayoshi Ishida, Michio Shimabukuro, Shusuke Yagi, Daiju Fukuda, Takeshi Soeki, H Sato, E Uematsu, Hirofumi Izaki, Hiro-omi Kanayama and Masataka Sata : Post-Transcriptional Regulation of Adiponectin by Micro-RNA 378 in Human Visceral and Subcutaneous Adipose Tissue., American Heart Association AHA 2013, Dallas, Nov. 2013.
18.	Tomoharu Fukumori, Senzaki1 Tomoichi, Fukawa1 Tomoya, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Izaki Horofumi, Masayuki Takahashi and Hiro-omi Kanayama : Long-term outcomes of trimodality therapy with radical transurethral resection of the bladder tumor (TUR-Bt), intra-arterial chemotherapy, and concurrent radiotherapy for locally advanced bladder cancer., 33rd Congress of The Societe Internationale D'Urologie, Sep. 2013.
19.	Masayoshi Ishida, Michio Shimabukuro, Shusuke Yagi, Daiju Fukuda, Takeshi Soeki, H Sato, E Uematsu, Hirofumi Izaki, Hiro-omi Kanayama and Masataka Sata : MicroRNA-100 regulates a cluster of adipocytokine expression: A human biopsy study in subcutaneous and visceral adipose tissue., ESC Congress 2013, Amsterdam, Aug. 2013.
20.	Masayoshi Ishida, Michio Shimabukuro, Shusuke Yagi, Daiju Fukuda, Takeshi Soeki, H Sato, E Uematsu, Hirofumi Izaki, Hiro-omi Kanayama and Masataka Sata : MicroRNA miR-378 regulates adipocytokine fate by targeting transcriptional factors in human visceral and subctaneous adipose tissue., ESC Congress 2013, Amsterdam, Aug. 2013.
21.	Toyomasa Katagiri, Tomoya Fukawa, Taisuke Matsuo and Hiro-omi Kanayama : DDX31 regulates p53 tumor suppressive activity in renal cell carcinomas, Amerian Association for Cancer Research (AACR) Annal Meeting 2013, Washington, D.C., Apr. 2013.
22.	Masayuki Takahashi, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : THE LOW TRANS-SCROTAL ORCHIDOPEXY FOR UNDESCENDED TESTES, The 32nd Congress of the Société Internationale dUrologie, Oct. 2012.
23.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : Clinical significance of neoadjuvant combined androgen blockade before I-125 prostate brachytherapy in patients with localized prostate cancer., 32th Congress of the Societe Internationale dUrologie, Oct. 2012.
24.	Tomokazu Senzaki, Tomoharu Fukumori, Hiroyoshi Nakatsuji, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : Predictive factors for urinary morbidity after I-125 prostate brachytherapy, 32th Congress of the Societe Internationale dUrologie, Oct. 2012.
25.	H. Sato, Michio Shimabukuro, Y. Hirata, Hirofumi Izaki, M. Higashida, Hirotsugu Kurobe, Hiro-omi Kanayama, Hiroshi Sakaue, Yutaka Nakaya and Masataka Sata : Region-specific regulation of the innate immune system, NLRP3 inflammasome, in human abdominal adipose tissue., ESC Congress 2012, Munich, Aug. 2012.
26.	T Fukumori, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : Clinical significance of neoadjuvant combined androgen blockade before I-125 prostate brachytherapy in patients with localized prostate cancer., 32th Congress of the Societe Internationale dUrologie, 2012.
27.	Masahiko Takemura, Hirofumi Izaki, Yasuyo Yamamoto, Masayuki Takahashi, Tomoharu Fukumori, Kunihisa Yamaguchi and Hiro-omi Kanayama : Laparoscopic adrenalectomy for adrenal metastases : Points of controversy, 国際泌尿器科学会ベルリン, Oct. 2011.
28.	Hirofumi Izaki, Masayuki Takahashi, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : The indication and limit of laparoscopic adrenalectomy for pheochromocytoma, 国際泌尿器科学会, Berlin, Oct. 2011.
29.	Tomoya Fukawa, Ono Masaya, Hisanori Uehara, Taisuke Matsuo, Nakamura Yusuke, Hiro-omi Kanayama and Toyomasa Katagiri : Identification and characterization of RCCDH as a novel molecular target for clear renal cell carcinoma., 70th Annual Meeting of the Japanese Cancer Association, Oct. 2011.
30.	Yasuyo Yamamoto, Hiro-omi Kanayama, Hirofumi Izaki, Masayuki Takahashi, Masahiko Takemura, Hiroyoshi Nakatsuji and Tomoharu Fukumori : Clinical experience of Interstitial cystitis treated with hydrodistension, 国際泌尿器科学会, Berlin, Oct. 2011.
31.	Masayuki Takahashi, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : A multi-center randomized Phase II study of the second-line maximum androgen blockade with an alternative antiandrogen combined with tegafur-uracil (UFT®) for prostate cancer with relapse after initial hormonal therapy, 2011 Annual Meeting of American Society of Clinical Oncology, Jun. 2011.
32.	Tomoharu Fukumori, Masa-aki Nishitani, M Takahashi, T Naroda, Hirofumi Izaki, I Elsamman, Susumu Kagawa and Hiro-omi Kanayama : Involvement of Matrix Metalloproteinase-3 in Hepatocyte Growth Factor-Induced Invasion of Bladder Cancer, BUJ International, Honolulu, Oct. 2004.

Proceeding of Domestic Conference:

1.	Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : Approaches for Benign Prostate Hyperplasia with detrusor underactivity, The Japanese Journal of Urology, Apr. 2023. (Keyword) Benign Prostate Hyperplasia / detrusor underactivity
2.	Hiro-omi Kanayama, Masashi Akaike, Koichi Tomita, Yoshihiro Tsuruo, Akiyoshi Nishimura, Koichi Sairyo and Keizo Wada : 徳島大学病院クリニカルアナトミー教育・研究センターの現状と展望, 第128回日本解剖学会総会・全国学術集会, Mar. 2023.
3.	Yasuyo Yamamoto and Hiro-omi Kanayama : 尿失禁手術で女性の健康長寿を目指す, The Nishinihon Journal of Urology, Nov. 2022. (Keyword) 尿失禁手術 / female / 健康長寿
4.	Masayuki Takahashi and Hiro-omi Kanayama : 進行性腎細胞癌に対する薬物療法のNext 10 Years, 第74回西日本泌尿器科学会, Nov. 2022.
5.	Masayuki Takahashi, Kei Daizumoto, 福田喬太郎, 安宅祐一朗, 泉和良, Yoshito Kusuhara, Tomoya Fukawa and Hiro-omi Kanayama : 進行性腎細胞癌に対するニボルマブ・イピリムマブ併用療法の検討: 多施設共同後ろ向き研究, 日本泌尿器腫瘍学会第8回, Oct. 2022.
6.	Masayuki Takahashi and Hiro-omi Kanayama : Current sequential therapy for advanced non-clear renal cell carcinoma, 第60回日本癌治療学会, Oct. 2022.
7.	Yasuyo Yamamoto and Hiro-omi Kanayama : 新時代における日本排尿機能学会∼すべての人々の幸せを願って∼ Japanese Continence Society in the New Era ∼ Wishing for Happiness for Everyone, 日本排尿機能学会誌, Sep. 2022. (Keyword) ダイバーシティ / 日本排尿機能学会
8.	Yasuyo Yamamoto, 西川木綿子, 小路優, Megumi Tsuda, 近藤心 and Hiro-omi Kanayama : 外来排尿自立指導 ∼必要な患者に届けるために∼, 日本排尿機能学会誌, Sep. 2022. (Keyword) 外来排尿自立指導
9.	Yutaro Sasaki, 小林早紀, Keito Shiozaki, Masayuki Takahashi, 須藤泰史 and Hiro-omi Kanayama : 小児精巣腫瘍の1例, 日本小児泌尿器科学会総会・学術集会, Jul. 2022.
10.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Yoshiteru Ueno, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 女性神経因性膀胱患者に対するボツリヌス毒素膀胱壁内注入療法の経験, 日本女性骨盤底医学会, Jul. 2022. (Keyword) female / 神経因性膀胱 / ボツリヌス毒素膀胱壁内注入療法
11.	堀克仁, Yutaro Sasaki, 角陸文哉, Keito Shiozaki, Kei Daizumoto, 冨田諒太郎, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : 当院での未固定遺体を用いた内シャント造設術トレーニングの試み ∼生体との違いについて∼, 日本泌尿器科学会四国地方会, Jul. 2022.
12.	Yutaro Sasaki, 堀克仁, 角陸文哉, Kei Daizumoto, 上野恵輝, 冨田諒太郎, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : 多診療科で行うロボット支援手術 ∼後方骨盤内臓全摘除術の1例∼, 日本泌尿器科学会四国地方会, Jul. 2022.
13.	Yasuyo Yamamoto, Megumi Tsuda, 安宅真利花, Kei Daizumoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 当院における難治性過活動膀胱に対するボツリヌス毒素膀胱壁内注入療法の臨床的検討, 日本老年泌尿器科学会誌, Vol.35, No.1, 144, Jun. 2022. (Keyword) 難治性過活動膀胱 / ボツリヌス毒素膀胱壁内注入療法
14.	Yutaro Sasaki, 橋本啓佑, Keito Shiozaki, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 女性のRARCにおける膣再建の新たな手法 ∼Benz closure technique∼, 泌尿器科再建再生研究会, Jun. 2022.
15.	橋本啓佑, Yutaro Sasaki, 安宅真利花, 多田航生, 中西亮太, 吉岡拓哉, Kei Daizumoto, Keisuke Ozaki, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : ロボット支援体腔内回腸導管造設術においてストマ造設を円滑に行うための工夫, 日本ロボット外科学会学術集会, Feb. 2022.
16.	Yutaro Sasaki, 福田喬太郎, Kei Daizumoto, Keito Shiozaki, Yoshito Kusuhara, Tomoya Fukawa, 中西良一, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, 神田和哉 and Hiro-omi Kanayama : 高齢患者(≧75歳)のロボット支援膀胱全摘除術における体腔内回腸導管造設術と尿管皮膚瘻造設術の比較, 日本泌尿器科学会総会, Dec. 2021.
17.	Yutaro Sasaki, Hirofumi Izaki, Masayuki Takahashi, 神田和哉 and Hiro-omi Kanayama : ICUDによる回腸導管造設術のピットフォール:回避するためにはPatient side surgeonの役割が重要である, 日本泌尿器科学会総会, Dec. 2021.
18.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 当院における外来排尿自立指導の臨床的検討, The Japanese Journal of Urology, Dec. 2021.
19.	Masayuki Takahashi and Hiro-omi Kanayama : 転移性腎細胞癌に対し，術前薬物療法が優先される, 第109回日本泌尿器科学会総会, Dec. 2021.
20.	Yutaro Sasaki, Kei Daizumoto, Keito Shiozaki, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, 神田和哉 and Hiro-omi Kanayama : 「アシステントガイド」の開発体腔内回腸導管造設時の尿管ステント留置を円滑に, 日本泌尿器内視鏡学会総会, Nov. 2021.
21.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 憩室口が遠位に存在する尿道憩室摘除術における工夫, The Nishinihon Journal of Urology, Vol.83, Nov. 2021.
22.	Yasuyo Yamamoto, Megumi Tsuda and Hiro-omi Kanayama : 排尿ケアの要，リハビリテーションに望むこと∼泌尿器科医の立場から∼, 日本排尿機能学会誌, Vol.32, No.1, Sep. 2021.
23.	Yasuyo Yamamoto, Kei Daizumoto, Yutaro Sasaki, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 夜間頻尿に対するデスモプレシンの使用経験, 日本排尿機能学会誌, Vol.32, No.1, Sep. 2021.
24.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 骨盤臓器脱に対し膣閉鎖術を行った症例の検討, 日本女性骨盤底医学会, Jul. 2021.
25.	Yutaro Sasaki, 小林早紀, Keito Shiozaki, Masayuki Takahashi, 須藤泰史 and Hiro-omi Kanayama : 会陰部異所性精巣の2例, 日本小児泌尿器科学会総会・学術集会, Jul. 2021.
26.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 難治性過活動膀胱に対するボツリヌス毒素膀胱壁内注入療法の初期治療経験, 日本老年泌尿器科学会誌, Vol.34, No.1, 109, May 2021.
27.	Masayuki Takahashi, Yoshito Kusuhara, Yutaro Sasaki, Kei Daizumoto, Keisuke Ozaki, Yoshiteru Ueno, Megumi Tsuda, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : ロボット支援下腎盂形成術-温故創新成人水腎症に対するロボット支援腎盂形成術の初期経験, 第33回日本内視鏡外科学会総会, Mar. 2021.
28.	Toshiaki Yoshimoto, Kouzou Yoshikawa, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yukako Takehara, K Yamaguchi, M Takahashi, Hiro-omi Kanayama and Mitsuo Shimada : Surgical approach for inguinal hernia following robot-assisted radical prostatectomy, 第33回日本内視鏡外科学会, Mar. 2021.
29.	Yasuyo Yamamoto, Tomoya Fukawa, Yoshito Kusuhara, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 骨盤臓器脱患者に対する腹腔鏡下仙骨腟固定術前の下部尿路症状の変化, 第33回日本内視鏡外科学会総会, Mar. 2021.
30.	Kunihisa Yamaguchi, Hiro-omi Kanayama, Masayuki Takahashi, Tomoya Fukawa and Yoshito Kusuhara : 腎移植後のリンパ漏にリンパ管造影が効果的であった3例, 日本臨床腎移植学会, Feb. 2021.
31.	Masayuki Takahashi, Tetsuhiro Yano, Kei Daizumoto, Yutaroh Sasaki, Keisuke Ozaki, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : 転移性腎細胞癌に対するニボルマブ・イピリムマブ併用療法の初期経験, 第108回日本泌尿器科学会総会, Dec. 2020.
32.	Yasuyo Yamamoto, Tomoya Fukawa, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 腹腔鏡下仙骨腟固定術前後で比較した下部尿路機能症状とQOLの変化, 第108回日本泌尿器科学会総会, Dec. 2020.
33.	Masayuki Takahashi and Hiro-omi Kanayama : 転移性腎癌の治療 Cytoreductive nephrectomyの適応とタイミング, 第72回西日本泌尿器科学会総会, Nov. 2020.
34.	Yasuyo Yamamoto, Tomoya Fukawa, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 骨盤臓器脱患者に対する腹腔鏡下仙骨腟固定術前後での下部尿路症状の変化, 第82回西日本泌尿器科学会総会, Nov. 2020.
35.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : TOT手術時のヘガールを用いたテープ調整の有用性, 第27回日本排尿機能学会, Oct. 2020.
36.	松本力三, Susumu Nishio, Kei Daizumoto, Sae Morita, 湯浅麻美, Yukina Hirata, 山尾雅美, Takahiro Tanaka, Hiro-omi Kanayama and Masataka Sata : 多房性嚢胞状腎細胞癌の2症例, 日本超音波医学会第30回四国地方会学術集会, Oct. 2020.
37.	Yoshihiro Uto, Kei Daizumoto, Yayoi Fukuhara, Hisanori Uehara and Hiro-omi Kanayama : 発育鶏卵を用いた患者由来がんモデルの開発, 第24回日本がん分子標的治療学会学術集会, Oct. 2020.
38.	Masayuki Takahashi, Kei Daizumoto, Tomoya Fukawa and Hiro-omi Kanayama : 転移性腎細胞癌に対するニボルマブ・イピリムマブ併用療法の初期経験, 第24回日本がん分子標的治療学会学術集会, Oct. 2020.
39.	Kei Daizumoto, Yayoi Fukuhara, Tomoya Fukawa, Toyomasa Katagiri, Hisanori Uehara, Masayuki Takahashi and Hiro-omi Kanayama : 尿路上皮癌に対するDDX31/NCL相互作用阻害による抗腫瘍効果の検討, 第79回日本癌学会学術総会, Oct. 2020.
40.	尾崎啓介, Kunihisa Yamaguchi, Hiro-omi Kanayama, Masayuki Takahashi and Tomoya Fukawa : -, Journal of Japanese Society for Dialysis Therapy, Vol.53, 813, Oct. 2020.
41.	西川木綿子, Yasuyo Yamamoto, Megumi Tsuda, Hiro-omi Kanayama, Akiyo Kanazawa, 高開登茂子 and 近藤心 : 排尿ケアチームによる継続的排尿自立支援とアウトカム評価の検討, 第33回日本老年泌尿器科学会総会, Sep. 2020.
42.	Megumi Tsuda, Yasuyo Yamamoto, Kei Daizumoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 泌尿器科疾患以外の患者に対する排尿ケアチーム介入の臨床的検討, 第33回日本老年泌尿器科学会総会, Sep. 2020.
43.	Masayuki Takahashi, Kei Daizumoto, 佐々木雄太郎, 尾﨑啓介, 上野恵輝, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : Case report of four patients with metastatic renal cell carcinoma who received nivolumab and ipilimumab combination therapy, Oct. 2019.
44.	Yasuyo Yamamoto, Tomoya Fukawa, Kei Daizumoto, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : RARPにおける術前残尿量と術後尿禁制の関連, 第26回日本排尿機能学会, Sep. 2019.
45.	Yasuyo Yamamoto, Tomoya Fukawa, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Hidehisa Mori, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 骨盤臓器脱と膀胱憩室を同時に治療した1例, 第21回女性骨盤底医学会, Jul. 2019.
46.	Masayuki Takahashi, Kei Daizumoto, 尾﨑啓介, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : 高齢腎癌患者に対する根治的腎摘除術/腎部分切除術の臨床的検討, 第50回腎癌研究会記念大会, Jul. 2019.
47.	Masayuki Takahashi, 佐々木雄太郎, 須藤泰史 and Hiro-omi Kanayama : 膀胱尿管逆流症術後にアセトアミノフェンにて急性腎不全，麻痺性イレウスをきたした1例, 第28回日本小児泌尿器科学会総会, Jul. 2019.
48.	Gulinu Maimaituxun, Michio Shimabukuro, Daiju Fukuda, Hirofumi Izaki, 平田陽一郎, 益崎裕章, Hiro-omi Kanayama and Masataka Sata : A link of adiponectin expression to kidney adipose tissue volume in human, 第4回J-ISCP(国際心血管薬物療法学会日本部会)年次学術集会, Jun. 2019.
49.	Yasuyo Yamamoto, Kei Daizumoto, Yoshito Kusuhara, Megumi Tsuda, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 排尿ケアチームが複数回介入した症例の検討, The Japanese Journal of Urology, Apr. 2019.
50.	Masayuki Takahashi, 西山美月, 福田喬太郎, Kei Daizumoto, 尾﨑啓介, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : 小児膀胱尿管逆流症に対する気膀胱下Cohen法の初期治療経験, 第107回日本泌尿器科学会総会, Apr. 2019.
51.	Takahiro Yoshida, Takeshi Nishino, Seiya Inoue, Masakazu Goto, Mitsuhiro Tsuboi, Mariko Aoyama, Hiroaki Toba, Mitsuteru Yoshida, Hiromitsu Takizawa, Akira Tangoku, Hiro-omi Kanayama and Yoshihiro Tsuruo : 《CST推進委員会・厚生労働班会議合同企画》未固定カダバーによる教育と研究徳島大学の取り組み, 第119回日本外科学会定期学術集会, Apr. 2019.
52.	尾崎啓介, Kunihisa Yamaguchi, Hiro-omi Kanayama, Masayuki Takahashi and Tomoya Fukawa : -, 日本臨床腎移植学会抄録集, 249, Feb. 2019.
53.	Yasuyo Yamamoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Yoshihiro Tsuruo : 腹腔鏡下仙骨膣固定術(LSC: Laparoscopic Sacrocollpopexy)導入にむけたトレーニング, 第31回日本内視鏡外科学会, Dec. 2018.
54.	Yasuyo Yamamoto and Hiro-omi Kanayama : 高齢女性の排尿障害について, 第70回西日本泌尿器科学会総会, Nov. 2018.
55.	Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama, Kei Daizumoto, Yoshito Kusuhara and Hidehisa Mori : 排尿ケアチーム設立時の現況と課題, 第70回西日本泌尿器科学会総会, Nov. 2018.
56.	Masayuki Takahashi, Kei Daizumoto, Ozaki Keisuke, Tsuda Megumi, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Clinicopathological study of the elderly patients with renal cell carcinoma who underwent radical/partial nephrectomy, 第56回日本癌治療学会学術集会, Oct. 2018.
57.	Masayuki Takahashi, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : CAPDカテーテル大網嵌入に対し腹腔鏡下に大網除去，カテーテル腹壁固定した小児の1症例, 第24回腹膜透析医学会学術集会・総会, Oct. 2018.
58.	Masayuki Takahashi, Kei Daizumoto, Yayoi Fukuhara, Minoru Kowada, Yoshimi Bando, Tomoya Fukawa, Tomoharu Fukumori and Hiro-omi Kanayama : The significance of insulin receptor expression in vascular endothelial cells of clear cell renal cell carcinoma, 第77回日本癌学会学術集会, Sep. 2018.
59.	Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 排尿ケアチーム設立時の現況と課題, 第25回日本排尿機能学会, Sep. 2018.
60.	Kei Daizumoto, Tetsuro Yoshimaru, Yosuke Matsushita, Tomoya Fukawa, Hisanori Uehara, 尾野雅哉, Masato Komatsu, Hiro-omi Kanayama and Toyomasa Katagiri : Crucial roles of DDX31 as related to the status of TP53 in bladder cancer progression, 第77回日本癌学会学術総会, Sep. 2018.
61.	Masayuki Takahashi and Hiro-omi Kanayama : 泌尿器科領域でのロボット手術の経験, 第18回日本VR医学会学術大会, Sep. 2018.
62.	Kunihisa Yamaguchi, Hiro-omi Kanayama, Masayuki Takahashi, Yasuyo Yamamoto and Tomoya Fukawa : タクロリムスの血中濃度上昇に術後疼痛に対するフェンタニルの影響が示唆された3例, Japanese Journal of Transplantation, Vol.53, 479, Sep. 2018.
63.	Yasuyo Yamamoto, Kei Daizumoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Yoshihiro Tsuruo : 腹腔鏡下仙骨膣固定術導入にむけたトレーニング, 第20回日本女性骨盤底医学会, Jul. 2018.
64.	Masayuki Takahashi, Kei Daizumoto, Keisuke Ozaki, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : ニボルマブ投与中にhyper-progressionが疑われた淡明細胞型腎細胞癌の1例, 第49回腎癌研究会, Jul. 2018.
65.	Masayuki Takahashi, Keisuke Ozaki, Yoshito Kusuhara, 福田喬太郎, 西山美月, Kei Daizumoto, Megumi Tsuda, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : 高齢の腎癌患者に対する手術, 第31回日本老年泌尿器科学会, May 2018.
66.	Yasuyo Yamamoto, Kei Daizumoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : TOT術後の過活動膀胱(OAB)治療に関する検討, 第106回日本泌尿器科学会総会, Apr. 2018.
67.	Hidehisa Mori, Tomoharu Fukumori, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : IPSS resolution, Apr. 2018.
68.	Masayuki Takahashi, Kei Daizumoto, Yayoi Fukuhara, Ozaki Keisuke, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Correlation of the insulin receptor expression changes by the administration of VEGFR-TKI and the resistance to the VEGFR-TKI in clear cell renal cell carcinoma, 第106回日本泌尿器科学会総会, Apr. 2018.
69.	Kei Daizumoto, Masayuki Takahashi, Taishi Miyazaki, Yayoi Fukuhara, Yoshito Kusuhara, Tomoya Fukawa, Tomoharu Fukumori and Hiro-omi Kanayama : 淡明細胞型腎細胞癌・周囲血管におけるインスリンレセプターの発現とVEGFR阻害薬の治療効果との関連性, The 27th Japanese Society for Mollecular and Cellular Urology, Feb. 2018.
70.	Tomoharu Fukumori and Hiro-omi Kanayama : High risk前立腺癌に対する放射線治療の優位性, 第31回日本泌尿器内視鏡学会総会, Nov. 2017.
71.	Masayuki Takahashi, 大豆本圭, 尾崎啓介, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : 新規導入施設における気膀胱下Cohen法の問題点と工夫, 第31回日本泌尿器内視鏡学会総会, Nov. 2017.
72.	Masayuki Takahashi, 大豆本圭, 尾崎啓介, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : アキシチニブ抵抗性バイオマーカーとしての腎癌組織中インスリンレセプター発現, 第55回日本癌治療学会学術集会, Oct. 2017.
73.	Tomoharu Fukumori, Hidehisa Mori, Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 高リスク限局性前立腺癌に対する I-125 密封小線源療法の治療成績と生化学的再発予測因子の検討, 第55回日本癌治療学会学術集会, Oct. 2017.
74.	大豆本圭, Tetsuro Yoshimaru, Tomoya Fukawa, Hisanori Uehara, 尾野雅哉, Masato Komatsu, Hiro-omi Kanayama and Toyomasa Katagiri : 筋層浸潤性膀胱癌の多段階進展機構におけるDDX31, Mutant p53, EGFR Axisの役割解明, 第76回日本癌学会学術総会, Sep. 2017.
75.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : TOT術後の過活動膀胱(OAB)治療に関する検討, 第24回日本排尿機能学会, Sep. 2017.
76.	Mitsuteru Yoshida, Hiromitsu Takizawa, Toru Sawada, Naoya Kawakita, Mitsuhiro Tsuboi, Koichiro Kajiura, Hiroaki Toba, Yukikiyo Kawakami, Kazuya Kondo, Akira Tangoku, Takashi Iwata, Masashi Akaike, Hiro-omi Kanayama, Kousaku Higashino and Yoshihiro Tsuruo : 鏡視下手術時代の教育の開発未固定遺体を用いた胸腔鏡手術トレーニングの経験, 第42回日本外科系連合学会学術集会, Jun. 2017.
77.	Kunihisa Yamaguchi, Hiro-omi Kanayama, Masayuki Takahashi, Tomoharu Fukumori and Yasuyo Yamamoto : 徳島大学における腎移植後サイトメガロウイルス感染に関する検討, The Nishinihon Journal of Urology, Vol.79, No.6, 203, Jun. 2017.
78.	Mitsuteru Yoshida, Hiromitsu Takizawa, Takahiro Yoshida, Mitsuhiro Tsuboi, Naoya Kawakita, Toru Sawada, Koichiro Kajiura, Hiroaki Toba, Yukikiyo Kawakami, Kazuya Kondo, Akira Tangoku, Takashi Iwata, Masashi Akaike, Hiro-omi Kanayama, 東野耕作 and Yoshihiro Tsuruo : 《考える外科学》未固定遺体とのシミュレーションを用いた新たな実践型内視鏡下低侵襲手術トレーニングプログラムの構築, 第117回日本外科学会定期学術集会, Apr. 2017.
79.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 排尿障害から診断を得た多系統萎縮症症例, The Japanese Journal of Urology, Apr. 2017.
80.	Kei Daizumoto, Yuichiro Atagi, Chizuru Kotoh, Minoru Kowada, Yoshito Kusuhara, Hidehisa Mori, Terumichi Shintani, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : ロボット支援前立腺全摘術後の尿失禁と内閉鎖筋体積の関連性の検討, The 105th Annual Meeting of the Japanese Urological Association, Apr. 2017.
81.	Masayuki Takahashi, 安宅祐一郎, 宇都宮聖也, 大豆本圭, 津田恵, Yoshito Kusuhara, Hidehisa Mori, Terumichi Shintani, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : アキシチニブ投与患者における腎癌組織中のインスリンレセプター発現のバイオマーカーとしての意義, 第105回日本泌尿器科学会総会, Apr. 2017.
82.	Tomoharu Fukumori, Tomoya Fukawa, Yoshito Kusuhara, Hidehisa Mori, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : The mechanism of tumor progression in prostate cancer by galectin-3 based on the gene profile, 第105回日本泌尿器科学会総会, Apr. 2017.
83.	Kunihisa Yamaguchi, Hiro-omi Kanayama, Tomoharu Fukumori, Masayuki Takahashi and Yasuyo Yamamoto : 当院における腎移植後サイトメガロウイルス感染の検討, 臨床腎移植学会総会, Feb. 2017.
84.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 地方での泌尿器科医療の魅力を上げるには?四国内でのsubspecialty獲得への大学を超えた連携の提言, 第100回四国地方会, Vol.79, No.6, 202, Jan. 2017.
85.	Yasuyo Yamamoto, Yoshito Kusuhara, Tomoya Fukawa, Hidehisa Mori, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 麻酔下膀胱水圧拡張術を施行した間質性膀胱炎の検討, 第16回間質性膀胱炎研究会, Jan. 2017.
86.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 当院で加療した高齢者陰唇癒着症の検討, 第23回日本排尿機能学会, Dec. 2016.
87.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : TOT手術後に再手術を施行した3症例, 第68回西日本泌尿器科学会総会, Nov. 2016.
88.	Masayuki Takahashi and Hiro-omi Kanayama : 小児腹腔内精巣どう扱うか? 腹腔内精巣に対する腹腔鏡下二期的Fowler-Stephens法, 第30回日本泌尿器内視鏡学会総会, Nov. 2016.
89.	Kunihisa Yamaguchi and Hiro-omi Kanayama : 新規広角軟性膀胱鏡の有用性の検討, Japanese Jounal of Endourology, Vol.29, No.3, 179, Nov. 2016.
90.	Tomoharu Fukumori, Hidehisa Mori, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : I-125, 第54回癌治療学会学術集会, Oct. 2016.
91.	Masayuki Takahashi, 大豆本圭, Yoshito Kusuhara, Tomoya Fukawa, Tomoharu Fukumori and Hiro-omi Kanayama : 腎がん分子標的治療の解析進行性腎細胞癌におけるアキシチニブの有効性とインスリンレセプター発現の関連性, 第54回日本癌治療学会学術集会, Oct. 2016.
92.	Masayuki Takahashi, 大豆本圭, Yoshito Kusuhara, Tomoharu Fukumori and Hiro-omi Kanayama : 進行性腎細胞癌におけるアキシチニブの腫瘍縮小率と生存期間の関連性の検討, 第47回腎癌研究会, Jul. 2016.
93.	Masayuki Takahashi, 須藤泰史 and Hiro-omi Kanayama : 小児膀胱尿管逆流症に対する気膀胱下Cohen法の初期経験, 第25回日本小児泌尿器科学会総会・学術集会, Jun. 2016.
94.	Tomoharu Fukumori, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Terumichi Shintani, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : 去勢抵抗性前立腺癌患者に対する新規薬剤(アビラテロン，エンザルタミド)の初期使用経験, 第104回日本泌尿器科学会総会, Apr. 2016.
95.	Tomoharu Fukumori, Tomoya Fukawa, 大豆本圭, 津田恵, 井内俊輔, Yoshito Kusuhara, Hidehisa Mori, Jun-ichiro Kagawa, Masatsugu Komori, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : 去勢抵抗性前立腺癌患者におけるエンザルタミドの初期使用経験, 第103回日本泌尿器科学会総会, Apr. 2016.
96.	Masayuki Takahashi and Hiro-omi Kanayama : 最新支持療法から学ぶ，泌尿器癌化学療法を安全に完遂する極意腎癌分子標的薬使用時の支持療法, 第104回日本泌尿器科学会総会, Apr. 2016.
97.	Kunihisa Yamaguchi, Yoshito Kusuhara, Hidehisa Mori, Yasuyo Yamamoto, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 生体腎移植後PMLに対しミルタザピンとメフロキンが奏功した1例, 第49回日本臨床腎移植学会, Mar. 2016.
98.	Tomoharu Fukumori, Hidehisa Mori, 赤沢早紀, 大豆本圭, 津田恵, Yoshito Kusuhara, Terumichi Shintani, Jun-ichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 前立腺癌密封小線源療法後のPSA再発予測因子の検討, 第67回西日本泌尿器科学会総会, Nov. 2015.
99.	Kunihisa Yamaguchi, Yasuyo Yamamoto, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 膀胱全摘+回腸を利用した尿路変更術後のイレウスに対する大建中湯早期内服の有効性の検討, 西日本泌尿器科学会総会, Nov. 2015.
100.	Kunihisa Yamaguchi, Yasuyo Yamamoto, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 膀胱全摘+回腸を利用した尿路変更術後のイレウスに対する大建中湯早期内服の有効性の検討, 西日本泌尿器科学会総会, Nov. 2015.
101.	Masayuki Takahashi and Hiro-omi Kanayama : 腎細胞癌治療ー手術から薬物療法までー分子標的薬に対し反応性の異なる腎転移に対し転移巣切除術を施行した1例, 第67回西日本泌尿器科学会総会ケーススタディ, Nov. 2015.
102.	Masayuki Takahashi and Hiro-omi Kanayama : 小児泌尿器科イノベーションエンドウロロジーの進歩小児に対する腹腔鏡下腎盂形成術, 第67回西日本泌尿器科学会総会, Nov. 2015.
103.	Kunihisa Yamaguchi, Yoshito Kusuhara, Hidehisa Mori, Yasuyo Yamamoto, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 生体腎移植御早期に肺非結核性抗酸菌症を発症した1例, Japanese Journal of Transplantation, Vol.50, No.6, 660, Nov. 2015.
104.	Masayuki Takahashi, 赤澤早紀, 大豆本圭, 津田恵, Yoshito Kusuhara, Hidehisa Mori, Terumichi Shintani, Jun-ichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : 当科における進行性腎細胞癌に対するアキシチニブの治療成績, 第53回日本癌治療学会学術総会, Oct. 2015.
105.	Tomoharu Fukumori, Hidehisa Mori, Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, 大豆本圭, 津田恵, Yoshito Kusuhara, Jun-ichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : I-125密封小線源療法のPSA再発症例の臨床的検討, 第53回日本癌治療学会学術集会, Oct. 2015.
106.	大豆本圭, Masato Komatsu, Ryuichiro Kimura, Tetsuro Yoshimaru, Hisanori Uehara, 尾野雅哉, Tomoya Fukawa, Hiro-omi Kanayama and Toyomasa Katagiri : P53変異型膀胱癌におけるDEAD box polypeptide31(DDX31)の機能解明, 第74回日本癌学会学術総会, Oct. 2015.
107.	Tomoharu Fukumori, Hidehisa Mori, 赤沢早紀, 大豆本圭, 津田恵, Yoshito Kusuhara, Terumichi Shintani, Jun-ichiro Kagawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 前立腺密封小線源療法後の排尿障害予測因子の検討, 第22回日本排尿機能学会, Sep. 2015.
108.	Yasuyo Yamamoto, Hidehisa Mori, Terumichi Shintani, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 家族性片麻痺性片頭痛が疑われ，間歇的自己導尿を行っている1姉妹例, 第22回日本排尿機能学会, Sep. 2015.
109.	Yasuyo Yamamoto, Hidehisa Mori, Terumichi Shintani, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : TOT手術後の尿路感染症に関する検討, 日本女性骨盤底医学会, Aug. 2015.
110.	Masayuki Takahashi, 須藤泰史 and Hiro-omi Kanayama : 小児泌尿器科医療，こんな局面，あなたならどうする? 低位停留精巣へのアプローチは? 陰嚢切開アプローチ, 第24回日本小児泌尿器科学会総会・学術集会, Jul. 2015.
111.	Masayuki Takahashi, 須藤泰史 and Hiro-omi Kanayama : CAPDカテーテル大網嵌入に対し腹腔鏡下に大網除去，カテーテル腹壁固定した1例, 第24回日本小児泌尿器科学会総会・学術集会, Jul. 2015.
112.	Takashi Kawanaka, Shunsuke Furutani, Akiko Kubo, Tomoharu Fukumori, Hitoshi Ikushima, Hiro-omi Kanayama and Masafumi Harada : 当院で長期経過観察をした前立腺癌I-125シード永久挿入療法の検討, 日本放射線腫瘍学会小線源部会, Jun. 2015.
113.	大豆本圭, Masato Komatsu, Tetsuro Yoshimaru, Hiro-omi Kanayama and Toyomasa Katagiri : 膀胱癌悪性化規定因子である新規核小体蛋白質DDX31の機能解析, 日本がん分子標的治療学会第19回学術集会, Jun. 2015.
114.	Yasuyo Yamamoto, Hidehisa Mori, Terumichi Shintani, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 75歳以上の高齢者に対する間欠導尿の導入に関する検討, 第28回日本老年泌尿器科学会, May 2015.
115.	Michio Shimabukuro, Daiju Fukuda, H Sato, S Nishimoto, T Hara, A Takashima, Y Hirata, Hirotsugu Kurobe, Shusuke Yagi, Takeshi Soeki, Hirofumi Izaki, Hiroshi Sakaue, Tetsuya Kitagawa, Hiro-omi Kanayama and Masataka Sata : Depot- and Gender-Specific Regulation of the Innate Immune System in Adipose Tissues: A Study from Human Biopsy Samples., 第79回日本循環器学会学術集会, Apr. 2015.
116.	Tomoharu Fukumori, 湊亮詠, 大豆本圭, 井内俊輔, 津田恵, Yoshito Kusuhara, Hidehisa Mori, Jun-ichiro Kagawa, Masatsugu Komori, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 去勢抵抗性前立腺癌患者におけるエンザルタミドの初期使用経験, 第103回日本泌尿器科学会, Apr. 2015.
117.	Yasuyo Yamamoto, Hidehisa Mori, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 徳島大学病院におけるフェソテロジンの使用経験, 第103回日本泌尿器科学会, Apr. 2015.
118.	Shunsuke Furutani, Akiko Kubo, Takashi Kawanaka, Takaharu Kudoh, Hitoshi Ikushima, Tomoharu Fukumori and Hiro-omi Kanayama : 5年以上経過した前立腺癌I-125シード治療症例における線量増加の有効性と安全性の検討, 日本放射線腫瘍学会27回学術大会, Dec. 2014.
119.	Kunihisa Yamaguchi, Hiro-omi Kanayama, Masayuki Takahashi, Tomoharu Fukumori and Yasuyo Yamamoto : 腎移植におけるHLA one way match症例, Japanese Journal of Transplantation, Vol.49, No.4-5, 378, Nov. 2014.
120.	大豆本圭, Masato Komatsu, Tetsuro Yoshimaru, Hisanori Uehara, Tomoya Fukawa, Hiro-omi Kanayama and Toyomasa Katagiri : 核小体がんタンパク質BCRG1は膀胱癌の進行に関連している, 第73回日本癌学会学術総会, Sep. 2014.
121.	Masayuki Takahashi, 大豆本圭, Masatsugu Komori, Jun-ichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : ドセタキセル70サイクル以上の投与により長期生存が得られた進行性前立腺癌の2例, 第52回日本癌治療学会学術集会, Aug. 2014.
122.	Hisaya Takahashi, 大豆本圭, Jun-ichiro Kagawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : ロボット支援腹腔鏡下腎部分切除術の初期経験, The Nishinihon Journal of Urology, Vol.76, No.8, 293, Aug. 2014.
123.	Masayuki Takahashi and Hiro-omi Kanayama : 進行性腎細胞癌の集学的治療 ~手術，放射線治療等~, 第102回日本泌尿器科学会総会卒後教育プログラム17, Apr. 2014.
124.	Masayuki Takahashi and Hiro-omi Kanayama : 進行腎がんのsequential therapy 三次治療以降のSequential therapyを考慮した治療戦略, 第102回日本泌尿器科学会総会, Apr. 2014.
125.	大豆本圭, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 両側腎腫瘍症例を発端者としたBirt-Hogg-Dube症候群の一家系, 日本泌尿器科総会, Apr. 2014.
126.	Yasuyo Yamamoto and Hiro-omi Kanayama : 泌尿器科周術期管理のすべて, Dec. 2013.
127.	Masayuki Takahashi, Masatsugu Komori, Jun-ichiro Kagawa, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Hisaya Takahashi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 分子標的薬投与中に腸管穿孔をおこした有転移腎癌の2例, 第51回日本癌治療学会学術集会, Oct. 2013.
128.	Yasuyo Yamamoto, Tomoharu Fukumori, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 前立腺肥大症に伴う蓄尿症状に対するシロドシン単独およびシロドシン・塩酸プロピベリン併用療法の検討, 第20回日本排尿機能学会, Vol.24, No.1, 198, Sep. 2013.
129.	Tomoharu Fukumori, Tomokazu Senzaki, Takashi Kawanaka, Akiko Kubo, Jun-ichiro Kagawa, Masatsugu Komori, Hisaya Takahashi, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 限局性前立腺癌に対するI-125密封小線源療法のPSA再発予測因子の検討, 第48回日本がん治療学会学術集会, Sep. 2013.
130.	Masayuki Takahashi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 分子標的薬投与中に腸管穿孔をきたした2例, 第44回腎癌研究会, Jul. 2013.
131.	Masayuki Takahashi, 須藤泰史 and Hiro-omi Kanayama : 尿管ポリープを伴った間欠性水腎症の1例, 第22回日本小児泌尿器科学会, Jul. 2013.
132.	Yasuyo Yamamoto, Tomoharu Fukumori, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Hisaya Takahashi, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 第25回日本老年泌尿器科学会市民公開講座「おしっこの悩みに答えます∼出ない・漏れる・溜まらない∼」のアンケート結果, 日本老年泌尿器科学会誌, Vol.26, No.1, 88, May 2013.
133.	Hiro-omi Kanayama : シンポジウム2・高齢者の泌尿器がん診療, 日本老年泌尿器科学会, May 2013.
134.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Masatsugu Komori, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 高齢(75歳以上)前立腺癌の診断および治療戦略を考える∼放射線治療の適応と照射方法∼, 第26回日本老年泌尿器科学会, May 2013.
135.	Hiro-omi Kanayama and 羽渕友則 : ハイリスク上部尿路上皮癌の治療戦略, 日本泌尿器科学会総会, Apr. 2013.
136.	Masayuki Takahashi and Hiro-omi Kanayama : 新しい治療戦略シリーズ転移を有する腎癌新たな治療薬として何が期待されるか?, 第101回日本泌尿器科学会総会, Apr. 2013.
137.	Tomoharu Fukumori, Jun-ichiro Kagawa, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Hisaya Takahashi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 前立腺肥大症に対するデュタステリド投与1年の臨床的検討∼早期の治療効果について∼, 日本泌尿器科学会総会, Apr. 2013.
138.	Masayoshi Ishida, Michio Shimabukuro, Shusuke Yagi, Daiju Fukuda, Takeshi Soeki, H Sato, E Uematsu, Sachiko Matsumoto, Hiroshi Sakaue, Hirofumi Izaki, Hiro-omi Kanayama and Masataka Sata : MicroRNA-100 Regulates Adipocytokine Expression in Subcutaneous and Visceral Adipose Tissue: An Observation from Human Biopsy Study., 第77回日本循環器学会学術集会, Mar. 2013.
139.	佐藤千穂, 冨岡麗子, 山上真樹子, 宮本登志子, Munehide Matsuhisa, Hiroshi Kitahata, Eiji Takeda, Hiro-omi Kanayama, Hiroaki Yanagawa, 木下成三 and 川島周 : 徳島県内の医療機関における倫理審査体制に関する状況調査, 第246回徳島医学会学術集会, Feb. 2013.
140.	Masayuki Takahashi, 小森正嗣, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 小児低形成腎/無機能腎に対する腹腔鏡下腎摘除術の検討, 日本泌尿器内視鏡学会, Nov. 2012.
141.	Rumi Katashima, 佐藤千穂, 冨岡麗子, 山上真樹子, 宮本登志子, 木下成三, 川島周, Munehide Matsuhisa, Hiroshi Kitahata, Eiji Takeda, Hiro-omi Kanayama and Hiroaki Yanagawa : 徳島県内の医療機関における倫理審査体制に関する状況調査, 第33回日本臨床薬理学会年会, Nov. 2012.
142.	Masayuki Takahashi and Hiro-omi Kanayama : 泌尿器癌の薬物療法近未来予測腎細胞癌治療アルゴリズムの近未来予測, 日本泌尿器科学会西日本総会, Nov. 2012.
143.	Masayuki Takahashi and Hiro-omi Kanayama : 泌尿器癌の薬物療法近未来予測腎細胞癌治療アルゴリズムの近未来予測, 日本泌尿器科学会西日本総会, Nov. 2012.
144.	Tomoharu Fukumori, Tomokazu Senzaki, 小森正嗣, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : Efficacy and safety of dose escalation in I-125 prostate, 第26回日本泌尿器内視鏡学会総会, Nov. 2012.
145.	川端留美, 大家真治, Masayuki Takahashi and Hiro-omi Kanayama : Up-regulation of IGFBP3 by 5-FU suppress the growth of androgen-independent human prostate cancer cells, 日本癌学会総会, Sep. 2012.
146.	Masayuki Takahashi and Hiro-omi Kanayama : 腎癌の網羅的遺伝子発現解析, 日本臨床分子形態学会, Sep. 2012.
147.	Tomoya Fukawa, Ono Masaya, Taisuke Matsuo, Hisanori Uehara, Nakamura Yusuke, Hiro-omi Kanayama and Toyomasa Katagiri : RCCDH Regulates p53 Tumor suppressor activity in renal cell carcinomas., The 71th Annual Meeting of the Japanese Cancer Association, Sep. 2012.
148.	Hiroyoshi Nakatsuji, アビルメードシーレンヤンバ, Tomoya Fukawa, Masayuki Takahashi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : The involvement of Plakophilin in bladder cancer invasion, 日本癌学会総会, Sep. 2012.
149.	Kunihisa Yamaguchi, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Hiro-omi Kanayama, 悦子李, 菅政治 and 岡本賢二郎 : 徳島大学における生体腎移植初回例の報告, Japanese Journal of Transplantation, Vol.46, No.6, 696, Aug. 2012. (Keyword) *腎臓移植
150.	Masayuki Takahashi, 須藤泰史 and Hiro-omi Kanayama : 精索静脈瘤手術の臨床的検討, 日本小児泌尿器科学会総会, Jul. 2012.
151.	N Kawano, Toshiyuki Niki, K Ogasawara, R Ota, M Kadota, Y Kawabata, T Hara, Takayuki Ise, T Matsuura, Yuka Ueda, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata, T Yamamoto, K Kawano, 角谷明佳, K Seto and Hiro-omi Kanayama : シスプラチン，エトポシド，ブレオマイシンの三剤化学療法併用中に急性心筋梗塞を発症した二例, 第245回徳島医学会学術集会(平成24年度夏期), Jul. 2012.
152.	Masayuki Takahashi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : エベロリムスを投与した進行性/転移性腎腫瘍患者の臨床的検討, 腎癌研究会, Jul. 2012.
153.	Y Nagai, Y Watanabe, T Suganami, Hirofumi Izaki, S Akira, K Miyake, Hiro-omi Kanayama, Michio Shimabukuro, Masataka Sata, T Sasaoka, Y Ogawa, K Tobe and K Takatsu : TLRファミリー分子RP105/MD-1は高脂肪食誘発性の肥満，脂肪組織炎症，インスリン抵抗性を制御する, 第33回日本炎症・再生医学会, Jul. 2012.
154.	Kunihisa Yamaguchi, Tomokazu Senzaki, Tomoya Fukawa, Hirofumi Izaki and Hiro-omi Kanayama : 徳島県における献腎摘出の現状, Jun. 2012.
155.	Yasuyo Yamamoto, Tomoharu Fukumori, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 高齢者に対する尿失禁手術(TOT手術)の臨床的検討, 日本老年泌尿器科学会, Jun. 2012.
156.	H Sato, Y Hirata, Michio Shimabukuro, M Tabata, Hirotsugu Kurobe, M Higashida, Asuka Shiota, Hirofumi Izaki, Hiro-omi Kanayama, S Takanashi, Tetsuya Kitagawa, Yutaka Nakaya and Masataka Sata : 心臓周囲脂肪NLRP3インフラマゾームのヒト冠動脈硬化症における役割, 第55回日本糖尿病学会年次学術集会, May 2012.
157.	Masayuki Takahashi, 瀬戸公介, 津田恵, Tomokazu Senzaki, 小森政嗣, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 低形成腎/無機能腎に対する腹腔鏡下腎摘除術の臨床的検討, 日本泌尿器科学会総会, Apr. 2012.
158.	Souji Kakiuchi, Masaki Hanibuchi, Hisatsugu Goto, Yuko Toyoda, Atsuro Saijo, Toshifumi Tezuka, Takashige Taoka, Masayuki Takahashi, Hiro-omi Kanayama and Yasuhiko Nishioka : mTOR阻害剤投与症例における間質性肺障害の臨床的特徴, 第109回日本内科学会講演会, Apr. 2012.
159.	Yasuyo Yamamoto, Hiroyoshi Nakatsuji and Hiro-omi Kanayama : 前立腺肥大症に伴う蓄尿症状に対するシロドシン単独およびシロドシン・塩酸プロピベリン併用療法の検討, Apr. 2012.
160.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 前立腺癌密封小線源療法後の排尿障害予測因子の検討, 第100回日本泌尿器科学会総会, Apr. 2012.
161.	Tomoharu Fukumori, Shunsuke Furutani, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 限局性前立腺癌に対する密封小線源療法のリスク分類別治療成績, 第27回前立腺シンポジウム, Dec. 2011.
162.	Rumi Katashima, 佐藤千穂, 丸笹美津子, 明石晃代, 高井繁美, 宮本登志子, 山上真樹子, Munehide Matsuhisa, Hiroshi Kitahata, Eiji Takeda, Hiro-omi Kanayama and Hiroaki Yanagawa : 徳島大学病院における臨床研究推進体制構築の試み, 第32回日本臨床薬理学会年会, Dec. 2011.
163.	Shunsuke Furutani, Hitoshi Ikushima, Maki Ohtomo, Akiko Kubo, Takashi Kawanaka, Takaharu Kudoh, Tomoharu Fukumori, Hiro-omi Kanayama and Masafumi Harada : 前立腺癌 I-125 シード単独治療における線量増加の有効性と安全性の検討, 日本放射線腫瘍学会第24回学術大会, Nov. 2011.
164.	津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, 岸本大輝, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : MIBG療法を施行した悪性褐色細胞腫の1例, The Nishinihon Journal of Urology, Vol.73, No.9, 503, Nov. 2011. (Keyword) *褐色細胞腫(薬物療法,外科的療法)
165.	小泉貴裕, 岸本大輝, 赤澤誠二, 津田恵, Kunihisa Yamaguchi, Hiro-omi Kanayama and Hisaya Takahashi : 腺癌を伴った原発性精巣カルチノイドの1例, The Nishinihon Journal of Urology, Vol.73, No.11, 634, Nov. 2011. (Keyword) *カルチノイド腫瘍(外科的療法)
166.	Masayuki Takahashi, 辻岡卓也, 中島英, 津田恵, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 進行性腎細胞癌に対する薬物療法いつ，何を，どう使う? 進行性腎癌に対する分子標的薬のsequential therapy, The Nishinihon Journal of Urology, Vol.73, 86, Nov. 2011. (Keyword) *腎細胞癌(薬物療法)
167.	辻岡卓也, 上野恵輝, Masahiko Takemura, 津田恵, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Masa-aki Nishitani : 血液透析患者に対してGemcitabine/Carboplatin併用療法を施行した浸潤性膀胱癌の一例, The Nishinihon Journal of Urology, Vol.73, 127, Nov. 2011. (Keyword) *Carboplatin(治療的利用)
168.	瀬戸公介, Masahiko Takemura, Hirofumi Izaki, 冨田諒太郎, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Masayuki Takahashi, Tomoharu Fukumori, Hiro-omi Kanayama, Teruyoshi Kageji and Shinji Nagahiro : 腹腔鏡下右副腎摘除術と小脳血管芽腫摘出術を一期的に施行したvon Hippel-Lindau病の1例, The Nishinihon Journal of Urology, Vol.73, 139, Nov. 2011. (Keyword) *von Hippel-Lindau病(合併症,外科的療法)
169.	Masahiko Takemura, 中島英, 富田諒太郎, 津田恵, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and 三浦浩康 : 不完全重複腎盂尿管に合併した上部尿路結石に対してf-TULを施行した2例, The Nishinihon Journal of Urology, Vol.73, 143, Nov. 2011. (Keyword) *砕石術
170.	Hirofumi Izaki, Masahiko Takemura, Masayuki Takahashi, 中辻弘能, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoya Fukawa, 津田恵, Tomoteru Kishimoto, 上野恵輝, Tomoharu Fukumori, Hiro-omi Kanayama and 三浦浩康 : 徳島大学におけるf-TULの試み導入期に注意したいこと, The Nishinihon Journal of Urology, Vol.73, 143, Nov. 2011. (Keyword) 病的狭窄(治療)
171.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Shunsuke Furutani, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 前立腺密封小線源療法前のcombined androgen blockade(CAB)療法の臨床的検討, The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 677, Oct. 2011. (Keyword) *Androgen Antagonists(治療的利用)
172.	Masayuki Takahashi, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 当科における進行性/転移性腎腫瘍患者に対するエべロリムスの使用経験, 第49回日本癌治療学会学術集会, Oct. 2011.
173.	佐藤寛美, 平田陽一郎, Michio Shimabukuro, Asuka Shiota, 田端実, Hirotsugu Kurobe, 東田真由子, Hirofumi Izaki, Hiro-omi Kanayama, 高梨秀一郎, Yutaka Nakaya, Tetsuya Kitagawa and Masataka Sata : 心臓周囲脂肪におけるインフラマゾームの病態的意義, 第32回日本肥満学会, Sep. 2011.
174.	柴田恵理子, Kojiro Nagai, Taichi Murakami, 山田諭, Seiji Kishi, Motokazu Matsuura, Hideharu Abe, Toshio Doi, 板東良美, 津田恵, Masayuki Takahashi and Hiro-omi Kanayama : 腎細胞癌に対する受容体チロシンキナーゼ阻害薬Sunitinib投与にてThrombotic microangiopathyを来した一例, 日本腎臓学会雑誌, Vol.53, No.6, 794, Aug. 2011.
175.	Takashige Taoka, Masami Kishi, Akio Takezaki, Katsuhiro Kinoshita, Yuko Toyoda, Souji Kakiuchi, Masaki Hanibuchi, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Hiro-omi Kanayama and Yasuhiko Nishioka : 当院におけるmTOR阻害薬投与患者に発症した間質性肺炎の臨床的検討, 第46回日本呼吸器学会中国・四国地方会, Jul. 2011.
176.	Masayuki Takahashi, 須藤泰史 and Hiro-omi Kanayama : 当科における低形成腎/無機能腎に対する腹腔鏡下腎摘除術の臨床的検討, 日本小児泌尿器科学会総会, Jul. 2011.
177.	Yasuyo Yamamoto, 津田恵, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 頻尿・尿失禁を主訴に女性泌尿器科外来を受診した患者の検討, 日本女性骨盤底医学会学術集会, Jul. 2011.
178.	中島英, 上野恵輝, Masahiko Takemura, 津田恵, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Masa-aki Nishitani : 血液透析患者に対してGemcitabine/Carboplatin併用療法を施行した浸潤性膀胱癌の一例, 日本泌尿器科学会四国地方会, Jul. 2011.
179.	冨田諒太郎, Kunihisa Yamaguchi, 上野恵輝, 中島英, 瀬戸公介, 辻岡卓也, 津田恵, Tomoya Fukawa, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Masahiko Takemura, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 肉眼的血尿から貧血をきたした悪性黒色腫の膀胱転移に対するTURの経験, 日本泌尿器科学会四国地方会, Jul. 2011.
180.	Tomoya Fukawa, Taisuke Matsuo, 中村祐輔, Hiro-omi Kanayama and Toyomasa Katagiri : 腎細胞癌新規分子標的遺伝子RCCDPの同定およびその機能解析, 第15回日本がん分子標的治療学会, Jun. 2011.
181.	山下陽子, 浜田優介, 高木優, 山田香苗, 高松愛子, 上田雅彦, Kunihisa Yamaguchi, Hiro-omi Kanayama, 近藤直樹, 岸史, Seiji Kishi, 荒岡利和, Motokazu Matsuura, Taichi Murakami, Hideharu Abe, Masayuki Nakamura, Kojiro Nagai and Toshio Doi : 糖尿病合併血液透析患者の自然分娩に至った1例, 日本透析医学会学術集会, Jun. 2011.
182.	アビルメドシーレンヤンバ, Hiroyoshi Nakatsuji, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : Participation of N-caderin in bladder cancer, 日本泌尿器科学会総会, Apr. 2011.
183.	Masahiko Takemura, 瀬戸公介, 辻岡拓也, 津田恵, Tomoya Fukawa, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Yasuyo Yamamoto, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 透析患者の泌尿器科悪性疾患に対する体腔鏡手術の臨床的検討, The Japanese Journal of Urology, Vol.103, No.2, 369, Apr. 2011. (Keyword) *血液透析
184.	Hiro-omi Kanayama : ここが変わった腎盂・尿管・膀胱癌取扱い規約, 日本泌尿器科学会総会, Apr. 2011.
185.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, 津田恵, Masahiko Takemura, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 前立腺癌密封小線源療法後のPSA failure 症例の臨床的検討, 日本泌尿器科学会総会, Apr. 2011.
186.	Yasuyo Yamamoto, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama, Tomohiko Miyatani and Kyoko Nishi : 徳島大学病院卒後臨床研修センターの取り組み∼若手医師・研修医・医学生への教育から泌尿器科医の増員にむけて, 日本泌尿器科学会総会, Apr. 2011.
187.	Hirofumi Izaki, Masayuki Takahashi, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Tomoharu Fukumori and Hiro-omi Kanayama : いかに泌尿器科入局者を増やすか!地方大学の卒前教育の取り組み, 日本泌尿器科学会総会, Apr. 2011.
188.	Hiroyoshi Nakatsuji, シーレンヤンバアビルメド, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : HGFによる膀胱がん浸潤亢進におけるToll like receptor 4 (TLR4) の関与, 日本泌尿器科学会総会, Apr. 2011.
189.	Masayuki Takahashi, Hiroaki Kawano, 村上佳秀, 須藤泰史, 稲井徹, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 去勢抵抗性前立腺癌に対する抗アンドロゲン剤抗体療法とUFT併用療法の有効性と安全性に関する無作為化第Ⅱ相臨床試験, 日本泌尿器科学会総会, Apr. 2011.
190.	Tomoteru Kishimoto, 上野恵輝, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Susumu Kagawa : 非虚血性持続勃起症の1例, 日本性機能学会東部総会, Mar. 2011.
191.	Masahiko Takemura, 津田恵, Tomoya Fukawa, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Yasuyo Yamamoto, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 2010年徳島大学病院泌尿器科臨床統計, 日本泌尿器科学会四国地方会, Jan. 2011.
192.	上野恵輝, Tomoteru Kishimoto, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 非虚血性持続勃起症の一例, 日本泌尿器科学会四国地方会, Jan. 2011.
193.	山本洋之, 甲藤和伸, 松下和弘, 大田和道, 杉田治, 戦泰和, 湯浅健司, 寺尾尚民, Hiro-omi Kanayama and 降幡睦夫 : 腹腔鏡下副腎摘除術後に局所再発を認めた副腎皮質癌の一例, 日本泌尿器科学会四国地方会, Jan. 2011.
194.	Hirofumi Izaki and Hiro-omi Kanayama : 透析患者の泌尿器科悪性疾患に対する体腔鏡手術の取り組み, 腹腔鏡的治療研究会, Nov. 2010.
195.	Tomoteru Kishimoto and Hiro-omi Kanayama : 射精障害による不妊症を契機に発見された汎下垂体機能低下症の1例, 日本生殖医学会総会・学術講演会, Nov. 2010.
196.	Kunihisa Yamaguchi, Masahiko Takemura, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, 岸本大輝, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Hiro-omi Kanayama, 須藤泰史, 上間建造, 河野明 and 濱尾巧 : 前立腺癌に対する長期内分泌療法中止に関する検討, 第62回日本泌尿器科学会西日本総会, Nov. 2010. (Keyword) Androgen Antagonists(治療的利用)
197.	Kunihisa Yamaguchi, Masahiko Takemura, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Hiro-omi Kanayama, 須藤泰史, 上間建造, 河野明 and 濱尾巧 : 前立腺癌に対する長期内分泌療法中止に関する検討, The Nishinihon Journal of Urology, Vol.72, 113, Nov. 2010. (Keyword) Androgen Antagonists(治療的利用)
198.	津田恵, Tomoteru Kishimoto, Masahiko Takemura, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 射精障害を契機に発見された汎下垂体機能低下症の1例, The Nishinihon Journal of Urology, Vol.72, 121, Nov. 2010. (Keyword) Cortisone(治療的利用)
199.	Yasuyo Yamamoto, 津田恵, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama, Ryuichi Taue and Masa-aki Nishitani : 徳島大学病院における膀胱水圧拡張術を施行した間質性膀胱炎の検討, The Nishinihon Journal of Urology, Vol.72, 169, Nov. 2010. (Keyword) 拡張法
200.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, 二宮郁, 白戸玲臣, 橋根勝義, Shunsuke Furutani, Hitoshi Ikushima, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 早期前立腺がんの治療戦略早期前立腺癌に対する密封小線源療法の臨床的検討, 第48回日本癌治療学会学術集会, Oct. 2010. (Keyword) *近距離照射治療法
201.	Masayuki Takahashi, 川端留美, 河野明, 村上佳秀, 須藤泰史, 稲井徹, 赤澤誠二, 浜尾巧, 林秀樹, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : ホルモン再燃前立腺癌に対する抗アンドロゲン剤交替療法とUFTの併用療法, 第48回日本癌治療学会学術集会, Oct. 2010. (Keyword) *Androgen Antagonists(治療的利用)
202.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, 二宮郁, 白戸玲臣, 橋根勝義, 古谷俊介, 生島仁史, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 早期前立腺がんの治療戦略早期前立腺癌に対する密封小線源療法の臨床的検討, The Journal of Japan Society for Cancer Therapy, Vol.45, No.2, 491, Oct. 2010. (Keyword) 近距離照射治療法
203.	Masayuki Takahashi, 川端留美, 河野明, 村上佳秀, 須藤泰史, 稲井徹, 赤澤誠二, 浜尾巧, 林秀樹, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : ホルモン再燃前立腺癌に対する抗アンドロゲン剤交替療法とUFTの併用療法, The Journal of Japan Society for Cancer Therapy, Vol.45, No.2, 595, Oct. 2010.
204.	Masahiko Takemura, Tomoya Fukawa, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Yasuyo Yamamoto, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 腹腔鏡下右副腎摘除術と小脳血管芽腫摘出術を一期的に施行したvon Hippel-Lindau病の1例, Japanese Journal of Endourology and ESWL, Vol.23, No.3, 206, Oct. 2010.
205.	Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 透析患者の泌尿器科悪性疾患に対する体腔鏡手術の臨床的検討, Japanese Journal of Endourology and ESWL, Vol.23, No.3, 248, Oct. 2010. (Keyword) 血液透析
206.	Tomoteru Kishimoto, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 精嚢嚢胞状拡張を伴った射精管閉塞の1例, Japanese Journal of Endourology and ESWL, Vol.23, No.3, 249, Oct. 2010.
207.	Hirofumi Izaki, Masayuki Takahashi, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Yasuyo Yamamoto, Tomoteru Kishimoto, Tomoharu Fukumori and Hiro-omi Kanayama : 転移性副腎腫瘍に対する腹腔鏡手術議論のポイント, Japanese Journal of Endourology and ESWL, Vol.23, No.3, 162, Oct. 2010. (Keyword) 腎細胞癌(転移性,外科的療法)
208.	Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 透析患者の泌尿器科悪性疾患に対する体腔鏡手術の臨床的検討, 24 Endourology ESWL, Vol.23, No.3, 248, Oct. 2010. (Keyword) *血液透析
209.	岸本大輝, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 精嚢嚢胞状拡張を伴った射精管閉塞の1例, 24 Endourology ESWL, Oct. 2010. (Keyword) 精嚢
210.	Yoshihito Furukita, 高嶋美佳, 兼松美幸, 湊拓也, Yota Yamamoto, 梶浦耕一郎, Hirokazu Takechi, Akira Tangoku, 津田恵, 岸本大輝 and Hiro-omi Kanayama : 腹腔鏡下に食道裂孔ヘルニアおよび左腎癌に対して一期的手術を施行した1例, 第23回日本内視鏡外科学会総会, Oct. 2010.
211.	Tomoya Fukawa, Taisuke Matsuo, 三木恒治, 中村祐輔, Hiro-omi Kanayama and Toyomasa Katagiri : Identiffication and characterization of RCCMP as a novel molecular target for clear cell-renal cell carcinoma, 69th Annual Meeting of the Japanese Cancer Association, Sep. 2010.
212.	Hiroyoshi Nakatsuji, シーレンヤンバアビルメード, Tomoya Fukawa, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 乳糜尿に対して後腹膜鏡下腎周囲リンパ管遮断術を施行した一例, 日本癌学会学術総会, Sep. 2010.
213.	Hiro-omi Kanayama : 予後因子, 腎癌研究会記念大会, Jul. 2010.
214.	津田恵, Tomoya Fukawa, Masahiko Takemura, 山本泰代, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : BCG膀胱内注入療法後に生じたReiter症候群の1例, 日本泌尿器科学会四国地方会, Jul. 2010.
215.	Masahiko Takemura, 津田恵, Tomoya Fukawa, 山本泰代, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 腹腔鏡下右副腎摘除術と小脳血管芽腫摘出術を一期的に施行したvon Hippel-Lindau病の1例, 日本泌尿器科学会四国地方会, Jul. 2010.
216.	Masayuki Takahashi, 須藤泰史 and Hiro-omi Kanayama : 乳糜尿に対して後腹膜鏡下腎周囲リンパ管遮断術を施行した1例, 第19回日本小児泌尿器科学会総会, Jul. 2010.
217.	Hirofumi Izaki, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Kunihisa Yamaguchi, Tomoteru Kishimoto, Masayuki Takahashi, Tomoharu Fukumori, Takushi Naroda, 木内慎一郎, 高橋久弥, 赤沢誠二, Masahiko Takemura, 林秀樹, 水田耕司, 橋本寛文, 榊学, 浜尾巧 and Hiro-omi Kanayama : 透析患者の泌尿器科悪性疾患に対する体腔鏡手術の臨床的検討, Journal of Japanese Society for Dialysis Therapy, Vol.43, No.Suppl.1, 370, Jun. 2010.
218.	Hiro-omi Kanayama : 前立腺癌化学予防の可能性, 日本老年泌尿器科学会, May 2010.
219.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 高齢者に対する前立腺癌密封小線源療法の臨床的検討, 日本老年泌尿器科学会誌, Vol.23, 75, May 2010. (Keyword) *近距離照射治療法
220.	Masayuki Takahashi, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 当科における80歳以上の腎腫瘍患者の臨床的検討, 第23回日本老年泌尿器科学会, May 2010.
221.	Masayuki Takahashi, 山本洋之, 湯浅明人, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 進行性腎癌に対するNeoadjuvant療法進行性腎癌に対するNeoadjuvant療法のUpdate, The Japanese Journal of Urology, Vol.101, No.2, 152, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205072211840 (CiNii: 1390001205072211840)
222.	Masayuki Takahashi, 山本洋之, 湯浅明人, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : DOUBLE-PHASE HELICAL CTによる腎腫瘍組織型予測, The Japanese Journal of Urology, Vol.101, No.2, 214, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205073840256 (CiNii: 1390001205073840256)
223.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, 山本洋之, 湯浅明人, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : I-125前立腺癌密封小線源療法後の排尿障害の予測因子の検討, The Japanese Journal of Urology, Vol.101, No.2, 242, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282680048519296 (CiNii: 1390282680048519296)
224.	アビルメッドシーレブニヤンバ, Hisanori Uehara, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Keisuke Izumi and Hiro-omi Kanayama : Change of Gene Expressions of Prostate Cancer Cells by Direct Contact with Osteoblasts, The Japanese Journal of Urology, Vol.101, No.2, 369, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205072421504 (CiNii: 1390001205072421504)
225.	Takahiro Koizumi, 山本洋之, 湯浅明人, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 転移を有さない再燃前立腺癌に対する放射線療法の検討, The Japanese Journal of Urology, Vol.101, No.2, 448, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282680047830912 (CiNii: 1390282680047830912)
226.	Yasuyo Yamamoto, Tomoharu Fukumori, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Hiro-omi Kanayama, 桜井紀嗣, 稲井徹, 斎木喬 and 上間健造 : 徳島県下の泌尿器科施設における過活動膀胱(OAB)の実態調査, The Japanese Journal of Urology, Vol.101, No.2, 481, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205071964672 (CiNii: 1390001205071964672)
227.	Hiroyoshi Nakatsuji, アビルメッドシーレブニヤンバ, 湯浅明人, 山本洋之, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 膀胱癌浸潤におけるプラコフィリン2の関与, The Japanese Journal of Urology, Vol.101, No.2, 527, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282680050442240 (CiNii: 1390282680050442240)
228.	Hiroyoshi Nakatsuji, Avirmed Shiirevnyamba, 湯浅明人, 山本洋之, Tomoya Fukawa, Takahiro Koizumi, 山本泰代, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 膀胱がん浸潤におけるプラコフィリン2の関与, 泌尿器科分子・細胞研究会, Feb. 2010.
229.	Hiroyoshi Nakatsuji, Avirmed Shiirevnyamba, 山本洋之, 湯浅明人, 布川智也, Takahiro Koizumi, 山本泰代, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 膀胱がん浸潤におけるプラコフィリンの関与, 中国四国泌尿器科悪性腫瘍研究会, Feb. 2010.
230.	Takahiro Koizumi, 山本洋之, 湯浅明人, 布川智也, 山本泰代, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : ホルモン抵抗性局所進行前立腺癌に対する放射線治療の検討, 中国四国前立腺疾患研究会, Feb. 2010.
231.	Tomoteru Kishimoto, 山本洋之, 湯浅明人, Tomoya Fukawa, Takahiro Koizumi, 山本泰代, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Hiro-omi Kanayama and 細川忠宣 : 2009年徳島大学泌尿器科臨床統計, 日本泌尿器科学会四国地方会, Jan. 2010.
232.	湯浅明人, 山本洋之, Tomoya Fukawa, Takahiro Koizumi, 山本泰代, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 回腸導管より出血を繰り返したストーマ静脈瘤の1例, 日本泌尿器科学会四国地方会, Jan. 2010.
233.	山本洋之, Masayuki Takahashi, 湯浅明人, Tomoya Fukawa, Takahiro Koizumi, 山本泰代, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 乳糜尿に対して後腹膜鏡下腎周囲リンパ管遮断術を施行した一例, 日本泌尿器科学会四国地方会, Jan. 2010.
234.	湯浅智之, 小畑利之, 矢野聖二, 岡本英治, 西岡安彦, 久保宣明, Masayuki Takahashi, Hiroyoshi Nakatsuji, 長屋寿雄, Hiro-omi Kanayama, Seiji Arase, 曽根三郎 and 蛯名洋介 : 可溶化インスリン受容体細胞外ドメイン(sIR)は癌患者血清中で増加している, 日本分子腫瘍マーカー研究会誌, Vol.25, 53-54, 2010. (Keyword) 腫瘍
235.	Shunsuke Furutani, Hitoshi Ikushima, Seiji Iwamoto, Akiko Kubo, Takashi Kawanaka, Kyosuke Osaki, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Hiro-omi Kanayama and Hiromu Nishitani : 膀胱温存を目的とした浸潤性膀胱癌に対するTUR-Bt+動注化学放射線療法の治療成績, 第47回日本癌治療学会学術集会, Oct. 2009.
236.	Hiroyoshi Nakatsuji, Noriyuki Nishimura, 山村里恵, Hiro-omi Kanayama and Takuya Sasaki : Actinin-4によるJRAB/MICAL-L2の細胞膜局在の制御機構, 第66回癌学会学術総会, Oct. 2007.
237.	Hiroyoshi Nakatsuji, Noriyuki Nishimura, 山村里恵, Hiro-omi Kanayama and Takuya Sasaki : JRAB/MICAL-L2の細胞膜局在におけるactinin-4の役割, 第59回日本細胞生物学会, May 2007.
238.	Shirane Yumiko, Masayuki Shono, Murakami Yoshihide, Yasushi Kurokawa, Hiro-omi Kanayama and Susumu Kagawa : アルブミンの蓚酸カリウム一水化物結晶成長促進作用, The 88^th Annual Meeting of the Japanese Urological Association, Jun. 2000. (Keyword) アルブミン / 蓚酸カリウム

Products:

1.	Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : A case that suffered an accidental bleeding from a tumor vessel flowing into an inferior vena cava after treating with a sealing device, Audio-Visual Journal of JUA, Vol.Vol.21, No.No.1, Jan. 2015.

Et cetera, Workshop:

1.	Yoshito Kusuhara, 大豆本圭, 尾崎啓介, 津田恵, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : ロボット支援腹腔鏡下腎盂形成術の初期経験, 第26回中国四国前立腺・腎尿路疾患研究会, Mar. 2018.
2.	Terumichi Shintani, Hidehisa Mori, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 膀胱癌悪性化におけるToll like receptor 4の機能解析, 第25回泌尿器科分子・細胞研究会, Feb. 2016.
3.	Terumichi Shintani, Hidehisa Mori, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 膀胱癌におけるToll like receptor 4の発現解析, 第67回西日本泌尿器科学会総会, Nov. 2015.
4.	Hiro-omi Kanayama : 腎細胞癌スニチニブはQOLを維持した無増悪性存期間を延長, Nikkei Medical, Vol.8, 8-9, 2010.
5.	Tomoyuki Yuasa, Seiji Yano, Yasuhiko Nishioka, Yoshiaki Kubo, Masayuki Takahashi, Hiroyoshi Nakatsuji, Hisao Nagaya, Hiro-omi Kanayama, Seiji Arase, Saburo Sone and Yousuke Ebina : Soluble insulin receptor ectodomain in the plasma is a possible broad-spectrum tumor marker, 第68回日本癌学会学術総会記事, 450, Oct. 2009.
6.	Tomoyuki Yuasa, Toshiyuki Obata, Seiji Yano, 岡本英治, Yasuhiko Nishioka, Yoshiaki Kubo, Masayuki Takahashi, Hiroyoshi Nakatsuji, Hisao Nagaya, Hiro-omi Kanayama, Seiji Arase, Saburo Sone and Yousuke Ebina : Soluble insulin receptor ectodomain level was elevated in the plasma of cancer patients, 第29回日本分子腫瘍マーカー研究会プログラム, 70-71, Sep. 2009.
7.	Hiro-omi Kanayama and 篠原信雄 : 初診時から遠隔転移を有する進行性腎癌において，原発巣切除は優先されるべきか?, Japanese Society of Renal Cancer, Vol.23, No.8, 107-118, 2005.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

Development of a next-generation patient-derived cancer model using chicken eggs and establishment of a drug screening method (Project/Area Number: 19K22689 )
Exosome-mediated muscle atrophy and new therapeutic approaches for cancer cachexia (Project/Area Number: 19H03516 )
Elucidation of the molecular mechanism of galectin-3 in the progression of urological cancer (Project/Area Number: 18K09136 )
Elucidation of tumor regulation mechanism of galectin-3 against castration-resistant prostate cancer and clinical application (Project/Area Number: 15K10592 )
The tumor control mechanism of galectin-3 in prostate cancer bone metastasis (Project/Area Number: 24592394 )
A study to examine the renal protective effect and the remote effect of ischemic preconditioning for renal ischemia/reperfusion injury (Project/Area Number: 23592380 )
Mechanism of tumor regulation by galactose-binding protein in hormone refractory prostate cancer (Project/Area Number: 21592048 )
The interaction of cancer cell and stromal cell in urinary cancer-The approach of stromal therapy- (Project/Area Number: 21390442 )
The molecular mechanism of Actinin-4 in proliferation, invasion and metastasis of cancer (Project/Area Number: 20591857 )
Application of galectin-3 in combined therapy of urogenital cancer (Project/Area Number: 19591854 )
The tumor control mechanism of galectin-3 in urological cancer invasion and metastasis (Project/Area Number: 18591756 )
Tumor control mechanism of galactoside-binding lectin in metastasis of urogenital cancer (Project/Area Number: 17591681 )
The role of galectin-3 in human renal cell cancer cells (Project/Area Number: 16591599 )
Interaction between interstitial and genitourinary cancer cells detected by microarray (Project/Area Number: 15390493 )
The roles IGF of family in renal cell carcinoma (Project/Area Number: 14571501 )
Development of novel immunotherapy for advanced renal cell carcinoma (Project/Area Number: 13470334 )
Cytokine, chemokine and antiangiogenic gene therapy for murine renal cell carcinoma (Project/Area Number: 12671536 )
Mecanism of urothelial cancer invasion and metastasis (Project/Area Number: 11470338 )
Analysis of gene expression associated cancer invasion and metastasis using in situ RT-PCR method (Project/Area Number: 10671476 )
Molecular Biological Analysis of function and signal transduction of renin-binding protein (Project/Area Number: 09671631 )
可溶性CD44変異型の腎細胞癌マーカーとしての有用性の検討-とくにexon v10を含む変異型について- (Project/Area Number: 08671818 )
Molecular Biological Analysis of Invasion and Metastasis in Urological Cancer. (Project/Area Number: 06454458 )
尿路性器癌の浸潤・転移機構におけるIV型コラゲナーゼ、TIMPの関与 (Project/Area Number: 04670964 )
尿路性器癌におけるプロテアソ-ムの異常発現機構に関する研究 (Project/Area Number: 02670710 )
Search by Researcher Number (10214446)

Professor Emeritus : Kanayama, Hiro-omi

Research

Personal Web Page

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Academic Paper (Unrefereed Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Products:

Et cetera, Workshop:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)